---
document_datetime: 2023-09-21 19:51:27
document_pages: 117
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/kadcyla-epar-h-c-2389-ii-0045-epar-assessment-report-variation_en.pdf
document_name: kadcyla-epar-h-c-2389-ii-0045-epar-assessment-report-variation_en.pdf
version: success
processing_time: 231.1112595
conversion_datetime: 2025-12-19 00:29:51.821649
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

14 November 2019 EMA/652550/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Kadcyla

International non-proprietary name: trastuzumab emtansine

Procedure No. EMEA/H/C/002389/II/0045

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                   | 7                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................7 |
| 2.1.1. About the product                                                                                                   | ........................................................................................... 10            |
| 2.2. Non-clinical aspects............................................................................................      | 11                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                  | 11                                                                                                        |
| 2.2.2. Discussion on non-clinical aspects .....................................................................            | 11                                                                                                        |
| 2.2.3. Conclusion on the non-clinical aspects                                                                              | ............................................................... 11                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 11     |
| 2.3.1. Introduction....................................................................................................    | 11                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 12           |
| 2.3.3. Discussion on clinical pharmacology...................................................................              | 12                                                                                                        |
| 2.3.4. Conclusions on clinical pharmacology.................................................................               | 12                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 13     |
| 2.4.1. Dose response study........................................................................................         | 13                                                                                                        |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 13  |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 57                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 62                                                                                                        |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 62   |
| 2.5.1. Discussion on clinical safety..............................................................................         | 91                                                                                                        |
| 2.5.2. Conclusions on clinical safety............................................................................          | 94                                                                                                        |
| 2.5.3. PSUR cycle                                                                                                          | ..................................................................................................... 94  |
| 2.6. Risk management plan                                                                                                  | ....................................................................................... 95                |
| 2.7. Update of the Product information......................................................................               | 112                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 112                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                         | 113                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................         | 113                                                                                                       |
| 3.1.1. Disease or condition                                                                                                | ...................................................................................... 113                |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 113                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................        | 113                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 113                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 114                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................         | 114                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 115                                                               |
| 3.6. Effects Table....................................................................................................     | 115                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 116                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 116                                                                                                       |
| 3.7.2. Balance of benefits and risks                                                                                       | .......................................................................... 116                            |
| 3.8. Conclusions                                                                                                           | ..................................................................................................... 116 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations  ............................................................................... 117

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

anti-drug antibody

ADR

adverse drug reaction

AE

adverse event

AEGT

adverse event group term

ALT

alanine aminotransferase

AST

aspartate aminotransferase

CCoD

clinical cut-off date

CEC

Clinical Events Committee

CHF

congestive heart failure

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

CSR

clinical study report

CTCAE

Common Terminology Criteria for Adverse Events

DM1

a derivative of maytansine

DFS

disease-free survival

DRFI

distant recurrence-free interval

E-R

exposure-response

EBC

early breast cancer

eCRF

electronic case report form

EF

ejection fraction

EFS

event-free survival

EORTC

European Organisation for Research and Treatment of

Cancer

ER

estrogen receptor

E.U.

European Union

FDA

Food and Drug Administration

FEC

5-fluorouracil, epirubicin, and cyclophosphamide

GCP

Good Clinical Practice

GHS

global health status

HER2

human epidermal growth factor receptor 2

HR

hazard ratio

HRQoL

health-related quality of life

iDCC

independent Data Coordinator Center

IDFS

invasive disease-free survival

iDMC

independent Data Monitoring Committee

IHC

immunohistochemistry

ISH

in situ hybridization

ITT

intent-to-treat

IV

QLQ-C30

QLQ-BR23

Intravenous

Quality of Life Questionnaire-Core 30

Quality of Life Questionnaire-Breast Cancer 23

LVEF

left ventricular ejection fraction

LVSD

left ventricular systolic dysfunction

MAH

Marketing Authorisation Holder

MBC

metastatic breast cancer

NAbs

neutralizing antibodies

NCI

National Cancer Institute

NRH

nodular regenerative hyperplasia

NSABP

National Surgical Adjuvant Breast and Bowel Project

NYHA

New York Heart Association

OS

overall survival

pCR

pathologic complete response

PD

pharmacodynamic

PgR

progesterone receptor

PK

pharmacokinetic

PopPK

population pharmacokinetics

PT

preferred term

PRO

patient-reported outcomes

q3w

every 3 weeks

QLQ

Quality of Life Questionnaire

RT

radiotherapy

<div style=\"page-break-after: always\"></div>

SAE SAP SOC SPA SPNBC T-DM1 TNBC TTZ ypTN

serious adverse event statistical analysis plan system organ class special protocol assessment second primary non-breast cancer Trastuzumab emtansine, Kadcyla triple-negative breast cancer Trastuzumab Post-neoadjuvant treatment pathological stage of the tumour and lymph nodes

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 4 February 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the adjuvant treatment of adult patients with HER2-positive early breast cancer for Kadcyla; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce editorial changes. An updated RMP version 9.0 has been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/001/2015 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP on 17 November 2011 (EMEA/H/SA/1401/4/2011/II). The Scientific Advice pertained to clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP were:

Rapporteur: Sinan B. Sarac

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 4 February 2019   |
| Start of procedure:                                  | 1 March 2019      |
| CHMP Rapporteur Assessment Report                    | 25 April 2019     |
| PRAC Rapporteur Assessment Report                    | 2 May 2019        |
| PRAC members comments                                | 7 May 2019        |
| Updated PRAC Rapporteur Assessment Report            | 9 May 2019        |
| PRAC Outcome                                         | 16 May 2019       |
| CHMP members comments                                | 20 May 2019       |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 23 May 2019       |
| Request for supplementary information (RSI)          | 29 May 2019       |
| CHMP Rapporteur Assessment Report                    | 20 August 2019    |
| PRAC Rapporteur Assessment Report                    | 23 August 2019    |
| PRAC members comments                                | 28 August 2019    |
| PRAC Outcome                                         | 5 September 2019  |
| CHMP members comments                                | 09 September 2019 |
| Updated CHMP Rapporteur Assessment Report            | 12 September 2019 |
| 2 nd Request for supplementary information (RSI)     | 19 September 2019 |
| CHMP Rapporteur Assessment Report                    | 30 October 2019   |
| PRAC Outcome                                         | 31 October 2019   |
| CHMP members comments                                | 04 November 2019  |
| Updated CHMP Rapporteur Assessment Report            | 8 November 2019   |
| Opinion                                              | 14 November 2019  |

## 2. Scientific discussion

## 2.1. Introduction

## Disease or condition

A new indication is proposed for Kadcyla, as a single agent, for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have invasive residual disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

The  amount of  residual  disease  is  an  important  prognosis  factor  assessed  after  neoadjuvant  systemic treatment.  Patients  with  early  breast  cancer  with  residual  invasive  tumour  are  patients  who  had  not achieved  pathological  complete  response  (pCR)  in  the  breast  and/or  axillary  lymph  nodes  following

<div style=\"page-break-after: always\"></div>

completion of preoperative systemic therapy. Pathologic complete response is defined by the absence of any residual  invasive  cancer  on  hematoxylin  and  eosin  evaluation  of  the  resected  breast specimen and all sampled ipsilateral lymph nodes following completion of the neoadjuvant systemic therapy (ypT0/cis ypN0). According to the ESMO Clinical practice guideline, the Residual Cancer Burden (RCB) is the preferred method for quantifying residual disease in clinical trials although other methods can be used according to regional preference.

## Epidemiology and risk factors, screening tools/prevention

Breast cancer was the second most commonly diagnosed cancer in the world and the most commonly diagnosed cancer among women with 2.09 million new cases and approximately 627,000 deaths in 2018 (IARC Breast Cancer 2018). This is a disease affecting 10%-12% of women worldwide (Benson et al. 2009). In 2018, the estimate of breast cancer incidence was 522,513 and the estimate of breast cancer mortality was 137,707 in Europe (GLOBOCAN, Breast cancer 2018).

The main screening tool consists in mammography sometimes combined with magnetic resonance imaging (MRI) (e.g. in women with familial history of breast cancer). Its introduction together with the ageing of the population has made the incidence of breast cancer increase.

Genetic predisposition, exposure to oestrogens, ionising radiation, low parity, high breast density and a history of atypical hyperplasia are important risk factors to develop breast cancer in women. In men, breast cancer is rare (1% of cases) and important risk factors consist in clinical disorders carrying hormonal imbalances (especially gynaecomastia and cirrhosis), radiation exposure, a positive family history and genetic predisposition (ESMO guideline).

## Biologic features

Approximately 15% -20% of human breast cancers overexpress the human epidermal growth (HER) factor -2, a transmembrane receptor tyrosine kinase, because of an amplification event in the gene encoding HER2 on chromosome 17. HER2-positive breast cancer is a heterogeneous disease. There is concurrent expression of oestrogen receptor (ER) or progesterone receptor (PgR) in nearly 50% of patients.

The vast majority of breast cancer cases in male patients are ductal invasive carcinomas of the luminal-like type.

## Clinical presentation, diagnosis and stage/prognosis

Clinical examination, imaging and pathological assessment are combined for diagnosis. Staging is based on the AJCC TNM staging system. The expression of ER/PgR, HER2 and proliferation markers (e.g. Ki67), the number of involved regional lymph nodes, tumour histology, the size, grade and the presence of peritumoral vascular invasion are important prognosis factors in early breast cancer. The ipsilateral breast recurrence risk is also related to the status of the surgical margins and the presence of ductal carcinoma in situ (DCIS) for patients undergoing breast-conserving therapy (BCT) (ESMO Guideline, 2019).

Without treatment, HER2 overexpression is associated with aggressive tumour growth and poor clinical outcomes (Slamon et al. 1987; Slamon et al 1989; Wolff et al. 2007; Chia et al. 2008; Ross et al. 2009). Ten-year   survival   of   breast   cancer   exceeds   70%   in   most European regions (Allemani C et al. 2013). Despite  the  use  of  trastuzumab-based  therapy  in  the  EBC  setting,  approximately  15%  to  25%  of HER2-positive patients will eventually have breast cancer recurrence.

## Management

Loco-regional surgery, radiotherapy (RT) and systemic anti-cancer treatment (chemotherapy, endocrine therapy, targeted therapy) combined with supportive measures are part of the treatment algorithm for early breast  cancer.  Tumour  biology,  tumour  burden,  patient  characteristics  and  preferences,  and  predicted sensitivity to treatment(s) are factors to be considered when deciding on the use of (neo)adjuvant therapies.

<div style=\"page-break-after: always\"></div>

Between 60% and 80% of newly diagnosed cancers are amenable to breast conservation (wide local excision and RT) at diagnosis or after primary systemic therapy.

Endocrine therapies are used in all luminal-like cancer. The use of chemotherapy depends on several factors as mentioned above and sensitivity to chemotherapy has been shown to depend on intrinsic phenotype such as HER2-positive (when combined with anti-HER2 therapy) and TNBC.

The use of adjuvant trastuzumab in HER2-positive (HER2+) early-stage breast cancer (EBC) improves patient outcomes as shown in several large, randomized trials. The 3-year disease-free survival (DFS) rate for patients receiving trastuzumab in these studies, all of whom had operable disease, was approximately 85% to 90% (Romond et al. 2005; Piccart-Gebhart 2005; Slamon et al. 2011). The most frequently used regimens  contain  anthracyclines  and/or  taxanes,  although  in  selected  patients  cyclophosphamide/ methotrexate/5-fluorouracil (CMF) may still be used (ESMO Guideline).

A  variety  of  trastuzumab-based  chemotherapy  regimens  are  considered  effective  for  the  treatment  of non-metastatic  HER2+  breast  cancer.  These  include  doxorubicin  and  cyclophosphamide  followed  by  a taxane  (docetaxel  or  paclitaxel)  plus  trastuzumab  (AC-TH);  docetaxel,  carboplatin,  and  trastuzumab (TCbH); and 5-fluorouracil, epirubicin, and cyclophosphamide in sequence with docetaxel plus trastuzumab (FEC-TH or THFEC). Additionally, pertuzumab, another anti-HER2 monoclonal antibody, has been approved in combination with trastuzumab and chemotherapy for the neoadjuvant (NEOSPHERE and TRYPHAENA trials) and adjuvant (APHINITY trial) of patients with 'high-risk' early HER2+ breast cancer (EPAR Perjeta).

For patients with operable EBC, it has been shown in several randomized trials that neoadjuvant treatment results  in  survival  outcomes  similar  to  adjuvant  therapy,  with  the  added  benefit  of  improving  breast conservation rates. The ESMO guideline recommends a neoadjuvant approach in subtypes highly sensitive to ChT, such as triple-negative and HER2-positive, in tumours &gt;2 cm.

It has also been shown that patients who achieve a pathological complete response (pCR) (defined as no invasive disease both in the breast and axilla), after neoadjuvant treatment have an improved prognosis compared  with  those  who  have  residual  invasive  disease  present  in  the  surgical  specimen  (non-pCR) (Rastogi et al. 2008). Although there are only limited data for neoadjuvant therapy conducted exclusively in patients with HER2-positive breast cancer, in general, pCR rates of approximately 40%-60% have been observed, and patients who attain a pCR have a more favourable prognosis than those who have residual invasive disease (Buzdar et al. 2005; Gianni et al. 2010; von Minckwitz et al. 2012; Cortazar et al. 2014).

A  meta-analysis  of  neoadjuvant  studies  by  Loibl  et  al.  evaluated  the  prognostic  value  of  pCR  in  662 HER2-positive patients who had received trastuzumab. With pCR defined as no invasive or non-invasive residual disease in the breast or lymph nodes, there was a significant benefit in OS for attainment of pCR (p &lt; 0.0001). Therefore, the absence of pCR after appropriate neoadjuvant therapy allows identification of a patient population at higher risk of disease recurrence. This is a clinical setting where the application of more effective  therapies  would  have  a  potentially  large  absolute  impact  on  patient  outcomes  and  can  be considered an area of unmet medical need.

It is recognized that HER2-positive patients without pCR after neoadjuvant treatment are at increased risk of recurrence. Until recently these patients were recommended to receive the same adjuvant therapies as would be used for any patient with HER2-positive breast cancer, regardless of surgical findings, that is, to complete 12 months of treatment with trastuzumab (SmPC Herceptin).

Furthermore, neratinib has recently been approved for the treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy and is recommended for use in clinical guideline albeit at the cost of significant toxicity mostly diarrhoea (EPAR Nerlynx).

<div style=\"page-break-after: always\"></div>

For male patient, tamoxifen is the standard adjuvant systemic therapy when of luminal-like type while chemotherapy and anti-HER2 therapy indications and regimens should follow the same recommendations as those for breast cancer in female patients (ESMO Guideline).

## 2.1.1. About the product

Trastuzumab emtansine (also known as ado-trastuzumab emtansine, T-DM1, Kadcyla) is an antibody-drug conjugate (ADC), specifically designed for the treatment of HER2+ breast cancer. It is composed of the following  components: trastuzumab,  a  humanized  antibody  directed  against  the  extracellular  region  of HER2; DM1, an anti-microtubule agent derived from maytansine; and a thioether linker molecule used to conjugate DM1 to trastuzumab. Trastuzumab emtansine (from now on Kadcyla) binds to HER2 with an affinity similar to that of unconjugated trastuzumab. It is hypothesized that after binding to HER2, Kadcyla undergoes receptor-mediated internalization, resulting in intracellular release of DM1 and subsequent cell death. DM1 is an inhibitor of tubulin polymerization; it binds to tubulin competitively with vinca alkaloids.

Kadcyla  as  monotherapy  was  approved  in  November  2013  for  the  treatment  of  adult  patients  with HER2-positive,  unresectable  locally  advanced  or  metastatic  breast  cancer  who  had  previously  received trastuzumab and a taxane, separately or in combination.

Because Kadcyla has shown activity in patients who have previously progressed after chemotherapy and HER2-directed therapy in the metastatic setting, there was a rationale to explore whether there may be a benefit of administering Kadcyla to patients with HER2-positive EBC who have not had an optimal response to standard neoadjuvant treatment regimens.

The present application is to extend the indication of Kadcyla to the adjuvant treatment of HER2+ early breast cancer patients  based on the primary analysis of efficacy and safety data from the pivotal study KATHERINE, a phase III, two-arm, randomised, multicentre, open label trial comparing Kadcyla versus trastuzumab  as  adjuvant  therapy  in  patients  with  HER2+  EBC  who  have  received  preoperative chemotherapy and HER2-targeted therapy including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast or axillary lymph nodes.

In addition, supportive safety data from the Phase II study TDM4874g/BO22857 (designed primarily to assess safety, with a focus on cardiac events) are provided.  Study TDM4874g/BO22857 was a Phase II, multicentre, multinational, single arm, open label trial to assess the clinical safety and feasibility of Kadcyla given  sequentially  after  anthracycline-based  chemotherapy,  as  adjuvant  or  neoadjuvant  therapy  for patients with early stage HER2-positive breast cancer.

The claimed indication was as follows: Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual disease, in the breast and/or lymph nodes, after pre-operative systemic treatment that included HER2-targeted therapy.

The recommended indication is as follows: Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy (see SmPC section 4.1).

The recommended dose of trastuzumab emtansine is 3.6 mg/kg bodyweight administered as an intravenous infusion every 3 weeks (21-day cycle).

Patients should receive treatment for a total of 14 cycles unless there is disease recurrence or unmanageable toxicity.

Patients treated with trastuzumab emtansine should have HER2 positive tumour status, defined as a score of 3 + by immunohistochemistry (IHC) or a ratio of ≥ 2.0 by in situ hybridization (ISH) or by fluorescence in situ hybridization (FISH) assessed by a CE-marked In Vitro Diagnostic (IVD) medical device. If a CE-marked

<div style=\"page-break-after: always\"></div>

IVD is not available, the HER2-status should be assessed by an alternate validated test (see SmPC section 4.2).

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP (see discussion on non-clinical aspects).

## 2.2.1. Ecotoxicity/environmental risk assessment

The predicted use of trastuzumab emtansine is not expected to increase due to the present type II variation, as this particular patient group is already included in the original refined Fpen, and will lead to worst-case PECs in surface waters and sewage treatment that are far below regulatory thresholds and levels of potential risk. As the PECsurfacewater for both T-DM1 and MCC-DM1 have been determined to be smaller than the 0.01 μg/L t hreshold as well as the logKow for MCC-DM1 was smaller than the 4.5 limit, there is no need for any further studies on environmental safety.

## 2.2.2. Discussion on non-clinical aspects

No new non-clinical data have been submitted in this application.

This new indication does not lead to a significant increase in environmental exposure further to the use of trastuzumab emtansine.

## 2.2.3. Conclusion on the non-clinical aspects

Considering the above data, trastuzumab emtansine is not expected to pose a risk to the environment. Any unused medicinal product or waste material should be disposed of in accordance with local requirements (see SmPC section 6.6).

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

Table 1: Tabular overview of clinical studies

| Protocol Location         | Study Design                                                                                                                                        | Diagnosis, Inclusion Criteria                                                                                                                                                                                                              | No. of Pts*             | Criteria for Evaluation                                             | Dose, Duration                                                                                   | Study Status                                                     |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| Pivotal study             | Pivotal study                                                                                                                                       | Pivotal study                                                                                                                                                                                                                              | Pivotal study           | Pivotal study                                                       | Pivotal study                                                                                    | Pivotal study                                                    |
| BO27938 KATHERI NE Global | Two-arm, Phase III, randomized, multicenter, multinational, open-label study of trastuzumab emtansine versus trastuzumab as adjuvant therapy        | HER2-positive primary breast cancer: patients who received neoadjuvant chemotherapy and HER2-directed therapy including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast or axillary lymph nodes | 148 6                   | Efficacy (IDFS, DFS, OS, and DRFI) PRO Safety, incl. cardiac safety | T-DM1: 3.6 mg/kg IV q3w Trastuzumab: Loading dose of 8 mg/kg, then 6 mg/kg IV q3w. for 14 cycles | Ongoing: Primary CSR planned for inclusion in submission Q1 2019 |
| Supportive safety study   | Supportive safety study                                                                                                                             | Supportive safety study                                                                                                                                                                                                                    | Supportive safety study | Supportive safety study                                             | Supportive safety study                                                                          | Supportive safety study                                          |
| TDM487 4g/ BO22857 Global | Open-label, single-arm, Phase II study of T-DM1 administered sequentially with anthracycline-based chemotherapy, as adjuvant or neoadjuvant therapy | Early stage HER2-positive breast cancer                                                                                                                                                                                                    | 153                     | Safety, incl. cardiac safety                                        | T-DM1: 3.6 mg/kg IV q3w, for 17 cycles                                                           | Study Completed Final CSR January 2014                           |

## 2.3.2. Pharmacokinetics

During the course of Study BO29738, one or more PK samples were collected from 428 patients in the trastuzumab emtansine arm and 405 patients in the trastuzumab arm. Patients who received 3.6 mg/kg of trastuzumab emtansine intravenously every 3 weeks had a mean Cycle 1 maximum serum concentration (Cmax) of trastuzumab emtansine of 72.6 (± 24.3) µg/mL, respectively.

## 2.3.3. Discussion on clinical pharmacology

Following trastuzumab emtansine administration, Cmax and Cmin of trastuzumab emtansine conjugate in Study BO27938 were comparable to PK data from Study TDM4370g/BO21977 (EMILIA) at Cycle 1 and at steady state. Consistent with PK data from Study TDM4370g/BO21977, repeated dosing of trastuzumab emtansine on a q3w regimen did not result in any noticeable accumulation of trastuzumab emtansine conjugate. Similarly, no difference in serum total trastuzumab and plasma DM1 Cmax or Cmin was observed between Study BO27938 and Study TDM4370g/BO21977. There is no evidence of plasma DM1 accumulation following repeat dosing of trastuzumab emtansine.

## 2.3.4. Conclusions on clinical pharmacology

The population pharmacokinetic analysis suggested no difference in trastuzumab emtansine exposure based on disease status (adjuvant vs. metastatic setting).

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No new dose-response study was submitted (see discussion on clinical aspects).

## 2.4.2. Main study

## Study KATHERINE (Study BO27938)

KATHERINE (Study BO27938) is a Phase III, two-arm, randomised, multicentre, multinational, open label study in patients with HER2-positive primary breast cancer who have received neoadjuvant chemotherapy and HER2-targeted therapy, including trastuzumab, followed by surgery, with a finding of pathologically documented residual invasive disease in the breast or axillary lymph nodes.

Figure 1: Overview of Study Design for Study KATHERINE

<!-- image -->

## Methods

## Study participants

## Inclusion criteria:

- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Life expectancy ≥ 6 months
- Adequate hematologic , renal and liver function
- For  women  who  were  not  postmenopausal  (≥12  months  of  non -therapy  induced  amenorrhea)  or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of &lt; 1% per year during the treatment period and for at least 7 months after the last dose of study
- Negative serum pregnancy test for premenopausal women including women who have had a tubal ligation and for women less than 12 months after the onset of menopause. For women who were not postmenopausal (≥ 12 months of non -therapy induced amenorrhea) or surgically sterile (absence of ovaries  and/or  uterus):  agreement  to  remain  abstinent  or  use  single  or  combined  contraceptive methods. Male patients whose partners were pregnant must have used condoms or truly refrain from sexual activity for the duration of the pregnancy.

<div style=\"page-break-after: always\"></div>

- Documentation of hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies.
- HER2+ breast cancer:
- o HER2-positive status was defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) prospectively and centrally confirmed on pretreatment biopsy material. ISH positivity was defined as a ratio of ≥ 2.0 for the number of HER2 gene copies to the number of signals  for  chromosome  17  copies.    A  central  laboratory  performed  both  IHC  and  ISH  assays; however,  only  one  positive  result  was  required  for  eligibility  into  the  study.  In  the  event  that sufficient material from the pretreatment biopsy was not available, central HER2 determination for eligibility on residual tumor tissue from the time of definitive surgery was allowed. Patients with synchronous bilateral invasive disease were eligible provided both lesions were HER2-positive.
- o The tumor had to be histologically confirmed invasive breast carcinoma
- o Clinical stage at presentation of T1-4, N0-3, M0 (Note:  Patients with T1a/bN0 tumors were not eligible).
- o Prior  to  enrollment,  patients  had  to  have  completed  preoperative  systemic  chemotherapy  and HER2-directed  treatment  (patients  may  have  received  more  than  one  HER2-directed  therapy). Systemic therapy must have been completed preoperatively and consist of at least 6 cycles of chemotherapy, with a total duration at least 16 weeks, including at least 9 weeks of trastuzumab and at least 9 weeks of taxane based chemotherapy.  Within these criteria:
-  Patients may have received an anthracycline as part of preoperative therapy in addition to taxane chemotherapy. Patients with cumulative doses of anthracyclines exceeding pre-specified levels were not eligible: Doxorubicin &gt; 240 mg/m 2 ; Epirubicin or Liposomal Doxorubicin-Hydrochloride  (Myocet)  &gt;  480  mg/m 2 ;  For  other  anthracyclines,  exposure equivalent to doxorubicin &gt; 240 mg/m 2 .
-  Patients receiving dose-dense chemotherapy regimens were eligible, provided at least 8 weeks of taxane-based therapy and at least 8 weeks of trastuzumab were given.  A dose-escalated (225 mg/m 2  once every 2 weeks [q2w]) dose-dense regimen of paclitaxel over 6 weeks is allowed.
- o Patients had to have undergone surgery resulting in removal of all clinically evident disease in the breast and lymph nodes. This entailed either a total mastectomy with no gross residual disease at the margin of resection, or breast-conserving surgery with margins of excision being histologically free of invasive tumor and ductal carcinoma in situ (DCIS).  If pathologic examination demonstrated tumor at the line of resection, additional operative procedures could be performed to obtain clear margins.  If this did not result in complete removal, the patient must undergo total mastectomy to be eligible.  Patients with margins positive for LCIS were eligible without additional resection.
- o In case of positive results from biopsies of axillary lymph node(s) performed prior to preoperative therapy, additional surgical evaluation of the axilla following preoperative therapy was required, unless only micrometastases were present in sentinel nodes preoperatively (i.e., if the greatest diameter of the nodal metastasis in a sentinel node is 0.2 mm or less), then no additional surgical evaluation of the axilla is required.
- o If  sentinel  node biopsy performed either before or after preoperative therapy was negative, no additional  surgery  evaluation of  the  axilla  was  required.  If  the  only  sentinel  node  identified  by isotope scan was in the internal mammary chain, surgical evaluation of the axilla was recommended. If  sentinel  node  biopsy  performed  after  preoperative  therapy  was  positive,  additional  surgical evaluation of the axilla was also recommended.  Lastly, axillary dissection in the absence of sentinel node evaluation was permitted after preoperative therapy.

<div style=\"page-break-after: always\"></div>

- The patient had to have pathologic evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy.  If invasive disease was present in both breasts, residual invasive carcinoma had to be present in at least 1 breast or axillary lymph node postoperatively.
- The patient's hormone receptor positivity status must have been determined, by either known positive ER or known positive PgR status; hormone receptor-negative status must be determined by both known negative ER and known negative PgR.
- Eligible patients had to be enrolled with no more than 12 weeks between the date of primary surgery and the date of randomization.

## Exclusion criteria:

- Stage IV (metastatic) breast cancer.
- History of any prior (ipsi- or contralateral) breast cancer except lobular CIS.
- Evidence of clinically evident gross residual or recurrent disease following preoperative therapy and surgery.
- An overall response of PD according to the investigator at the conclusion of preoperative systemic therapy.
- Treatment  with  any  anti-cancer  investigational  drug  within  28  days  prior  to  commencing  study treatment.
- History of other malignancy within the last 5 years except for appropriately treated CIS of the cervix, non-melanoma  skin  carcinoma,  Stage  I  uterine  cancer,  or  other  non-breast  malignancies  with  an outcome similar to those mentioned above.
- Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it was contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation).
- Current NCI CTCAE (Version 4.0) Grade ≥ 2 periphera l neuropathy.
- Cardiopulmonary dysfunction as defined by any of the following:
- o History of NCI CTCAE (Version 4.0) Grade ≥ 3 symptomatic CHF or NYHA criteria Class ≥ II
- o Angina  pectoris  requiring  anti-anginal  medication,  serious  cardiac  arrhythmia  not  controlled  by adequate medication, severe conduction abnormality, or clinically significant valvular disease
- o High-risk uncontrolled arrhythmias.
- o Significant symptoms (Grade ≥ 2) relating to left ventricular dysfunction, cardiac arrhythmia, or cardiac ischemia while or since receiving preoperative therapy.
- o History of a decrease in LVEF to &lt; 40% with prior trastuzumab treatment (e.g., during preoperative therapy)
- o Uncontrolled hypertension.
- o Evidence of transmural infarction on ECG.
- o Requirement for continuous oxygen therapy.
- Prior treatment with Kadcyla.

<div style=\"page-break-after: always\"></div>

- Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound-healing disorders; ulcers).
- For female patients, current pregnancy and/or lactation.
- Major surgical procedure unrelated to breast cancer or significant traumatic injury within approximately 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment.
- Any known active liver disease, for example, disease due to HBV, HCV, autoimmune hepatic disorders, or sclerosing cholangitis.
- Concurrent, serious, uncontrolled infections or known infection with HIV.
- History of intolerance, including Grade 3 to 4 infusion reaction or hypersensitivity to trastuzumab or murine proteins or any components of the product.
- Active, unresolved infections at screening requiring treatment.
- Assessment by the investigator as being unable or unwilling to comply with the requirements of the protocol.

## Treatments

Patients should have received their first dose of study treatment the day of randomization if possible, but no later than five business days after randomization.

Kadcyla arm: Kadcyla was administered on Day 1 of a 3-week cycle at the approved dose of 3.6 mg/kg IV. The total dose was calculated based on the patient's weight on Day 1 of (or up to 3 days before) each cycle with no upper limit. Changes in weight of &lt;10% from baseline did not require dose recalculation.

Trastuzumab arm : Trastuzumab was administered on Day 1 of a 3-week cycle at a maintenance dose of 6 mg/kg IV. A loading dose of 8 mg/kg was required if &gt; 6 weeks had elapsed since the prior dose of trastuzumab.

Patients received study treatment for a total of 14 cycles; treatment was discontinued prior to 14 cycles in the event of disease recurrence, unacceptable toxicity, or study termination by the Sponsor. Patients who discontinued  Kadcyla  could  have  completed  the  duration  of  their  study  therapy  with  trastuzumab  if appropriate based on toxicity considerations.

## Concomitant therapy

Although one inclusion criterion  stated  the  requirement of  an  International normalized  ratio  (INR)  and activated partial  thromboplastin time (aPTT)  ≤ 1.5 x ULN, patients under anticoagulant or antiplatelet therapy were allowed to participate. Patients on anti-coagulant treatment should have had their platelet count monitored closely during treatment with trastuzumab emtansine.

Radiotherapy and/or hormonal therapy (for patients with hormone receptor-positive tumours) concurrent with study treatment was administered if indicated.

## Criteria for dose modification or withdrawal from treatment:

Kadcyla could be reduced by a maximum of 2 dose levels, to 2.4 mg/kg, according to the dose-modification guidelines.

<div style=\"page-break-after: always\"></div>

Table 2: Dose reduction for trastuzumab emtansine - Study KATHERINE

| DoseLevel                             | Dose                |
|---------------------------------------|---------------------|
|                                       | 3.6 mg/kg           |
|                                       | 3.0 mg/kg           |
|                                       | 2.4 mg/kg           |
| Indication for further dose reduction | Off study treatment |

Dose delays of up to 42 days from the last administered dose were permitted. After appropriate recovery from an adverse event, Kadcyla could have been resumed with one dose level reduction (e.g., Kadcyla reduced from 3.6 mg/kg to 3 mg/kg or from 3 mg/kg to 2.4 mg/kg). For patients who had an event while being  treated  with  Kadcyla  2.4  mg/kg,  study  treatment  was  discontinued.  The  dose  of  Kadcyla,  once reduced, could not be re-escalated.

There were no dose reductions permitted for trastuzumab.

## Prior treatment:

Patients must have completed neoadjuvant systemic treatment consisting of at least 6 cycles with a total duration  of  at  least  16  weeks,  including  at  least  9  weeks  of  trastuzumab  and  at  least  9  weeks  of taxane-based chemotherapy (or, if receiving dose-dense chemotherapy regimens, at least 6-8 weeks of taxane-based therapy and at least 8 weeks of trastuzumab). HER2-directed therapy and chemotherapy could be given concurrently. Patients could have received more than one HER2-directed therapy. Patients could have received an anthracycline as part of neoadjuvant therapy (see also inclusion criteria).

## Objectives

Primary  efficacy  objective:  To  compare  invasive  disease-free  survival  (IDFS)  in  patients  with  residual invasive  breast  cancer  after  treatment  with  preoperative  chemotherapy  and  HER2-directed  therapy including trastuzumab followed by surgery between the two treatment arms.

Secondary efficacy objectives: To compare IDFS including second non-breast cancers, DFS, OS, and distant recurrence-free interval (DRFI) between the two treatment arms.

Safety objectives: To compare cardiac safety and overall safety between the two treatment arms according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0.

PRO objectives: To compare Patient Reported Outcomes (PROs) between the two treatment arms using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) questionnaire and Quality of Life Questionnaire - Breast Cancer (QLQ-BR23) module.

PK objectives: To characterize the PK of Kadcyla (including total trastuzumab and DM1) in Kadcyla treated patients;  To characterize the PK of trastuzumab in trastuzumab-treated patients and permit an intra-study comparison of trastuzumab exposure in the two treatment arms; To investigate exposure-effect (efficacy and safety) relationships in this patient population.

Exploratory objectives: To assess correlations between biomarker status and efficacy and/or safety; To assess the incidence of anti-therapeutic antibodies (ATAs) and the effect of ATAs on PK, safety, and efficacy.

## Outcomes/endpoints

## Primary endpoint

The primary efficacy endpoint of the study was invasive disease free survival (IDFS) defined as the time between randomization and date of first occurrence of any one of the following IDFS event:

<div style=\"page-break-after: always\"></div>

- Ipsilateral invasive breast tumour recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion)

- Ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall and/or skin of the ipsilateral breast)

-  Distant  recurrence  (i.e.,  evidence  of  breast  cancer  in  any  anatomic  site  other  than  the  two  above mentioned sites that has either been histologically confirmed or clinically diagnosed as recurrent invasive breast cancer)

## - Contralateral invasive breast cancer

- Death attributable to any cause including breast cancer, non-breast cancer or unknown cause (but cause of death should be specified if at all possible).

## Key secondary endpoints:

- IDFS including second primary non-breast cancer (IDFS-SPNBC): defined the same way as IDFS for the primary  endpoint  but  including  second  primary  non-breast  invasive  cancer  as  an  event  (with  the exception of non-melanoma skin cancers and carcinoma in situ [CIS] of any site)
- Disease-free survival: defined as the time between randomization and the date of the first occurrence of an  invasive  disease-free  survival  event  including  second  primary  non-breast  cancer  event  or contralateral or ipsilateral DCIS
- Overall survival (OS): defined as the time from randomization to death due to any cause
- Distant recurrence-free interval (DRFI): defined as the time between randomization and the date of distant breast cancer recurrence

## Patient-Reported Outcome analyses:

HRQOL data were captured using the following questionnaires: the European Organisation for Research and Treatment  of  Cancer  (EORTC)  Quality  of  Life  Questionnaire-Core  30  (QLQ-C30),  Quality  of  Life Questionnaire-Breast Cancer 23 (QLQ-BR23), and the EuroQoL EQ-5D-3L.

## Safety reporting and analysis:

Safety analyses were performed on the safety-evaluable population. The safety of trastuzumab emtansine was  assessed  through  treatment  exposure,  summaries  of  AEs,  SAEs,  cardiac-specific  AEs,  LVEF measurements, and laboratory test results (including thrombocytopenia and transaminases). The specific safety outcome measures assessed, as specified in the protocol, included:

- Incidence, type and severity of all AEs based on NCI CTCAE Version 4.0 (including incidence and type of Grade≥3 AEs)
- Incidence, type, and severity of SAEs
- Incidence and type of AEs leading to dose discontinuation, modification, or delay
- Cause of death on study
- Abnormal laboratory values
- LVEF decreases
- Cardiac events, defined as death from cardiac cause or severe CHF (NYHA Class III or IV) with a decrease in LVEF of ≥10 percentage points from baseline to an LVEF of &lt;50%.

<div style=\"page-break-after: always\"></div>

For classification purposes, lower level terms were assigned by the Sponsor to the original terms entered on the CRF, using the most up-to-date version of the Medical Dictionary for Regulatory Activities (MedDRA 21.0) terminology for adverse events and diseases and the [Roche INN (International Non-proprietary Name) Drug Terms and Procedures Dictionary for medications and treatments.

## Biomarkers assessment:

Mandatory tumor tissue samples were collected for biomarker analysis after central HER2 testing for eligibility. HER2-positive BC was defined in the study by an IHC score of 3 + or gene amplified by ISH as defined by a ratio of ≥ 2.0 f or the number of HER2 gene copies to the number of chromosome 17 copies. In addition, tumor tissue samples were used in the analysis of phosphatidylinositol-3-kinase catalytic subunit alpha isoform (PIK3CA) mutation status.

The analysis methods for these biomarkers were performed according to manufacturer's instructions as follows:

· HER2 IHC was measured using Pathway HER2 (4B5) IHC assay (Ventana).

· HER2 ISH was measured using INFORM Dual ISH DNA Probe Cocktail (Ventana).

· PIK3CA mutations in exons 1, 4, 7, 9 and 20 in DNA were analyzed using the commercially available cobas PIK3CA Mutation Test (Roche Molecular Diagnostics) and the cobas z 480 analyzer (Roche Molecular Systems Inc.).

## Sample size

The sample size of the study was primarily driven by the analysis of IDFS.  To detect a hazard ratio (HR) of 0.75 in IDFS (a 6.5% improvement in 3-year IDFS from 70% in the control arm to 76.5% in the Kadcyla arm), approximately 384 IDFS events were required to achieve 80% power at a 2-sided significance level of 5%.  Approximately 1484 patients were planned to be enrolled in the study.

The study was expected to be fully enrolled around 35 months after the first patient enrolled in the study (FPI). The final IDFS analysis will be performed after approximately 384 events have occurred, which is projected to be approximately 64 months from FPI.

With the study sample size of 1484 patients and approximately 10 years of follow up from the date of randomization of the first patient, this study had approximately 56% power to detect a HR of 0.8 in OS (a 2.8% improvement in 3-year OS from 85% in the control arm to 87.8% in the Kadcyla arm) at a two sided significance level of 5%.

## Randomisation

Patients were randomized in a 1:1 ratio by a permuted block randomization scheme to one of the two treatment arms (trastuzumab or Kadcyla) through use of the IVRS/IWRS. Randomization was stratified by the following stratification factors:

- Clinical stage at presentation: inoperable (Stage T4NxM0 or TxN2-3M0) versus operable (Stages T1-3 N0 to 1 M0)
- Hormone receptor status: ER or PgR positive versus ER and PgR negative/unknown
- Preoperative HER2-directed therapy: trastuzumab versus trastuzumab plus additional HER2-directed agent(s)
- Pathologic nodal status evaluated after preoperative therapy: node positive versus node negative/not done.

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

This was an open-label study.

## Statistical methods

## Analysis populations:

Two analysis populations were used for the analysis of data from this study:

- The randomized patient population included all patients who were randomized to the study, regardless of whether they received any study treatment.
- The safety-evaluable population included all randomized patients who received any amount of study treatment.

Analyses of demographics and other baseline information were based on the randomized patient population, and per treatment assigned by the IVRS/IWRS.

The randomized patient population was to form the basis for all efficacy analyses. In all efficacy analyses, following the intent-to-treat principle, patients were to be included in the treatment group to which they were randomized by the IVRS/IWRS.

All safety analyses were performed on the safety-evaluable population and were based on actual treatment received. Specifically, a patient was included in the Kadcyla arm in safety analyses if the patient received any treatment with Kadcyla, regardless of the initial treatment assignment by IVRS/IWRS.

## Efficacy analyses/endpoints:

## Primary endpoint, IDFS:

The log-rank test, stratified by the protocol-defined stratification factors, was planned to compare IDFS between the two treatment arms. The unstratified log-rank test results were also planned as a sensitivity analysis. If, at the time of analysis, the smallest stratum was &lt; 5 patients in either arm and it was considered that robust stratified analyses cannot be conducted, the unstratified analysis was to be used as the primary analysis. The Cox proportional hazards model was used to estimate the HR between the 2 treatment arms and its 95% CI, and the unstratified analysis was considered the primary result. The Kaplan-Meier approach was used to estimate 3-year IDFS rates and corresponding 95% CIs for each treatment arm.

IDFS-SPNBC and DFS were secondary endpoints and served as the sensitivity analyses for the primary analysis of IDFS. Additional sensitivity analyses to assess the robustness of the primary endpoint IDFS included the following:

- Censoring patients at the time they started a new anti-cancer therapy before experiencing an IDFS event. This included patients who continued on trastuzumab after discontinuation of Kadcyla before 14 cycles  without  experiencing  an  IDFS  event.  For  these  patients,  data  were  censored  at  the  time  of initiation of trastuzumab treatment.
- Censoring patients at the time they discontinued study treatment due to any reason before experiencing an IDFS event. This included patients who continued on trastuzumab after discontinuation of Kadcyla before 14 cycles without experiencing an IDFS event. For these patients, data were censored at the time of last Kadcyla treatment.

## Secondary endpoints:

Secondary endpoints were analyzed in a similar manner as the primary endpoint to estimate 3-year event rates (and 5-year survival rate for OS) for each treatment arm and the HR between the two treatment arms

<div style=\"page-break-after: always\"></div>

with  95% CI. A testing hierarchy was used to control the overall type I error rate at 5%. The formal hypothesis testing of OS was planned to be performed when the primary endpoint IDFS reached statistical significance.

## Censoring:

For the analyses of IDFS, IDFS including second primary non-breast cancer, DFS and DRFI, data for patients who do not experience an event will be censored at the date they are last known to be alive and event free. Data for patients who are randomized without any post-baseline assessments will be censored at the date of randomization plus 1 day.

For the analysis of OS, data for patients who are alive at the time of the data cutoff will be censored at the last date they were known to be alive. Data for patients who are randomized without any post-baseline information will be censored at the date of randomization plus 1 day.

## Efficacy analyses timings:

One interim analysis and one final analysis of IDFS were planned. The interim efficacy analysis of IDFS was planned after 257 (67%) of the targeted 384 IDFS events had occurred. At this interim analysis, IDFS was tested  at  the  significance  level  determined  using  the  Lan-DeMets  alpha  spending  function  with  an O'Brien-Fleming stopping boundary (p &lt; 0.0124 or observed HR &lt; 0.732) so that the overall 2-sided type I error rate would be maintained at the 5% level for the IDFS primary endpoint if needed.

Table 3: Summary of planned analyses of invasive disease-free survival - Study KATHERINE

<!-- image -->

| Analysis of IDFS   |   No.of events | Efficacy Stopping Boundary *   | Estimated Timing   |
|--------------------|----------------|--------------------------------|--------------------|
| Interim            |            257 | p0.0124or observed HRc0.732    | 48 months          |
| Final              |            384 | pc0.0462 or observed HRc0.816  | 64 months          |

HR=hazard ratio:IDFS=invasive disease-free survival.

p-value will be based on 2-sided stratified log-rank test.

Time from the enrollment of first patient to data cutoff.

The interim analysis was to be performed by the iDCC statistician and the results were to be presented to the iDMC by the iDCC statistician. The purpose of the interim analysis was to evaluate whether there was an overwhelming difference in the efficacy observed in the Kadcyla arm compared with the trastuzumab arm in terms of IDFS. The study was to continue until 10 years of follow-up and IDFS analysis to be updated when 384 IDFS events have occurred.

Three formal interim OS analyses and one final OS analysis were planned as shown in the table below. The first OS interim analysis was to be performed at the time of the interim IDFS analysis. The second interim OS analysis was to be performed at the time of the final IDFS analysis (when 384 IDFS events have occurred), followed by the third OS interim analysis at approximately 2 years (88 months from FPI) after the second OS interim analysis. The final OS analysis was to be performed at the end of 10 years of follow-up.

<div style=\"page-break-after: always\"></div>

Table 4: Summary of planned analyses of overall survival - Study KATHERINE

<!-- image -->

| Analysis Of Os                                                            | No. of Events                                                             | Efficacy Stopping Boundary                                                | Estimated Timing                                                          |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Interim 1 (at interim IDFS)                                               | 150                                                                       | p0.0009 or observed HR0.5826                                              | 48 months                                                                 |
| Interim 2 (at final IDFS)                                                 | 206                                                                       | p0.0053 or observed HR0.6785                                              | 64 months                                                                 |
| Interim 3                                                                 | 279                                                                       | p0.0184 or observed HR -0.754                                             | 88 months                                                                 |
| Final                                                                     | 367                                                                       | p0.0435 or observed HR0.8099                                              | 119 months                                                                |
| HR=hazard ratio:IDFS=invasive disease-free survival: OS=overall survival. | HR=hazard ratio:IDFS=invasive disease-free survival: OS=overall survival. | HR=hazard ratio:IDFS=invasive disease-free survival: OS=overall survival. | HR=hazard ratio:IDFS=invasive disease-free survival: OS=overall survival. |

The overall type I error was controlled at 0.05 for the formal OS interim analyses and final OS analysis using the Lan-DeMets alpha spending function with an O'Brien-Fleming boundary. The boundaries used at each interim and final OS analysis depend on the timing of the analyses and the number of death events actually included in the analyses.

## Subgroup analyses:

Subgroup analyses of IDFS and OS were to be performed based on age, race, stratification factors, and other potential baseline prognostic factors as appropriate.

PRO:

Summaries of the compliance rates by treatment arm were provided at each assessment time point as specified in the protocol. Compliance rate was defined as the number of patients who completed each assessment (i.e., at least 1 item has been answered on the EORTC QLQ-C30 and BR23) divided by the total number of eligible patients at that time point according to protocol specified assessment schedule.

For scoring of the QLQ-C30 and QLQ-BR23 questionnaires, if more than 50% of the constituent items were completed, a pro-rated score was computed consistent with the scoring manuals and validation papers. For subscales with less than 50% of the items completed, the subscale was considered to be missing. Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) of absolute scores and change  from  baseline  scores  of  the  QLQ-C30  and  QLQ-BR23  subscales  were  summarized  at  each assessment time point for the two treatment arms. Only patients with a baseline assessment and at least one post-baseline assessment were included in this analysis.

The  proportion  of  patients  that  experienced  a  clinically  meaningful  deterioration  (or  worsening)  in symptoms, in their function, or in GHS/HRQoL were summarized, and the difference in proportions between treatment arms was evaluated with chi-squared statistical analysis.

Assessment  of  clinically  meaningful  deterioration  in  symptoms  (score  decrease)  and  functions  (score increase) was based on the published thresholds reported by Cocks et al. 2012 for each applicable subscale. Specifically, the score increase for each symptom scale reported and used was ≥15 points in constipation or diarrhea, ≥14 points in appetite loss, ≥11 points in dyspnea, nausea/vomiting, or pain, ≥10 points in fatigue , any hair loss, or systemic therapy side effects, ≥9 points increase in insomnia. The score decrease for each function scale reported and used was ≥10 points in physical functioning, ≥7 points in cognitive functioning, and ≥14 points in role functioning. For the rest of the function and symptom scales, a ≥10 points change was considered clinically meaningful.

A clinically meaningful deterioration in GHS/HRQoL was defined as a score decrease of ≥10 points, based on the thresholds reported by both Cocks et al. 2012 and Osoba et al, 1998.

<div style=\"page-break-after: always\"></div>

Repeated measures mixed-effects models were performed on the function scales and the GHS/HRQoL scale of the EORTC QLQ-C30 and QLQ-BR23. Each model had a variable for time, a variable for treatment group, and a variable for treatment-by-time interaction. Covariates were added as appropriate.

## Results

Since the pre-specified efficacy  boundaries  were  crossed,  the  Independent  Data  Monitoring  Committee (iDMC)  recommended  an  early  release  of  study  data  the  results  from  the  interim  analysis  are  now designated as the primary analysis of IDFS and presented below.

## Participant flow

<!-- image -->

*One patient was randomized twice in error. The patient was first randomized to the trastuzumab arm but did not receive treatment. The patient was included in the trastuzumab intention-to-treat population. The patient was then randomized to the Kadcyla arm and treated with Kadcyla. The patient was thus included in the Kadcyla safety population (n=740) based on treatment actually received. This patient's data has been analysed as follows, to ensure adherence to the principles of analysis populations and non-duplication of data: Data for the first assigned randomized treatment to trastuzumab is included in any randomized population numbers and ITT efficacy analyses, but does not contribute to any safety analyses; data from the same patient under their second randomization ID does not contribute to any randomized population numbers or ITT efficacy analyses, but are included in all safety analyses, under the Kadcyla arm. One patient was randomized to trastuzumab but was administered 13 cycles of trastuzumab and one cycle of Kadcyla in error so was included in the Kadcyla safety population.

One patient was randomized to Kadcyla but was administered 9 cycles of trastuzumab in error and was thus included in the trastuzumab safety population.

†Three of these patients are being followed for disease recurrence and survival.

‡Two of these patients are being followed for disease recurrence and survival.

Figure 2: Participant flow (clinical cut-off date: 25 July 2018) - Study KATHERINE

At the CCOD of 25 July 2018, all patients had completed treatment and the majority of patients were alive and ongoing in the study (80.3% in the trastuzumab arm, 85.5% in the Kadcyla arm). Of those patients in follow-up, most patients had not yet had an IDFS reported. A total of 98 patients had died (56 [7.5%] in the trastuzumab arm and 42 [5.7%] in the Kadcyla arm).

<div style=\"page-break-after: always\"></div>

```
Randomized Patient Population Prot0co1: B027938 Status: FINAL Snapshot Date: 12sEP2018 Clinical Cut-0ff Date: 25JUL2018
```

Table 5: Patient disposition during study - Study KATHERINE

| Trastugumab                                                    | (N=743)    | Trastuzumab Emtansine (N=743)   |
|----------------------------------------------------------------|------------|---------------------------------|
| Alive and ongoing in study                                     | 597(80.3%) | 635(85.5%)                      |
| Completed Study                                                | 0          | 0                               |
| Discontinued from study without further follow-up  146 (19.7t) |            | 108 (14.5%)                     |
| Discontinued with IDeS event reported DEATH due to             |            |                                 |
| Adverse event                                                  | 1(0.1%)    | ( 0.1%)                         |
| Breast cancer                                                  | 52 ( 7.0%) | 39 (5.24)                       |
| Other                                                          | 3(0.4)     | (0.3%]                          |
| Underlying Cancer a Contributing Factor in Death               | 3(0.45)    | 2(0.3%)                         |
| Yes                                                            | 1 (0.16)   |                                 |
| No                                                             | 0          | 0 0                             |
| Unkmowm                                                        | 2(0.3)     | 2 (0.34)                        |
| ENTIRE WITHDRAWAL BY SUBJECT                                   | 12(1.6%)   | 0.54)                           |
| LOST TO FOLLOW-UP                                              | 2(0.35)    | 0                               |
| OTHER                                                          | 1 ( 0.1%)  | 1 0.1%)                         |
| PHYSICIAN DECISION                                             | 1 ( 0.1%)  | 1 ( 0.14)                       |
| Discontinued without prior IDFs event reported                 |            |                                 |
| ENTIRE WITHDRAWAL BY SUBJECT                                   | 60 (8.16)  | 46( 6.24)                       |
| LOST TO FOLLOW-UP                                              | 10 (1.36)  | 8 ( 1.14)                       |
| OTHER                                                          | 4 (0.55)   | 0.5%)                           |
| PHYSICIAN DECISION                                             | 0          | 2 ( 0.34)                       |

program/t\\_ds\\_stud.sas Output: root/elinical\\_studies/R05304020/CDPT3519/B027938/data\\_analysis/CSR\\_INTERIM/prod/ output/t\\_ds\\_stud\\_IT.out 08N0V2018 12:53

Table 6: Duration of follow-up - Study KATHERINE

```
Rendomised Patient Population Protocol: B027938 Status: FINAL Snepshot Date: 12SEP2018 Clinical Cut-Off Date:25JuL2018
```

Tragtusimeb (N=743)

Duration of Follow-up (months)

95h CI for Madien

Hadian

25h end 751-ile

Teastusumeb Emtansine

(N=743)

41.43 [40.84,42.84] 34.99,49.18 0.1 to 62.7

16*06

33.91,48.39

Min to Mhor

(39.98,41.69]

0.1 to 62.6

Duration of Follow-up is caleulated as time from rendomisation to clinieal cut-off date or pequurq6a dn-nott9a 3o uotaeanp uetpen *antte 8q o4 tnou 6en quataed a44 6aep 46et 649 with Keplan-Meier hethod.  The confidence interval (Cl) for the median was conputad wsing the method of Broolmeyer and Crowley.

```
progrrm/t_ef Eu.sa9 output/t_ef_fu_Ir.out 23N0V2018 17:12
```

Page l of 1

Page l of 1

<div style=\"page-break-after: always\"></div>

Table 7: Patient disposition during treatment period - Study KATHERINE

Randomined Patient Population

Protoco1: B027938

BtatUS: FINAL

Bnapshot Date: 12sEP2018

Clinieal Cut-0ff Date: 25jul2018

Table 8: Patient disposition during treatment period: patients who received trastuzumab as study treatment after discontinuing trastuzumab emtansine - Study KATHERINE

<!-- image -->

```
Patient Disposition during Treatment Period : Patients who reoeived trastunumsb ey study treatment after discontinming trastugumeb emtangine, Switch Batients Protocol:B027938Stat19:F1NAL Snapshot Date: 12sEP2018 CliniealCut-0ff Date: 25jul2018
```

```
Trastueumeb Status (N=71) 63(88.78) After switch,disoontinuedtrastunumeb treatment dneto 8(11.3) Adverse Event 2(2.8) Physician Decigion 2 ( 2.8) Withdrrwal By Subject 4 ( 5.61)
```

```
fom. Patient wey
```

```
Progrem: root/e1inical_studies/R05304020/CDPr3519/B027938/data_pnalysig/CSR_IN1eRIM/prod/progrem/t_d9_trt.959 Output: root/elinieal_studies/R05304020/CDP13519/B027938/data_Pnelyais/CSR_INreRIM/prod/output/t_ds_trt_CR.o ut 08N0V2018 12:53 Page 1 of 1
```

<div style=\"page-break-after: always\"></div>

## Recruitment

A total of 1925 patients with HER2-positive EBC were screened, of whom 1486 patients were randomized from 268 centres across 28 countries: Argentina (3 centres), Austria (4), Belgium (4), Brazil (10), Canada (12), China (7), Columbia (3), Czech Republic (3), France (16), Germany (47), Greece (2), Guatemala (1), Hong Kong (3), Ireland (6), Israel (6), Italy (19), Mexico (5), Panama (2), Peru (5), Serbia (2), South Africa (6), Spain (13), Sweden (3), Switzerland (2), Taiwan (5), Turkey (5), UK (14), US (60).

First patient was randomised on 03 April 2013; last patient was randomised on 31 December-2015. Clinical data cut-off was on 25 July 2018.

## Conduct of the study

## Protocol amendments:

The first version of the protocol was issued on 19 October 2012. Five amendments to the protocol have been made. The key changes are summarized below.

Version 2 of the protocol (dated April 2013) made the following changes:

- Clarification and details of IHC and ISH assays used for determining HER2 status.
- Inclusion of patients who had received dose-dense chemotherapy regimens, provided at least 8 weeks of taxane-based therapy and at least 8 weeks of trastuzumab had been given.
- Revision  of  language  to  differentiate  radiotherapy  for  T3  disease  with  and  without  lymph  node involvement.
- Recommendations for hormonal therapy were revised to allow 5 to 10 years, rather than only 5 years, of tamoxifen therapy as a result of changing practice guidelines.
- Guidelines for managing the specific adverse events of nodular regenerative hyperplasia and interstitial lung disease were added. For nodular regenerative hyperplasia, a new appendix for guidelines for liver biopsy was added.
- Radiotherapy-related  toxicity  was  split  into  interstitial  lung  disease  and  skin  toxicity,  in  order  to differentiate between radiation-induced and drug-induced toxicities.
- Text  on  use  of  strong/potent  CYP3A4/5  inhibitors  was  revised  to  provide  further  instruction  to investigators, and remove erythromycin from the list of examples as it is only a moderate CYP3A4/5 inhibitor, not a potent inhibitor.
- Suspected transmission of an infection agent by the study drug was added as an adverse event of special interest.

Version 3 of the protocol (dated September 2013) made the following key updates:

- The duration of patient monitoring following first dose of Kadcyla was changed from 60 minutes to 90 minutes.
- Assessment  of  total  protein  at  baseline  was  added  to  the  list  of  assessments  because  it  was inadvertently omitted.
- Requirements for long-term reporting of concomitant medication, adverse events and serious adverse events were clarified.
- Detail on severe/fatal haemorrhage was added under the identified risk of hematologic toxicity.

<div style=\"page-break-after: always\"></div>

Protocol Version 4 (dated March 2014) introduced the following key changes:

- Addition of language to allow shorter duration of an escalated dose-dense administration of paclitaxel.
- Inclusion  criteria  were  revised  to  clarify  that  if  pre-chemotherapy  LVEF  assessments  were  not conducted, the screening LVEF assessment must be at least 55% in order for the patient to be eligible.
- Dose modifications related to increases in AST and for thrombocytopenia were revised. Guidelines for Grade 1-2 pneumonitis were updated such that to require diagnosis of drug-related ILD/pneumonitis should lead to permanent discontinuation of Kadcyla treatment.

Protocol Version 5 (dated July 2014) was issued rapidly after Version 4, to correct a small but significant error in language in the general inclusion critieria, and indicate that left ventricular ejection fraction (LVEF) should  be ≥ 50%  prior  to  receiving  neoadjuvant  chemotherapy  instead  of  after  receiving  neoadjuvant chemotherapy.

A local version of the protocol was created for Argentina at Version 5, to allow for the following specific local requirements:

- Per local regulations, pregnancy testing had to be conducted at each cycle and then at each month in the follow up period for 7 months.
- Since HIV testing was not part of standard of care, the exclusion criteria for Argentina were amended to include the documentation of negative HIV status prior to study entry.

## Version 6 of the protocol (dated October 2015) made the following key changes:

- Data that became available from the Phase III study TDM4788g/BO22589 was included.
- The reporting of LVSD events as SAEs was clarified.
- Pregnancy reporting requirements were updated, in line with the Global Enhancement Pharmacovigilance Pregnancy Program.
- The changes in the local Argentinian version of Protocol Version 6 mirrored the changes in the global version.

## Changes to planned analyses:

The primary analysis to compare IDFS between the two treatment arms was planned to be a log-rank test, stratified by the protocol-defined stratification factors per IxRS, with the unstratified log-rank test results to be provided as a sensitivity analysis. However, per the SAP specifications, since the smallest stratum was found  to  have  &lt;  5  patients  in  either  arm,  it  was  deemed  that  robust  stratified  analyses  could  not  be conducted, and thus the unstratified analysis is used as the primary analysis. In light of this, the pre-planned sensitivity analysis to evaluate use of stratification factors per eCRF was no longer relevant and thus was not performed.

<div style=\"page-break-after: always\"></div>

## Protocol deviations:

Table 9: Major protocol deviations - Study KATHERINE

```
Randomized Patient Population Protoco1:B027938 FINAL Snapshot Date:12SEp2018 Clinical Cut-0ff Date:25JUL2018
```

| Protocol Deviations of Interest                              | Trastuzumab (N=743)   | Trastuzumab Emtansine (N=743)   |
|--------------------------------------------------------------|-----------------------|---------------------------------|
| No.Of Patients With At Least One                             |                       |                                 |
| Protocol Deviation                                           | 93 (12.55)            | 156 (21.03)                     |
| Major Exclusion Criteria Deviation                           | 12 (1.6)              | 6 (0.8)                         |
| Major Inclusion Criteria Deviation                           | 72 9.73)              | 79 (10.6)                       |
| Major On-Study Protocol Deviation                            | 9 1.23)               | 83 (11.2%)                      |
| Major Exclusion Criteria Deviation                           |                       |                                 |
| Patients With At Least One Exclusion Criteria Deviation      | 12 (1.6)              | 6 C 0.8%)                       |
| Active Liver Disease: 15                                     |                       | 0.35)                           |
| Active, Unres Infections Requiring Treatment: 18             | 0.53)                 |                                 |
| Exceed Cumulative Dose Of Anthracyclines: 9                  | 1 0.15)               |                                 |
| Hbv/Hev But Liver Tests Not Repeated In Scr: 15              | 6 0.83)               | 1 0.14)                         |
| History Of Other Malignancy In Last 5 Years: 6               | 0                     | 1 0.1%)                         |
| Pd By Inv At End Of Preoperative Systemic Chemo:             | 1 0.14)               | 0                               |
| Prohibited Cardiopulmonary Dysfunction: 10                   | 0                     | 2 0.3)                          |
| Major Inclusion Criteria Deviation                           |                       |                                 |
| Patients With At Least One Inclusion Criteria Deviation      | 72 9.74)              | 79 (10.6%)                      |
| <=12 Wks From Primary Surgery To Randomization: 7            | 6 0.83)               | 6 0.85)                         |
| Adequate Anc, Platelets, Hemoglobin:13a-C                    | 1 0.14)               | 2 0.3)                          |
| Adequate Ast, Alt,Bilirubin,Alk:13f-H                        | 4 0.5%)               | 10 1.3)                         |
| Adequate Coagulation Labs: 13e                               | 8 1.1$)               | 7 0.95)                         |
| Adequate Contraception Methods: 14                           | 0                     | 3 0.4)                          |
| Adequate Creatinine: 13d                                     | 0                     | 0.39)                           |
| Adequate Excision Of Breast And Lymph Disease: 5             | 7 0.92)               | 26 0.85)                        |
| Adequate Organ Function Missing Required Labs: 13            | 10 1.34)              | 7 C 0.98)                       |
| Adequate Systemic Chemo And Tras Prior To Sx:4               | 7 0.93)               | 6 0.85)                         |
| Confirmed Her2-Positive Bc By Central Lab: 1                 | 5 0.7%)               | 6 0.8)                          |
| Documented Hov And Hev Status Per Protocol: 16               | 10 1.3$)              | 9 1.2%)                         |
| Inadequate Baseline Lvef: 13.1                               | 3 0.43)               | 7 0.93)                         |
| Negative Pregnancy Test Per Protocol: 15                     | 3 0.431               | 0                               |
| NoIef/Signed Ief Approved ByIrb/Ec: 6                        | 13 1.75)              | 15 2.0%)                        |
| Pathologic Evidence Of Residual Inv Disease: 6               | 1 0.1$)               | 0                               |
| Major On-Study Protocol Deviation                            |                       |                                 |
| Patients With At Least One Major On-Study Protocol Deviation | 6 (1.2) 0             | 83 (11.23)                      |
| Dose Delay > 42 Days For Toxicity                            |                       | 1 0.1%)                         |
| Dose Deviating >20s of Planned Dose                          | 1 0.14)               | 0                               |
| Dose Not Reduced/Held Per Protocol                           | 4 （ 0.53)             | 78 (10.58)                      |
| Drug Not Discontinued Despite Meeting Criteria               | 1 0.131               | 0                               |
| Received Incorrect Study Medication                          | 1 0.14)               | 2 0.38)                         |
| Received Prohibited Concomitant Medication                   | 1 ( 0.13)             |                                 |
| Sae Not Reported Within The Expected Timelines               | 0.14)                 | 3 (0.4%)                        |

## Program:

root/clinical\\_studies/R05304020/CDPT3519/B027938/data\\_analysis/CSR\\_INTERIM/prod/output/t\\_dv\\_IT.out 23N0/2018 16:56

root/clinical\\_studies/R05304020/CDPT3519/B027938/data\\_analysis/CSR\\_INTERIM/prod/program/t\\_dv.sas :andano

<div style=\"page-break-after: always\"></div>

## Baseline data

## Table 10: Demographic and baseline characteristics - Study KATHERINE

```
Randomized Patient Population Protocol: B027938 Status: FINAL Snapshot Date:12sEP2018 Clinical Cut-Off Date: 25JuL2018
```

<!-- image -->

|                                           | Trastuzumab (N=743)    | Trastuzumab Emtansine (N=743)   |
|-------------------------------------------|------------------------|---------------------------------|
| Age (yr)                                  |                        |                                 |
| n                                         | 743                    | 743                             |
| Mean (SD)                                 | 49.2 (10.9)            | 49.0(10.4)                      |
| Median                                    | 49.0                   | 49.0                            |
| Range                                     | 23 - 80                | 24 - 79                         |
| Age (yr)                                  |                        |                                 |
| n                                         | 743                    | 743                             |
| 40                                        | 153 (20.6%)            | 143 (19.24)                     |
| 40-64                                     | 522 (70.3)             | 542 (72.9t)                     |
| 65-74                                     | 61 (8.24)              | 56 (7.54)                       |
| >=75                                      | 7 (0.95)               | 2 (0.3)                         |
| Sex                                       |                        |                                 |
| n                                         | 743                    | 743                             |
| Male                                      | 3 (0.4%)               | 2 (0.3)                         |
| Female                                    | 740(99.6)              | 741(99.74)                      |
| Ethnicity                                 |                        |                                 |
| n                                         | 743                    | 743                             |
| Hispanic or Latino                        | 107 (14.4)             | 91                              |
| Not Hispanic or Latino                    | 543 (73.1)             | 579 77 9号                       |
| Not Stated                                | 49 (6.6)               | 35 (4.74)                       |
| Unknown                                   | 44 ( 5.9)              | 38 ( 5.14)                      |
| Race                                      |                        |                                 |
| n                                         | 743                    | 743                             |
| American Indian or Alaska Native          | 50 (6.7)               | 36 (4.8)                        |
| Asian                                     | 64 [8.6%)              | 65 8.74)                        |
| Black or African American                 | 19 [ 2.6)              | 21 (2.86)                       |
| Native Hawaiian or other Pacific Islander | 1 (0.14)               | 0                               |
| White                                     | 531 (71.5%)            | 551 (74.24)                     |
| Multiple                                  | 1 (0.1%)               | 1 0.14)                         |
| Unknown                                   | 77 (10.4%)             | 69 (9.34)                       |
| Region                                    |                        |                                 |
| n                                         | 743                    | 743                             |
| North America                             | 164 [22                | 1.70 (22.                       |
| Western Europe                            | 403 (54.2%)            | 403 (54.2%)                     |
| Rest of the World                         | 176 (23.76)            | 170(22.94)                      |
| Weight (kg) at baseline                   |                        |                                 |
| n                                         | 732                    | 738                             |
| Mean (SD)                                 | 71.19 (15.67)          | 70.64(14.64)                    |
| Median                                    | 68.95                  | 68.45                           |
| Range                                     | 43.0 - 145.5           | 40.0 - 169.0                    |
| Height (cm) at baseline                   |                        |                                 |
| n                                         | 732                    | 738                             |
| Mean (SD)                                 | 163.02 (7.25)          | 163.17 (7.10)                   |
| Median                                    | 163.00                 | 163.00                          |
| Range                                     | 142.0 - 188.0          | 137.0 - 186.0                   |
| BMI (WHO Classification)                  |                        |                                 |
| n                                         | 743                    | 743                             |
| Underweight                               | 17 (2.3%)              | 21 (2.84)                       |
| Normal                                    | 306 (41.2) 225 (30.3)  | 306 (41.2%) 245 (33.0%)         |
| Overweight Obese Unknown                  | 184 (24.8%) 11 ( 1.5t) | 166 (22.34) 5 ( 0.74)           |

<div style=\"page-break-after: always\"></div>

|                                                                                   | Trastuzumab (N=743)     | Trastuzumab Emtansine (N=743)   |
|-----------------------------------------------------------------------------------|-------------------------|---------------------------------|
| Hormone receptor status (IxRS)                                                    |                         |                                 |
| n                                                                                 | 743                     | 743                             |
| Negative (ER negative and PgR negative/unknowm) Positive (ER and/or PgR positive) | 210 (28.34) 533 (71.74) | 213 (28.7%) 530 (71.3)          |
| Hormone receptor status (eCRF)                                                    |                         |                                 |
| n                                                                                 | 743                     | 743                             |
| Negative (ER negative and PgR negative/unkmowm)                                   | 203 (27.3)              | 209 (28.1)                      |
| Positive (ER and/or PgR positive)                                                 | 540 (72.74)             | 534(71.9%)                      |
| Preoperative HER2-directed therapy (IxRS)                                         |                         |                                 |
| n                                                                                 | 743                     | 743                             |
| Trastuzumab only                                                                  | 600 (80.8%)             | 601 (80.9%)                     |
| Trastuzumab plus additional HER2                                                  | 143 (19.24)             | 142 (19.14)                     |
| Preoperative HER2-directed therapy (eCRE)                                         |                         |                                 |
| n Trastuzumab only                                                                | 743                     | 743                             |
|                                                                                   | 596 (80.24)             | 600 (80.8%)                     |
| Trastuzumab plus additional HER2                                                  | 147 (19.84)             | 143 (19.24)                     |
| Preoperative Pertuzumab (eCRF)                                                    |                         |                                 |
| n                                                                                 | 743                     | 743                             |
| Received pertuzumab                                                               | 139 (18.7%)             | 133 (17.9%)                     |
| Did not receive pertuzumab                                                        | 604 (81.3)              | 610 (82.1)                      |
| Prior Anthracycline received                                                      |                         |                                 |
| n                                                                                 | 743 564 (75.96)         | 743 579 (77.94)                 |
| Received prior anthracyeline                                                      |                         | 164 (22.1%)                     |
| Did not receive prior anthracycline                                               | 179 (24.1)              |                                 |
| Menopausal Status at screening                                                    |                         |                                 |
| n                                                                                 | 743                     | 743                             |
| Pre menopausal                                                                    | 413 (55.6%)             | 399(53.7%)                      |
| Post menopausal                                                                   | 330 (44.4%)             | 344(46.3%)                      |
| ECoG Performance Status                                                           |                         |                                 |
| n                                                                                 |                         | 743                             |
| 0                                                                                 | 613                     | 597 (80.3%)                     |
| 1                                                                                 | 130 (17.5)              | 146 (19.7%)                     |
| LVEF pre-chemotherapy                                                             |                         |                                 |
| n                                                                                 | 573 64.31(6.22)         | 597                             |
| Mean (SD) Median                                                                  |                         | 63.93 (6.19)                    |
| Quartiles                                                                         |                         |                                 |
|                                                                                   |                         | 64.00                           |
|                                                                                   | 65.00                   |                                 |
|                                                                                   | 60.00 - 69.00           | 60.00 - 67.60                   |
| Range                                                                             | 46.0 - 85.0             | 46.0 - 86.0                     |
| LVEF at screening                                                                 |                         |                                 |
| n                                                                                 | 743                     | 743                             |
| Mean (SD)                                                                         | 62.66 (6.02)            | 62.66 (5.85)                    |
| Median                                                                            | 62.00                   | 62.00                           |
| Quartiles                                                                         | 59.00 - 66.57           | 59.00 - 66.00                   |
| Range                                                                             | 50.0-90.0               | 50.0- 80.0                      |
| ECG at screening                                                                  |                         |                                 |
| n                                                                                 | 739                     | 741                             |
| Normal                                                                            | 633 (85.74)             | 619 (83.5%)                     |
| Abnormal, not clinically significant                                              | 105 (14.24)             | 122 (16.54)                     |
| Abnormal, clincally significant                                                   | ( 0.14)                 | 0                               |

Program:

:andang root/clinical\\_studies/R05304020/CDPT3519/B027938/data\\_analysis/CSR\\_INTERIM/prod/program/t\\_dm.sas

root/clinical\\_studies/R05304020/CDPT3519/B027938/data\\_analysis/CSR\\_INTERIM/prod/output/t\\_dm\\_IT.out

Page 2. of 2

09N0V2018 17:27

Abridged from t\\_cm\\_IT

Tumor prognostic characteristics including hormone receptor status (positive: 72.3%, negative: 27.7%), clinical stage at presentation (inoperable: 25.3%, operable: 74.8%) and pathological nodal status after preoperative therapy (node positive: 46.4%, node negative or not evaluated: 53.6%) were similar in the study arms.

The majority of the patients (76.9%) had received an anthracycline-containing neoadjuvant chemotherapy regimen. 19.5% percent of patients received another HER2-targeted agent in addition to trastuzumab as a component of neoadjuvant therapy; 93.8% of these patients received pertuzumab. All of the patients had received taxanes as part of neoadjuvant chemotherapy.

<div style=\"page-break-after: always\"></div>

## Table 11: Breast cancer characteristics - Study KATHERINE

Breast Cancer Characteristics, Randomized Patient Population

Protocol: BO27938   Status: FINAL

Snapshot Date: 12SEP2018   Clinical Cut-Off Date: 25JUL2018

|                                                                                   | Trastuzumab Trastuzumab Emtansine                                                                      |       |       |       |      |           |
|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-------|-------|-------|------|-----------|
| Site of Primary Tumor                                                             | (N=743) (N=743) ______________                                                                         |       |       |       |      |           |
| n                                                                                 | 743 743 388 (52.2%) 371 (49.9%)                                                                        |       |       |       |      |           |
| left right                                                                        | 352                                                                                                    |       |       |       |      |           |
| bilateral                                                                         | (47.4%) 366 (49.3%) 3 ( 0.4%) 6 ( 0.8%)                                                                |       |       |       |      |           |
| since initial diagnosis (in months from                                           | 731 734 8.34 (1.79)                                                                                    |       |       |       |      |           |
| Time randomization) n                                                             | 8.42 (1.73)                                                                                            |       |       |       |      |           |
| Mean (SD) Median                                                                  | 8.25                                                                                                   |       |       |       |      |           |
| Range                                                                             | 8.25 0.0 - 22.1                                                                                        |       |       |       |      |           |
|                                                                                   | 0.5 -                                                                                                  |       |       |       |      |           |
|                                                                                   | 20.6                                                                                                   |       |       |       |      |           |
| Histological                                                                      | 743 743 688 (92.6%) 21 ( 2.8%)                                                                         |       |       |       |      |           |
| subtype n Ductal                                                                  | 679 (91.4%) 16 ( 2.2%)                                                                                 |       |       |       |      |           |
| Lobular NOS Other                                                                 | 38 ( 5.1%) 17 ( 2.3%)                                                                                  |       |       |       |      |           |
|                                                                                   | 9 ( 1.2%) 18 ( 2.4%)                                                                                   |       |       |       |      |           |
| Histological grade n                                                              | 743 743 57 ( 7.7%)                                                                                     |       |       |       |      |           |
| Well-differentiated Moderately differentiated                                     | 56 ( 7.5%) 263 (35.4%) 276 (37.1%) 282 (38.0%)                                                         |       |       |       |      |           |
| Poorly differentiated Unknown Primary Tumor Estrogen Receptor (ER) status (local) | 283 (38.1%) 141 (19.0%) 128 (17.2%)                                                                    |       |       |       |      |           |
| n Negative                                                                        | 743 743 223 (30.0%) 520 (70.0%)                                                                        |       |       |       |      |           |
|                                                                                   | 219 (29.5%)                                                                                            |       |       |       |      |           |
| Positive                                                                          | 524 (70.5%)                                                                                            |       |       |       |      |           |
| Tumor Receptor(PR) status                                                         | (local) 743                                                                                            |       |       |       |      |           |
| Primary Progesterone n Negative                                                   | 743 322 (43.3%) 410 (55.2%)                                                                            |       |       |       |      |           |
| Positive                                                                          | 316 (42.5%) 11 ( 1.5%)                                                                                 |       |       |       |      |           |
| Unknown                                                                           | 416 (56.0%) 11 ( 1.5%)                                                                                 |       |       |       |      |           |
| Primary Tumor ER/PR status (local)                                                | 743 743                                                                                                |       |       |       |      |           |
| n                                                                                 | 203 (27.3%) 209 534                                                                                    |       |       |       |      |           |
| Positive                                                                          |                                                                                                        |       |       |       |      |           |
| Negative/Unknown initial diagnosis)                                               | (28.1%) 540 (72.7%) (71.9%)                                                                            | (at   |       |       |      |           |
| Primary Tumour Stage n cT1                                                        | 743 743 81 (10.9%) 99 (13.3%) 389 (52.4%) 365 (49.1%) 177 (23.8%) 59 ( 7.9%)                           |       |       |       |      |           |
| cT2 cT3                                                                           | 185 43 ( 5.8%)                                                                                         |       |       |       |      |           |
|                                                                                   | 54 (                                                                                                   |       |       |       |      |           |
| cT4,cT4a,cT4b,cT4c cT4d                                                           | 0                                                                                                      |       |       |       |      |           |
|                                                                                   | 34 (                                                                                                   |       |       |       |      |           |
|                                                                                   | (24.9%) 7.3%) 4.6%)                                                                                    |       |       |       |      |           |
| cTX (at initial diagnosis)                                                        | 0 ________________________________________________________________________________________________ 743 | Stage |       | Lymph | Node |           |
| Regional n cN0                                                                    | 743 239 (32.2%) 237 (31.9%) 385 (51.8%) 75 (10.1%)                                                     |       |       |       |      |           |
| cN1                                                                               | 370 (49.8%) 43 ( 5.8%)                                                                                 |       |       |       |      |           |
| cN2 cN3                                                                           | 99 (13.3%)                                                                                             |       |       |       |      |           |
| cNX                                                                               | 33 ( 4.4%) 2 ( 0.3%) 3 ( 0.4%)                                                                         |       |       |       |      |           |
| pathologically assessed at                                                        | initial diagnosis (prior to 743                                                                        |       | Nodes |       |      |           |
| Were Lymph n Yes                                                                  | Chemotherapy)? 743 309 (41.6%) 434 (58.4%)                                                             |       |       |       |      |           |
|                                                                                   | Neoadjuvant 319 (42.9%)                                                                                |       |       |       |      |           |
| No                                                                                |                                                                                                        |       |       |       |      |           |
|                                                                                   | 424 (57.1%)                                                                                            |       |       |       |      |           |
| Number of Positive Lymph Nodes (at initial n                                      | diagnosis) 319 309                                                                                     |       |       |       |      |           |
| Median Interquartile Range                                                        | 1.07 (2.78) 1.07 (1.87) 1.00 1.00 0.00 - 1.00 0.00 - 1.00 0.0 - 25.0                                   |       |       |       |      |           |
| Range                                                                             |                                                                                                        |       |       |       |      |           |
|                                                                                   | 0.0 - 45.0                                                                                             |       |       |       |      |           |
| Primary Tumour Stage n                                                            | 743 38 ( 5.1%) 20 ( 2.7%)                                                                              |       |       |       |      |           |
| ypT0 ypTis ypT1mic                                                                | 31 ( 138 104                                                                                           |       |       |       |      |           |
| ypT1a                                                                             |                                                                                                        |       |       |       |      |           |
| ypT1b                                                                             |                                                                                                        |       |       |       |      |           |
|                                                                                   | 172                                                                                                    |       |       |       |      |           |
| ypT1c ypT1                                                                        | (14.0%) (23.1%) 3 ( 0.4%)                                                                              |       |       |       |      |           |
|                                                                                   | 174 (23.4%)                                                                                            |       |       |       |      |           |
| ypT2                                                                              | 51 ( 6.9%)                                                                                             |       |       |       |      |           |
| ypT3                                                                              | 12 ( 1.6%)                                                                                             |       |       |       |      |           |
| ypT4                                                                              | 0                                                                                                      |       |       |       |      |           |
| ypTX                                                                              |                                                                                                        |       |       |       |      |           |
|                                                                                   | 57 ( 10 ( 1.3%) 1 ( 0.1%)                                                                              |       |       |       |      |           |
|                                                                                   | 185                                                                                                    |       |       |       |      |           |
|                                                                                   | (24.9%) 7.7%)                                                                                          |       |       |       |      |           |
|                                                                                   | 0                                                                                                      |       |       |       |      |           |
|                                                                                   | 184                                                                                                    |       |       |       |      |           |
|                                                                                   | (24.8%)                                                                                                |       |       |       |      |           |
|                                                                                   | 86 (11.6%)                                                                                             |       |       |       |      |           |
|                                                                                   | 135 (18.2%)                                                                                            |       |       |       |      |           |
|                                                                                   | 33 ( 4.4%)                                                                                             |       |       |       |      |           |
| (at definitive                                                                    |                                                                                                        |       |       |       |      |           |
|                                                                                   | 4.2%) (18.6%)                                                                                          |       |       |       |      |           |
|                                                                                   | 13 ( 1.7%)                                                                                             |       |       |       |      |           |
| surgery)                                                                          |                                                                                                        |       |       |       |      |           |
|                                                                                   | 39 ( 5.2%)                                                                                             |       |       |       |      |           |
|                                                                                   | 743                                                                                                    |       |       |       |      |           |
|                                                                                   |                                                                                                        |       |       |       |      | Mean (SD) |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

```
Regional Lymph Node Stage (at definitive surgery) n                                                               743               743 ypN0                                                        335 (45.1%)       344 (46.3%) ypN1                                                        213 (28.7%)       220 (29.6%) ypN2                                                        103 (13.9%)        86 (11.6%) ypN3                                                         30 ( 4.0%)        37 ( 5.0%) ypNX                                                         62 ( 8.3%)        56 ( 7.5%) Were Lymph Nodes pathologically assessed at definitive surgery following Neoadjuvant Therapy? n                                                               743               743 Yes                                                         676 (91.0%)       679 (91.4%) No                                                           67 ( 9.0%)        64 ( 8.6%) Number of Positive Lymph Nodes (at definitive surgery) n                                                             676               679 Mean (SD)                                                   1.99 (3.37)       1.83 (3.22) Median                                                          1.00              1.00 Interquartile Range                                         0.00 - 3.00       0.00 - 2.00 Range                                                       0.0 - 22.0        0.0 - 23.0 ________________________________________________________________________________________________ Note: Staging at initial diagnosis refers to clinical staging, staging at definitive surgery refers to pathologic staging. Program: root/clinical_studies/RO5304020/CDPT3519/BO27938/data_analysis/CSR_INTERIM_ADHOCS/prod/program/PR6551_t_dm_bc.sa s
```

Two thirds (996 out of 1486, 67%) of patients had 'small' post-neoadjuvant tumour sizes (ypT0, ypTis, ypTmic, ypT1a, ypT1b, ypT1c).  All but two of the patients with ypN0 staging had residual invasive disease at primary tumour. These two patients did not fill the inclusion criteria and constitute a major protocol violation.

Table 12: Central HER2 Status as used for eligibility - Study KATHERINE

```
Central HER2 Status as used for eligibility, Randomized Patient Population Protocol: B027938 Status: FINAL Snapshot Date: 12SEp2018 Clinical Cut-0ff Date: 25JUL2018
```

<!-- image -->

|                                                                                                                                                                              | Trastuzumab Emtansine (N=743)                                                                                                                                                | Trastuzumab (N=743)                                                                                                                                                          |                                                                                                                                                                              | Total (N=1486)                                                                                                                                                      |                                                                                                                                                                     |                                                                                                                                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pre-surgical (60l) sample used for eligibility 603 (8l.2t)                                                                                                                   |                                                                                                                                                                              |                                                                                                                                                                              | 592 (79.76)                                                                                                                                                                  | 1195 (80.4)                                                                                                                                                         |                                                                                                                                                                     |                                                                                                                                                                     |
| Surgical (70l) sample used for eligibility                                                                                                                                   | 138 (18.6)                                                                                                                                                                   |                                                                                                                                                                              | 151(20.3%)                                                                                                                                                                   | 289(19.4%)                                                                                                                                                          |                                                                                                                                                                     |                                                                                                                                                                     |
| Central HER2 status* by ISH                                                                                                                                                  |                                                                                                                                                                              |                                                                                                                                                                              |                                                                                                                                                                              |                                                                                                                                                                     |                                                                                                                                                                     |                                                                                                                                                                     |
| n                                                                                                                                                                            | 743                                                                                                                                                                          |                                                                                                                                                                              | 743                                                                                                                                                                          | 1486                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                                     |
| Negative                                                                                                                                                                     | 4( 0.5t)                                                                                                                                                                     | 7                                                                                                                                                                            | (0.9%)                                                                                                                                                                       | 11( 0.7)                                                                                                                                                            |                                                                                                                                                                     |                                                                                                                                                                     |
| Positive                                                                                                                                                                     | 722 (97.24)                                                                                                                                                                  |                                                                                                                                                                              | 707(95.2%)                                                                                                                                                                   | 1429(96.2)                                                                                                                                                          |                                                                                                                                                                     |                                                                                                                                                                     |
| Unknown                                                                                                                                                                      | 17(2.3)                                                                                                                                                                      |                                                                                                                                                                              | 29(3.96)                                                                                                                                                                     | 46(3.1)                                                                                                                                                             |                                                                                                                                                                     |                                                                                                                                                                     |
| Central HER2 status* by IHC                                                                                                                                                  |                                                                                                                                                                              |                                                                                                                                                                              |                                                                                                                                                                              |                                                                                                                                                                     |                                                                                                                                                                     |                                                                                                                                                                     |
| n                                                                                                                                                                            | 743                                                                                                                                                                          |                                                                                                                                                                              | 743                                                                                                                                                                          | 1486                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                                     |
| IHC0/1+                                                                                                                                                                      | 13 ( 1.74)                                                                                                                                                                   |                                                                                                                                                                              | 12(1.6%)                                                                                                                                                                     | 25( 1.7)                                                                                                                                                            |                                                                                                                                                                     |                                                                                                                                                                     |
| IHC2+                                                                                                                                                                        | 168 (22.6)                                                                                                                                                                   | 158                                                                                                                                                                          | (21.34)                                                                                                                                                                      | 326(21.9%)                                                                                                                                                          |                                                                                                                                                                     |                                                                                                                                                                     |
| IHC3+                                                                                                                                                                        | 559 (75.24)                                                                                                                                                                  | 573                                                                                                                                                                          | (77.15)                                                                                                                                                                      | 1132 (76.2)                                                                                                                                                         |                                                                                                                                                                     |                                                                                                                                                                     |
| Unknown                                                                                                                                                                      | 3(0.4)                                                                                                                                                                       | 0                                                                                                                                                                            |                                                                                                                                                                              | 3(0.2)                                                                                                                                                              |                                                                                                                                                                     |                                                                                                                                                                     |
| Central combined IHC/ISH status*                                                                                                                                             |                                                                                                                                                                              |                                                                                                                                                                              |                                                                                                                                                                              |                                                                                                                                                                     |                                                                                                                                                                     |                                                                                                                                                                     |
| n1                                                                                                                                                                           | 743                                                                                                                                                                          |                                                                                                                                                                              | 743                                                                                                                                                                          | 1486                                                                                                                                                                |                                                                                                                                                                     |                                                                                                                                                                     |
| ISH+/IHC3+                                                                                                                                                                   | 540(72.74)                                                                                                                                                                   | 537                                                                                                                                                                          | (72.36)                                                                                                                                                                      | 1077(72.56)                                                                                                                                                         |                                                                                                                                                                     |                                                                                                                                                                     |
| ISH+/IHC2+                                                                                                                                                                   | 168 (22.6%)                                                                                                                                                                  | 158                                                                                                                                                                          | (21.36)                                                                                                                                                                      | 326(21.9%)                                                                                                                                                          |                                                                                                                                                                     |                                                                                                                                                                     |
| ISH+/IHCO or ISH+/IHC1+                                                                                                                                                      | (1.74)                                                                                                                                                                       | 12                                                                                                                                                                           | (1.6%)                                                                                                                                                                       | 25 [1.74]                                                                                                                                                           |                                                                                                                                                                     |                                                                                                                                                                     |
| ISH+/IHC unknown                                                                                                                                                             | 13 1 (0.14)                                                                                                                                                                  | 0                                                                                                                                                                            |                                                                                                                                                                              | 1 (<0.14)                                                                                                                                                           |                                                                                                                                                                     |                                                                                                                                                                     |
| ISH-/IHC3+                                                                                                                                                                   | (0.5t)                                                                                                                                                                       | 7                                                                                                                                                                            | (0.96)                                                                                                                                                                       | 11 (0.76)                                                                                                                                                           |                                                                                                                                                                     |                                                                                                                                                                     |
| IHC Unkmown/ISH Unkmown                                                                                                                                                      | 2 (0.34)                                                                                                                                                                     | 0                                                                                                                                                                            |                                                                                                                                                                              | 2 [ 0.1%]                                                                                                                                                           |                                                                                                                                                                     |                                                                                                                                                                     |
| ISH Unknown/IHC3+                                                                                                                                                            | 15 ( 2.0%)                                                                                                                                                                   | 29                                                                                                                                                                           | (3.95)                                                                                                                                                                       | 44( 3.0%]                                                                                                                                                           |                                                                                                                                                                     |                                                                                                                                                                     |
| HER2-status derived from the pre-treatment or surgical specimen. Two patients uMouqun ue aneu pue 1se4 xgureud HSiaOI gauu e4a uo peseq enTaTsod aie dnoibqms +HsI/+zoHI eu4 | HER2-status derived from the pre-treatment or surgical specimen. Two patients uMouqun ue aneu pue 1se4 xgureud HSiaOI gauu e4a uo peseq enTaTsod aie dnoibqms +HsI/+zoHI eu4 | HER2-status derived from the pre-treatment or surgical specimen. Two patients uMouqun ue aneu pue 1se4 xgureud HSiaOI gauu e4a uo peseq enTaTsod aie dnoibqms +HsI/+zoHI eu4 | HER2-status derived from the pre-treatment or surgical specimen. Two patients uMouqun ue aneu pue 1se4 xgureud HSiaOI gauu e4a uo peseq enTaTsod aie dnoibqms +HsI/+zoHI eu4 | in                                                                                                                                                                  |                                                                                                                                                                     |                                                                                                                                                                     |
| Ventana DDisH test result. A missing HER2 status is presented for vv .! due to protocol violation, but the sample of this patent was HER2-positive (rerandomized as          | Ventana DDisH test result. A missing HER2 status is presented for vv .! due to protocol violation, but the sample of this patent was HER2-positive (rerandomized as          | Ventana DDisH test result. A missing HER2 status is presented for vv .! due to protocol violation, but the sample of this patent was HER2-positive (rerandomized as          | Ventana DDisH test result. A missing HER2 status is presented for vv .! due to protocol violation, but the sample of this patent was HER2-positive (rerandomized as          | Ventana DDisH test result. A missing HER2 status is presented for vv .! due to protocol violation, but the sample of this patent was HER2-positive (rerandomized as | Ventana DDisH test result. A missing HER2 status is presented for vv .! due to protocol violation, but the sample of this patent was HER2-positive (rerandomized as | Ventana DDisH test result. A missing HER2 status is presented for vv .! due to protocol violation, but the sample of this patent was HER2-positive (rerandomized as |
| Program:                                                                                                                                                                     | Program:                                                                                                                                                                     | Program:                                                                                                                                                                     | Program:                                                                                                                                                                     | Program:                                                                                                                                                            | Program:                                                                                                                                                            | Program:                                                                                                                                                            |
| root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_her2.sa S                                                                       | root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_her2.sa S                                                                       | root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_her2.sa S                                                                       | root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_her2.sa S                                                                       | root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_her2.sa S                                                              | root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_her2.sa S                                                              | root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_her2.sa S                                                              |
| :qndang                                                                                                                                                                      | :qndang                                                                                                                                                                      | :qndang                                                                                                                                                                      | :qndang                                                                                                                                                                      | :qndang                                                                                                                                                             | :qndang                                                                                                                                                             | :qndang                                                                                                                                                             |
| root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INIERIM/prod/output/t_dm_her2_IT.                                                                         | root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INIERIM/prod/output/t_dm_her2_IT.                                                                         | root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INIERIM/prod/output/t_dm_her2_IT.                                                                         | root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INIERIM/prod/output/t_dm_her2_IT.                                                                         | root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INIERIM/prod/output/t_dm_her2_IT.                                                                | root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INIERIM/prod/output/t_dm_her2_IT.                                                                | root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INIERIM/prod/output/t_dm_her2_IT.                                                                |
| out                                                                                                                                                                          | out                                                                                                                                                                          | out                                                                                                                                                                          | out                                                                                                                                                                          | out                                                                                                                                                                 | out                                                                                                                                                                 | out                                                                                                                                                                 |
| 06N0V2018 13:29 Page l of 1                                                                                                                                                  | 06N0V2018 13:29 Page l of 1                                                                                                                                                  | 06N0V2018 13:29 Page l of 1                                                                                                                                                  | 06N0V2018 13:29 Page l of 1                                                                                                                                                  | 06N0V2018 13:29 Page l of 1                                                                                                                                         | 06N0V2018 13:29 Page l of 1                                                                                                                                         | 06N0V2018 13:29 Page l of 1                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

Regarding HER-2 status, three samples were retested for HER2 positivity using IQFISH Dako PharmDx since DDISH HER2 testing from Ventana gave invalid results. Two patients were enrolled based on the Dako FISH results.

```
Randomized Patient Population Protoco1: B027938 Status: FINAL SnapshotDate:12sEp2018
```

Table 13: Summary of PIK3CA mutation status - Study KATHERINE

```
Clinical Cut-Off Date:25JUL2018 Trastuzumab Trastuzumab Emtansine (N=743) (N=743) Pik3cA mutation status Staining score n 743 743 Mutated 174(23.49) 176 (23.74) Non-mutated 503(67.76) 510(68.6%) Unknown/missing 66(8.96) 57(7.74) Program: root/elinical_studies/R05304020/CDPr3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_pikmut. S85 Output: root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/output/t_dm_pikmut_I T.out 23N0V2018 17:29 Page l of 1
```

## Table 14: Cardiac history by treatment regimen - Study KATHERINE

```
Randomized Patient Population Prot0co1: B027938 Status: FINAL Snapshot Date: 12SEp2018 Clinical Cut-0ff Date: 25JuL2018
```

|                                                      | Trastuzumab (N=743)   | Trastuzumab Emtansine (N=743)   |
|------------------------------------------------------|-----------------------|---------------------------------|
| Total mumber of patients with at least one condition | 63 (8.5%)             | 67 (9.0%)                       |
| Ouerall total number of conditions                   | 69                    | 74                              |
| Previous Cardiae History                             |                       |                                 |
| Total number of patients with at least one condition | 6 (0.8号)              | (0.5%]                          |
| Total number of conditions                           | 6                     | 4                               |
| Angina Pectoris                                      | 0                     | 0                               |
| Arterial Hypertension                                | (0.14)                | 1 (0.14)                        |
| Cardiag Arrhythmias That Required Treatment          | 1 (0.14)              | 1 (0.1%)                        |
| Heart Failure                                        | 0                     | 0                               |
| Myocardial Infarction                                | 0                     | 1 (0.14)                        |
| Other                                                | 4 (0.5%)              | 1 (0.1%)                        |
| Current Cardiae History                              |                       |                                 |
| Total number of patients with at least one condition | 57 (7.74)             | 64 (8.64)                       |
| Total number of conditions                           | 63                    | 70                              |
| Angina Pectoris                                      |                       | 1 [0.14)                        |
| Arterial Hypertension                                | 29 (3.9%)             | 33 (4.4%)                       |
| Cardiac Arrhythmias That Reguired Treatment          | 3 (0.4%)              | 5 (0.74)                        |
| Heart Failure                                        | 1 (0.14)              | 0                               |
| Myocardial Infarction                                | 2 (0.35)              | 0                               |
| Other                                                | 28 (3.89)             | 31(4.2)                         |

```
Program: root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/ progrsm/t_ch.sas Output: root/clinical_studies/R05304020/CDpT3519/B027938/data_analysis/CSR_INTERIM/prod/ output/t_ch_Ir.out 09NOV201B 1I:39 Page l of 1 spacing modified from t_ch_IT
```

<div style=\"page-break-after: always\"></div>

## Table 15: Prior breast cancer therapy - Study KATHERINE

```
Randomized Patient Population Protoco1:B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date: 25JUL2018
```

|                                                                   | Trastuzumab (N=743)   | Trastuzumab Emtansine (N=743)   |
|-------------------------------------------------------------------|-----------------------|---------------------------------|
| Cumulatiue Dose of Prior Anthracyclines [mg/m2]                   |                       |                                 |
| (for Patients with knowm dose)                                    |                       |                                 |
| n                                                                 | 522                   | 525                             |
| Mean (SD)                                                         | 268.7(98.03)          | 263.9(100.77)                   |
| Median                                                            | 282.0                 | 295.0                           |
|                                                                   | 9 - 600               | 2-488                           |
| Prior Therapy Type                                                |                       |                                 |
| Chemo (Anthracycline)                                             | 564 75.951            | 579 77.911                      |
| Chemo (Non-Anthracyeline)                                         | 743 (100.04)          | 743 (100.04)                    |
| Hormonal                                                          | 524                   | 528 71.14)                      |
| Trastuzumab                                                       | 70.5%) 743 (100.0t)   | 743 (100.04)                    |
| HER2-directed therapy other than trastuzumsb                      | 147 19.851            | 143 19.24)                      |
|                                                                   | 1 0.14)               | 2 0.34)                         |
| Overall Clinical Response after Neoadjuvant Therapy               |                       |                                 |
| Complete response                                                 | 82 11.0+)             | 74 (10.0)                       |
| Partial response                                                  | 501 67.4%)            | 66 67.24)                       |
| Stable disease                                                    | 72 9.741              | 7.941                           |
| Unknown but no progression                                        | 86                    | 69 110 14.84)                   |
| Not applicable                                                    | 11.6+) 2 0.3%)        | 1 0.1)                          |
| Prior Therapy Administered                                        |                       |                                 |
| Trastuzumab                                                       |                       |                                 |
| n                                                                 | 743 743 (100.0%)      | 743 743 (100.0%)                |
| Trastuzumab overall Other HER2-targeted agents                    |                       |                                 |
| n                                                                 | 147 2 0.34)           | 143 0.54)                       |
| Afatinib Lapatinib                                                | 5 1                   | 6 0.8t)                         |
| Neratinib                                                         | 0.7%) 0.14)           | 1 0.14)                         |
| Pertuzumab                                                        | 139 (18.74)           |                                 |
| Nanoparticle Paclitaxel                                           | 743                   | 133 (17.94)                     |
| Other agents                                                      |                       |                                 |
| Taxanes overall n                                                 |                       | 743                             |
| Docetaxel                                                         | 424 57.161            | 407 54.84)                      |
| Paclitaxel                                                        | 6 0.8%) 331 44.5%)    | 6 0.8号) 098 (47.14)             |
| *cispiatin/*cyclophosphamide/*epirubicin/*etoposide/ Fluorouracil | 0                     | 3 0.44)                         |
| Bevacizumab Bkml20                                                | 1 0.14)               | 1 0.14)                         |
|                                                                   | 0                     | 1 0.14)                         |
| Blinded Bkml20                                                    | 0 1 0.14)             | 1 0.1t) 0                       |
| Capecitabine Carboplatin                                          | 147 19.841 6          | 138 18.6) 0.54)                 |
| Cisplatin Cyelophosphamide                                        | 0.841 426 57.341      | 4 440 59.24)                    |
| Cyclophosphamide/Fluorouracil                                     | 0.1)                  | 0.14)                           |
|                                                                   | 1                     |                                 |
|                                                                   |                       | 10                              |
| Cyelophosphamide/Fluorouracil/Methotrexate                        | 1 0.14)               |                                 |
| Doxorubicin                                                       | 199                   | 194 26.14)                      |
|                                                                   | 26.86) 49.341         |                                 |
| Epirubiein                                                        | 366                   | 389 52.49) 142                  |
| Fluorouracil                                                      | 140 18.8%)            | 19.1t) 0.44)                    |
| Methotrexate                                                      | 4 0.561 2 0.351       | 3 0                             |
| Pirarubicin Tegafur                                               | 1 0.191               | 0                               |
| Vinorelbine                                                       |                       |                                 |
|                                                                   | 0.1%)                 | 0                               |

```
Program: root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/pr0gram/t_dm_trt.sas :andano root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/output/t_dm_trt_IT.o ut 27DEC2018 18:05
```

*Note that due to a transcriptional error the regimen *cisplatin + epirubicin +fluorouracil (FEC) is showing as

*cisplatin/*cyclophosphamide/*epirubicin/*etoposide/Fluorouracil in this table; patients received the standard FEC combination and did not receive either cyclophosphamide or etoposide.

<div style=\"page-break-after: always\"></div>

## Table 16: Breast cancer surgery - Study KATHERINE

```
Breast Cancer Surgery. Randomized Patient. Population Prot0col:B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date: 25JUL2018
```

<!-- image -->

|                                                                                    | Trastuzuwmab (N=743)              | Trastuzumab Emtansine (N=743)       |
|------------------------------------------------------------------------------------|-----------------------------------|-------------------------------------|
| Time to definitive surgery (in months from randomization) n Mean (SD) Median Range | 743 -1.85 (1.41) -1.61 -14.2 -9.3 | 743 -1.92 (2.32) -1.64 -49.3 - 10.8 |
| Patients with any type of definitive breast cancer surgery                         | 743 (100.0%)                      | 743(100.06)                         |
| Lumpectomy/partial mastectomy                                                      | 297( 40.0%)                       | 295 (39.76)                         |
| Simple/radical/modified radical mastectomy                                         | 446(60.0%)                        | (60.3%)                             |
| Other surgeries and biopsies                                                       | 663(89.2%)                        | 665 (89.55)                         |
| Reconstructive surgery                                                             | 57 [ 7.741                        | 68 9.25)                            |
| Re-excision of surgical margins                                                    | 24( 3.21)                         | 30 [ 4.05)                          |
| Sentinel node biopsy/axillary sampling                                             | 270( 36.3)                        | 263 (35.45)                         |
| Axillary dissection                                                                | 360 (48.5)                        | 367 (49.46)                         |
| Biopsy                                                                             | 552(74.34)                        | 557( 75.06)                         |

```
Program: root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/program/t_dm_surg.sa S :andang root/elinical_studies/R05304020/CDPr3519/B027938/data_analysis/CSR_INTERIM/prod/output/t_dm_surg_IT. out 21N0V2018 11:08 Paqelof 1
```

## Numbers analysed

## Table 17: Analysis Populations by Treatment Regimen - Study KATHERINE

```
RandomizedPatients Protocol:B027938 StatuS:FINAL Snapshot Date: 12SEP2018 ClinicalCut-Off Date: 25JUL2018
```

|                                      |   Trastuzumab |   TrastuzumabEmtansine |
|--------------------------------------|---------------|------------------------|
| Patients randomised - ITT population |           743 |                    743 |
| Safety Population                    |           720 |                    740 |
| Randomized to Trastuzumab            |           719 |                      1 |
| RandomizedtoTrastuzumabemtansine     |             1 |                    739 |

Patients who received no Study Treatment are excluded from the Safety Analysis Population.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary efficacy endpoint:  IDFS (ITT)

Table 18: Summary of time to first IDFS event - Study KATHERINE

Randomized Patient Population

Protoco1:B027938

Status: FINAL

Snapshot Date: 12SEP2018

ClinicalCut-Off Date:25JUL2018

<!-- image -->

|                                                                                                                                                                                                                                                                | Trastuzumab (N=743)                               | Trastuzumab Emtansine (N=743)                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Patients with event (名) Earliest contributing event Distant recurrence - non CNS Distant recurrence -CNS Locoregional recurrence Contraiateral breast cancer Death without prior event Patients without event (8) Time to event (months) Median 958CIforMedian | 165 (22.2%) 79 30 43 10 3 578 (77.8%) NE 41.59,NE | 91 (12.28) 32 11 32 652 (87.8%) NE NE NE          |
| 258 and 758-ile Range Stratified Analysis p-value_(log-rank) Hazard Ratio 958CI                                                                                                                                                                                | 0.1*1 to62.6*                                     | 0.1* to 62.7* <.0001 0.48 (0.37,0.62)             |
| Unstratified Analysis p-value_(log-rank) Hazard Ratio 958CI 3-years Duration Patients remaining at risk Event Free Rate (8) 958CI                                                                                                                              | 342 77.02 (73.78,80.26)                           | <.0001 0.50 (0.39, 0.64) 409 88.27 (85.81, 90.72) |

primary analysis. Hazard ratios were estimated by Cox regression. Stratified hazard ratio and p-value have been adjusted for the randomization stratification variables as recorded in the IxRs: clinical stage at presentation , honmone receptor status,  preoperative HER2directed therapy, and pathologic nodal status evaluated after preoperative therapy. Patients who experience &gt;l IDrs event are reported in the category associated with their earliest IDFS event. If &gt;l event is reported on the same date, patients are reported in the category according to the following hierarchy: [l] Distant recurrence; [2] Locoregional recurrence;[3] Contralateralbreast cancer;[4]Deathwithoutprior event.cNS metastases isasubsetofDistantrecurrence.

Kaplan-MeierPlotofTime toFirstIDFSEvent(Months),RandomizedPatientPopulation

Protocol:BO27938 Status:FINAL

<!-- image -->

Program:root/cinical\\_studies/RO5304020/CDPT3519VBO27936/data\\_analysis/CSR\\_INTERIM\\_ADHOCS/prodiprogram/PR5197\\_g\\_ef\\_.km.sas Output: r0ot/clinica1\\_studlies/RO5304020/CDPT3519/BO27938/data\\_analysis/CS R\\_INTERIM\\_ADH OCSJpr0d/putput/PR5197\\_g\\_ef\\_icm\\_IDFS\\_IT.pdf 03MAY2019 13:33

Figure 3:  Kaplan-Meier Plot of Time to First IDFS Event (Months), Randomized Patient Population - Study KATHERINE

<div style=\"page-break-after: always\"></div>

Table 19: Summary of IDFS reasons for censoring- Study KATHERINE

<!-- image -->

The diverse categories of recurrence that fulfilled the definition of IDFS event were provided (see Table 18 ). In this case the earliest event was considered. The different numbers presented in Table 20 imply that some patients might have ascended in category because they experienced an additional IDFS event, one with a higher hierarchy, within 61 days of the first one. CNS recurrence was prioritised in the hierarchy above non-CNS recurrence in cases where the patient had both types of relapse at the same IDFS event defining date.

The percentages presented in the Table 20 are calculated using the N of each arm (i.e. 743) as a denominator. Taking into account the possibility of additional IDFS events in the following assessment, the numbers of patients categorised as 'contralateral breast cancer' and 'death without prior event' were stable whereas a few patients with 'locoregional recurrence' were moved to the distant recurrence categories. The high proportion of patients with CNS recurrence in the Kadcyla arm was maintained.

Table 20: Summary of first occurrence of an IDFS event applying hierarchy and time window by treatment regimen: randomized patient population- Study KATHERINE

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 21: Summary of first occurrence of an IDFS event applying no hierarchy - Study KATHERINE

```
Patient Population Prot0co1:B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date: 25JUL20l8
```

|                                       | Trastuzumab (N=743)   | Trastuzumab (N=743)   | Trastuzumab Emtansine (N=743)   |
|---------------------------------------|-----------------------|-----------------------|---------------------------------|
| Iotal Patients with IDFS Event: n (&) |                       | 165 (22.2)            | 91 (12.28)                      |
| Category of IDFS Event: n ()          |                       |                       |                                 |
| Distant recurrence - CNS              | 30                    | (18.28)               | 43 (47.38)                      |
| Distant recurrence - non CNS          | 86                    | (52.1)                | 38 (41.8%)                      |
| Locoregional Event                    | 52                    | (31.58)               | 14 (15.48)                      |
| Contralateral Event                   | 10                    | (6.1)                 | 3 (3.3%)                        |
| Death                                 | 3                     | 1.8%)                 | 2 ( 2.28)                       |

categories.

```
Program: root/clinical_studies/R05304020/CDPI3519/B027938/data_analysis/C5R_INIERIM_ADH0C5/prod/program/PR540 9t_ef_sum.sas Output: root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INIERIM_ADH0CS/prod/output/ PR5409_t_ef_sum_IDES_IT.out. 26JUN2019 15:22 Page l of 1
```

Note: the 61-day time window was not applied.

*The denominator for the proportions in the category of IDFS events in this table is the total of patients with IDFS event in each arms, i.e. 165 in trastuzumab and 91 in Kadcyla

Table 22: Summary of CNS recurrence - Study KATHERINE

Summary\\_of\\_CNS\\_recurrence, Randomized Patient Population

Protocol:B027938Status:FINAL

Snapshot Date: 12SEP2018  Clinical Cut-0ff Date: 25JUL2018

|                                                                                                                              |   (N=743) |   Trastuzumab Trastuzumab Emtansine (N=743) |
|------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------------------|
| Total mumber of patients with CNs recurrence*                                                                                |        40 |                                          45 |
| CNS recurrence as earliest IDFS event                                                                                        |        08 |                                          43 |
| CNS recurrence as first IDFS event, including patients with additional IDES events within 6i days of their first IDFS event* |        32 |                                          44 |
| CNS recurrence after first IDFS event*                                                                                       |         8 |                                           1 |
| Total mumdber of patients with CNS as only event^                                                                            |        21 |                                          36 |

*Patients who experience a CNS recurrence within 6l\\_days of their 1st IDFS event are reported in the category\\_^CNS recurrence as first IDES event'. CNS recurrence occurring more\\_than 61 days after the first IDES event are reported in the category CNS recurrence after first IDES event\". ^No time window applied.

root/clinical\\_studies/R05304020/CDPT3519/B027938/data analysis/CSR INTERIM ADH0CS/prod/program/

root/clinical\\_studies/R05304020/CDPT3519/B027938/data analysis/CSR INIERIM ADH0CS/prod/output/ PR5409 t ef cms time IT.out

```
Program: PR5409 t ef cns time.sas Output: 26JUN2019 15:23 Page 1 of 1
```

<div style=\"page-break-after: always\"></div>

Table 23: Competing risk analysis of incidence of first IDFS events for 1486 patients - Study KATHERINE

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary efficacy endpoints

## IDFS including Second Primary Non-breast Cancer (IDFS-SPNBC)

## Table 24: Summary of Time to First IDFS Including SNPBC - Study KATHERINE

```
Randomized Patient Population Protocol: B027938 Status: FINAL Snapshot Date: 12sEP2018 Clinical Cut-Off Date: 25JUL2018
```

<!-- image -->

Censored value.Hazard ratios were estimated by Cox regression. Stratified hazard ratio and p-value have been adjusted for the randomization stratification variables as recorded by IxRs: clinical stage at presentation , hormone receptor status, preoperative HER2directed therapy, and pathologic nodal status evaluated after preoperative therapy. Patients who experience &gt;l IDFs event are reported in the category associated with their earliest IDFs event. If &gt;l event is reported on the same date, patients are reported in the category according\\_to the following hierarchy: [1] Distant recurrence; [2] Locoregional recurrence; [3] Contralateral breast cancer; [4] Second primary non-breast invasive cancer [5] Death without prior event.CNs metastases is a subset of Distant recurrence.

Program: root/clinical\\_studies/R05304020/cDPT3519/B027938/data\\_analysis/CSR\\_INTERIM/prod/

```
program/t_ef_tte.sas
```

Output: root/clinical\\_studies/R05304020/CDPT3519/B027938/data\\_analysis/CSR\\_INTERIM/prod/ output/t ef tte SPNBC IT.out

<div style=\"page-break-after: always\"></div>

Figure 4: Kaplan-Meier curve of time to IDFS including second primary non-breast cancer Study KATHERINE

<!-- image -->

## Disease Free Interval (DFS)

```
Randomized Patient Population Protoco1:B027938 Status: FINAL Snapshot Date: 12sEP2018 ClinicalCut-Off Date: 25JUL2018
```

Table 25: Summary of Time to First DFS Event - Study KATHERINE

|                                                                      | Trastuzumab (N=743)          | Trastuzumab Emtansine (N=743)   |
|----------------------------------------------------------------------|------------------------------|---------------------------------|
| Patients with event () Patients without event (&)                    | 167 (22.5) 576 (77.5%)       | 98 (13.2%) 645 (86.8%)          |
| Time to event (months) Median 95 CI for Median 25% and 75&-ile Range | NE NE 41.17,NE 0.1* to 62.6* | NE NE NE 0.1* to 62.7*          |
| Stratified Analysis p-value (log-rank) Hazard Ratio 95% CI           |                              | <.0001 0.51 (0.40, 0.66)        |
| Unstratified Analysis p-value (log-rank) Hazard Ratio 95 CI          |                              | <.0001 0.53 (0.41, 0.68) 408    |
| 3-years Duration Patients remaining at risk Event Free Rate () 95 CI | 341 76.89 (73.65, 80.14)     | 87.41 (84.88, 89.93)            |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Output: root/:linical\\_studies/RO5304020VCDPT3519/BO27938/data\\_analysis.CSR\\_INTERIM\\_ADHOC S/prod/output/PR5197\\_g\\_ef\\_im\\_DFS\\_IT pxif 03MA Y2C19 13:49

Figure 5: Kaplan-Meier Plot of Time to First DFS Event (Months), Randomized Patient Population - Study KATHERINE

## Overall Survival (OS)

```
Randomized Patient Population Protocol: B027938 StatuS: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date: 25JUL2018
```

Table 26: Summary of Overall Survival - Study KATHERINE

<!-- image -->

Kaplan-MeierPlotofOverallSurvival(Months),RandomizedPatientPopulation

Protocol:BO27938Status:FINAL

SnapshotDate:12SEP2018ClinicalCut-OffDate:25JUL2018

<div style=\"page-break-after: always\"></div>

<!-- image -->

Output: r0ot/clinica\\_studies/ROS304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM\\_AOHOCSJpr0d/output/PRS197\\_g\\_ef\\_km\\_OS\\_IT.pdif 03MAV2019 13:36

Figure 6: Kaplan-Meier Plot of Overall Survival - Study KATHERINE

## Distant recurrence free interval (DRFI)

## Table 27: Summary of Distant Recurrence-Free Interval (DRFI) - Study KATHERINE

```
Randomized Patient Population Protoco1:B027938 StatuS: FINAL Snapshot Date: 12sEP2018 Clinical Cut-Off Date: 25JUL2018
```

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 7: Kaplan-Meier Plot of Distant Recurrence-Free Interval (DRFI) - Study KATHERINE

<!-- image -->

## Patient reported outcomes (PRO)

Table 28: Summary of Completion Rates by Visit and Treatment Regimen for EORTC-QLQ-C30 and EORTC-QLQ-BR23 Questionnaires (ITT Population) - Study KATHERINE

|                                                       | EORTC QLQ-C30         | EORTC QLQ-C30                  | EORTCQLQ-BR23         | EORTCQLQ-BR23                   |
|-------------------------------------------------------|-----------------------|--------------------------------|-----------------------|---------------------------------|
| Visit                                                 | Trastuzumab (N = 743) | Trastuzumab Emtansine (N =743) | Trastuzumab (N = 743) | Trastuzumab Emtansine (N = 743) |
| Screening                                             |                       |                                |                       |                                 |
| Evaluable patients a                                  | 743                   | 743                            | 743                   | 743                             |
| Completed ≥ 1 question b                              | 632 (85.1%)           | 655 (88.2%)                    | 630 (84.8%)           | 655 (88.2%)                     |
| Cycle 5                                               |                       |                                |                       |                                 |
| Evaluable patients a                                  | 674                   | 684                            | 674                   | 684                             |
| Completed ≥ 1 question b                              | 592 (87.8%)           | 610 (89.2%)                    | 591 (87.7%)           | 610 (89.2%)                     |
| Cycle 11                                              |                       |                                |                       |                                 |
| Evaluable patients a                                  | 613                   | 636                            | 613                   | 636                             |
| Completed ≥ 1 question b                              | 528 (86.1%)           | 529 (83.2%)                    | 527 (86.0%)           | 528 (83.0%)                     |
| TrastuzumabCompletion/Early Discontinuation           |                       |                                |                       |                                 |
| Evaluable patients a                                  | 743                   | 73                             | 743                   | 73                              |
| Completed ≥ 1 question b                              | 584 (78.6%)           | 58 (79.5%)                     | 584 (78.6%)           | 58 (79.5%)                      |
| TrastuzumabEmtansine Completion/Early Discontinuation |                       |                                |                       |                                 |
| Evaluable patients a                                  | 0                     | 743                            | 0                     | 743                             |
| Completed ≥ 1 question b                              | 0                     | 526 (70.8%)                    | 0                     | 526 (70.8%)                     |
| FU Month 6                                            |                       |                                |                       |                                 |
| Evaluable patients a                                  | 621                   | 667                            | 621                   | 667                             |
| Completed ≥ 1 question b                              | 446 (71.8%)           | 496 (74.4%)                    | 446 (71.8%)           | 496 (74.4%)                     |
| FU Month12                                            |                       |                                |                       |                                 |
| Evaluable patients a                                  | 568                   | 628                            | 568                   | 628                             |
| Completed ≥ 1 question b                              | 414 (72.9%)           | 458 (72.9%)                    | 414 (72.9%)           | 456 (72.6%)                     |

Note:PercentagesarebasedonthenumberofITTpopulation.

a Evaluable patients as defined by the protocol and, for cycle 5, cycle 11, follow-up Month 6, and follow-upMonth 12, additionally including all patientswhocompleted themeasure at this time point even if not mandatedbytheprotocol.Evaluablepatients in the trastuzumabemtansine arm atthetrastuzumabcompletion/earlydiscontinuationvisitreflected thenumberofpatients randomized tothetrastuzumabemtansine armbutreceived atleastonedoseoftrastuzumab

b Measure completion is defined as the completion of at least 1 question on the respective questionnaire (EORTC QLQ-C30/EORTC QLQ-BR23).

Sources:EORTCQLQ-C30completionrates,EORTCQLQ-BR23completionrates

<div style=\"page-break-after: always\"></div>

## Table 29: Clinically Meaningful Deterioration in Functions (Cognitive, Physical, Role) and GHS/HRQoL by Visit - EORTC QLQ-C30 - Study KATHERINE

```
Randomized Patient Population Protocol:B027938 Status: FINAL Snapshot Date:12sEP2018 Clinical Cut-0ff Date: 25JuL2018
```

Parameter Trastuzumab Trastuzumab Emtansine Timepoint (N=743) (N=743) Cogmitive Functioning n* 612 (100.0%) 640 (100.0%) Cycle 5 177 (28.9%) 187 29.2%) Cycle 11 182 (29.7%) 181 28.3%) Trastuzumab completion/earlydiscontinuation 190 (31.0%) 19 3.0%) Trastuzumab emtansine completion/early 0 183 （ 28.6%) discontinuation Follow-up Month 6 147 24.0%) 182 28.4%) Follow-up Month 12 127 (20.8%) 173 27.0%) Physical Functioning n* 612 (100.0%) 640 (100.0%) Cycle 5 98 (16.0) 119 18.6) Cycle 11 73 11.9%) 106 16.6%) Trastuzumab completion/earlyciscontinuation 91 14.9) 8 1.3%) Trastuzumab emtansine completion/early 0 112 17.5*) discontinuation Follow-up Month 6 61 10.0%) 78 ( 12.2) Follow-up Month 12 59 9.68) 81 12.7%) Global Health Status/ QoL n* 612 (100.0%) 640 (100.0%) Cycle 5 116 (19.0) 140 21.9) Cycle 11 91 14.9%) 132 ( 20.6%) Trastuzumab completion/earlydiscontinuation 112 18.3%) 9 1.4%) Trastuzumab emtansine completion/early 0 114 （ 17.8%) discontinuation Follow-up Month 6 82 13.4%) 93 （ 14.5) Follow-up Month 12 60 9.8%) 82 ( 12.8%) Role Functioning n* 612 (100.0%) 640 (100.0%) Cycle 5 133 21.7) 169 26.4%) Cycle 11 110 18.0%) 140 21.9%) Trastuzumab completion/earlydiscontinuation 122 19.9%) 13 2.0%) Trastuzumab emtansine completion/early 0 129 (20.2%) discontinuation Follow-up Month 6 67 (10.9%) 107 (16.7) Follow-up Month 12 70 (11.4%) 93(14.5%) *n = number of patients with baseline and at least one post-baseline assessment in the respective subscale. Clinically meaningful deterioration is defined as a decrease in score of 10 points in Physical function and HRQoL; decrease of 7 points in Cognitive function and decrease of 14 points in Role function.

<div style=\"page-break-after: always\"></div>

## Table 30: Clinically Meaningful Deterioration in Certain Symptoms by Visit - EORTC QLQ-C30 and EORTC QLQ-BR23 - Study KATHERINE

```
Clinically Meaningful Increase in symptoms - EORTC QLQ-C30 and QLQ-BR23, by Visit, Randomized Patient Population Protocol: B027938 Status: FINAL Snapshot Date: 12SEP2018 ClinicalCut-Off Date:25JUL2018
```

| Parameter Timepoint                                    | Trastuzumab (N=743)   | Trastuzumab (N=743)   | Trastuzumab Emtansine (N=743)   | Trastuzumab Emtansine (N=743)   |
|--------------------------------------------------------|-----------------------|-----------------------|---------------------------------|---------------------------------|
| Appetite Loss                                          |                       |                       |                                 |                                 |
| n*                                                     | 612                   | (100.0%)              |                                 | 640 (100.0%)                    |
| Cycle 5                                                | 65                    | (10.6%)               | 134                             | (20.9%)                         |
| Cycle 11                                               | 53                    | 8.7%)                 | 84                              | 13.1%)                          |
| Trastuzumab completion/early discontinuation           | 58                    | 9.5%)                 | 5                               | 0.8%)                           |
| Trastuzumab emtansine completion/early discontinuation | 0                     |                       | 96                              | 15.0%)                          |
| Follow-up Month 6                                      | 34                    | 5.6%)                 | 45                              | 7.0%)                           |
| Follow-up Month 12                                     | 44                    | 7.2%)                 | 39                              | 6.1%)                           |
| Any Hair Loss                                          |                       |                       |                                 |                                 |
| n*                                                     | 44                    | (100.0%)              | 43                              | (100.0%)                        |
| Cycle 5                                                | 3                     | 6.8%)                 | 3                               | 7.0%)                           |
| Cycle 11                                               | ②                     | 4.5%)                 | 2                               | 4.7%)                           |
| Trastuzumab completion/early discontinuation           | 4                     | 9.1%)                 |                                 |                                 |
| Trastuzumab emtansine completion/early discontinuation | 0                     |                       | 4                               | 9.3%)                           |
| Follow-up Month 6                                      | 7                     | (15.9%)               | 4                               | 9.38)                           |
| Follow-up Month 12                                     | 8                     | (18.2%)               | 5                               | (11.6%)                         |
| Systemic Therapy Side Effects                          |                       |                       |                                 |                                 |
| n*                                                     | 610                   | (100.0%)              | 638                             | (100.0%)                        |
| Cycle 5                                                | 82                    | 13.4%)                | 166                             | 26.0%)                          |
| Cycle 11                                               | 78                    | 12.8%)                | 153                             | 24.0%)                          |
| Trastuzumab completion/early discontinuation           | 94                    | 15.4%)                | 6                               | 0.9%)                           |
| Trastuzumab emtansine completion/early discontinuation | 0                     |                       | 139                             | 21.8%)                          |
| Follow-up Month 6                                      | 82                    | 13.4%)                | 88                              | (13.8%)                         |
| Follow-up Month 12                                     | 75                    | 12.3%)                |                                 | 91( 14.3%)                      |
| Diarrhoea                                              |                       |                       |                                 |                                 |
| n*                                                     |                       | 612 (100.0%)          | 640                             | (100.0%)                        |
| Cycle 5                                                | 63                    | (10.3%)               | 53                              | 8.38)                           |
| Cycle 11                                               | 69                    | (11.3%)               | 35                              | 5.5%)                           |
| Trastuzumab completion/early discontinuation           | 56                    | 9.2%)                 | 9                               | ( 1.4%)                         |
| Trastuzumab emtansine completion/early discontinuation | 0                     |                       | 31                              | 4.8%)                           |
| Follow-up Month 6                                      | 35                    | 5.7%)                 | 42                              | 6.68)                           |
| Follow-up Month 12                                     | 37                    | 6.0%)                 | 42                              | 6.6%)                           |
| Dyspnea                                                |                       |                       |                                 |                                 |
| n*                                                     | 612                   | (100.0%)              |                                 | 640 (100.0%)                    |
| Cycle 5                                                | 112                   | (18.3%)               |                                 | 132 ( 20.6%)                    |
| Cycle 11                                               | 102                   | (16.7%)               |                                 | 96 ( 15.0%)                     |
| Trastuzumab completion/early discontinuation           | 111                   | (18.1%)               | 13                              | （ 2.0%)                         |
| Trastuzumab emtansine completion/early                 | 0                     |                       | 86                              | (15.3%)                         |
| discontinuation                                        |                       |                       |                                 |                                 |
| Follow-up Month 6                                      |                       | 83(13.6%)             |                                 | 103 ( 16.1%)                    |
| Follow-up Month 12                                     |                       | 101 ( 16.5%)          |                                 | 110 ( 17.2%)                    |

<div style=\"page-break-after: always\"></div>

| Fatigue                                                |     |              |     |             |
|--------------------------------------------------------|-----|--------------|-----|-------------|
| n*                                                     |     | 612 (100.0%) | 640 | (100.0%)    |
| Cycle 5                                                | 204 | (33.3%)      | 267 | 41.7%)      |
| Cycle 11                                               |     | 171 ( 27.9%) | 210 | 32.8%)      |
| Trastuzumab completion/early discontinuation           | 175 | (28.6%)      | 15  | 2.3%)       |
| Trastuzumab emtansine completion/early discontinuation | 0   |              | 197 | 30.8%)      |
| Follow-up Month 6                                      | 129 | 21.1%)       | 157 | 24.5%)      |
| Follow-up Month 12                                     | 135 | 22.1%)       | 145 | 22.7%)      |
| Nausea / Vomiting                                      |     |              |     |             |
| n*                                                     | 612 | (100.0%)     | 640 | (100.0%)    |
| Cycle 5                                                | 82  | 13.4%)       | 114 | 17.8*)      |
| Cycle 11                                               | 73  | (11.9%)      | 102 | (15.9%)     |
| Trastuzumab completion/early discontinuation           | 63  | ( 10.3%)     | 8   | 1.3%)       |
| Trastuzumab emtansine completion/early discontinuation | 0   |              | 81  | 12.7%)      |
| Follow-up Month 6                                      | 50  | 8.2%)        | 54  | 8.4%)       |
| Follow-up Month 12                                     | 45  | 7.4%)        | 56  | ( 8.88)     |
| Insomnia                                               |     |              |     |             |
| n*                                                     | 612 | (100.0%)     | 640 | (100.0%)    |
| Cycle 5                                                | 141 | 23.0%)       | 146 | 22.8%)      |
| Cycle 11                                               | 144 | （ 23.5%)     | 136 | 21.38)      |
| Trastuzumab completion/early discontinuation           | 142 | 23.2%)       | 15  | 2.3%)       |
| Trastuzumab emtansine completion/early discontinuation | 0   |              | 125 | 19.5$)      |
| Follow-up Month 6                                      | 116 | (19.0%)      | 114 | (17.8%)     |
| Follow-up Month 12                                     | 97  | 15.8%)       |     | 111 ( 17.3) |
| Pain                                                   |     |              |     |             |
| n*                                                     | 612 | (100.0%)     | 640 | (100.0%)    |
| Cycle 5                                                | 163 | (26.6%)      | 184 | (28.8)      |
| Cycle 11                                               | 147 | 24.0%)       | 175 | (27.3%)     |
| Trastuzumab completion/early discontinuation           | 146 | 23.9%)       | 14  | 2.2%)       |
| Trastuzumab emtansine completion/early discontinuation | 0   |              | 164 | 25.6%)      |
| Follow-up Month 6                                      |     | 126 (20.6%)  | 148 | 23.1%)      |
| Follow-up Month 12                                     |     | 107 (17.5%)  | 129 | (20.2%)     |

*n=number of patients with baseline and at least one post-baseline assessment in the respective subscale.

(deterioration) of 1l points in Nausea and yomiting, Pain, Dyspnoea; increase of 9 points

Clinically meaningful increase in symptoms is defined as an increase in score in Insomnia; increase of 14 points in Appetite loss; increase of 15 points in Diarrhoea,

Constipation; increase of 10 points in Fatigue, Systemic therapy side effects, Hair loss.

<div style=\"page-break-after: always\"></div>

Table 31: Summary of Clinically Meaningful Deterioration in Certain QLQ-C30 and QLQ-BR23 Subscales (ITT Population) - Study KATHERINE

<!-- image -->

## Ancillary analyses

## Sensitivity analyses

Table 32: Overview of Sensitivity Analysis Results for IDFS (ITT Population) - Study KATHERINE

| Analysis                      | 3-year IDFS event-free rates (95% CI)   | 3-year IDFS event-free rates (95% CI)   | HR for IDFS   | 95% CI     |
|-------------------------------|-----------------------------------------|-----------------------------------------|---------------|------------|
|                               | Trastuzumab (N=743)                     | Trastuzumab emtansine (N=743)           |               |            |
| Assessment of Robustness      |                                         |                                         |               |            |
| Censoring for new anti-cancer | 77.4%                                   | 88.1%                                   | 0.51          | 0.39, 0.66 |
| Therapy                       | (74.2, 80.7)                            | (85.5, 90.7)                            |               |            |
| Censoring for Discontinuation | 81.6%                                   | 90.2%                                   | 0.54          | 0.39, 0.74 |
| of Study Treatment            | (78.3, 84.8)                            | (87.6, 92.8)                            |               |            |

Source: t\\_ef\\_tte\\_nact\\_IT,t\\_ef\\_tte\\_disc\\_IT

<div style=\"page-break-after: always\"></div>

## Subgroup analyses

IDFSForestPlotbySubgroups,RandomizedPatientPopulation

Protocol:BO27938Status:FINAL

SnapshotDate:12SEP2018ClinicalCut-OffDate:25JUL2018

|                                                                                                       |             | Trastuzumab (N=743)   | Trastuzumab (N=743)   |                 | Trastuzumab Emtansine (N=743)   | Trastuzumab Emtansine (N=743)   | Trastuzumab Emtansine (N=743)   |                 |                                           | Trastuzumab      |                    |
|-------------------------------------------------------------------------------------------------------|-------------|-----------------------|-----------------------|-----------------|---------------------------------|---------------------------------|---------------------------------|-----------------|-------------------------------------------|------------------|--------------------|
| Baseline RiskFactors                                                                                  | n           | Patients pergroup     | NEvents               | 3Year IDFS      | Patients pergroup               | NEvents                         | 3Year IDFS                      | Hazard Rato     | 95%CI                                     | Emtansine better | Trastuzumab better |
| All                                                                                                   | 1486        | 743                   | 165                   | 77.0            | 743                             | 91                              | 88.3                            | 0.50            | (0.39.0.64)                               |                  |                    |
| Clinical stageatpresentation Inoperable e                                                             | 375 1111    | 190 553               | 70 95                 | 60.2 82.8       | 185 558                         | 42 49                           | 76.0 92.3                       | 0.54 0.47       | (0.37,0.80) (0.33,0.66)                   | 王 H 1            |                    |
| Hormonereceptor status Negative(ERnegative andPgRnegative/unknown) Positive (ERand/orPgRpositive)     | 412 1074    | 203 540               | 61 104                | 66.6 80.7       | 209 534                         | 38 53                           | 82.1 90.7                       | 0.50 0.48       | (0.33,0.74) (0.35.0.67)                   | 王                |                    |
| PreoperativeHER2-directed therapy Trastuzumab alone Trastuzumabplus additional HER2-directed agent(s) | 1196 290    | 596 147               | 141 24                | 75.9 81.8       | 600 143                         | 78 13                           | 87.7 90.9                       | 0.49 0.54       | (0.37,0.6) (0.27,1.06)                    |                  |                    |
| Pathological nodal statusafterpreoperativetherapy Node positive Node negative/not done                | 689 797     | 346 397               | 103 62                | 67.7 84.6       | 343 400                         | 62 29                           | 83.0 92.8                       | 0.52 0.44       | (0.38,0.71) (0.28,0.68)                   | 王                |                    |
| AgeGroup (yrs) <40                                                                                    | 296         |                       | 37                    | 74.9            | 143                             | 20                              | 86.5                            | 0.50            | (0.29.0.86)                               | 1                |                    |
| 40-64                                                                                                 | 1064        | 153 522               | 113                   | 77.1            | 542                             | 64                              | 88.8                            | 0.49            | (0.36,0.67)                               |                  |                    |
| 65-74 >=75                                                                                            | 117 9       | 61 7                  | 13 2                  | 80.5 85.7       | 56 2                            | 7 0                             | 86.9 100.0                      | 0.60 <0.01      | (0.24,1.51) (0.00.NE)                     |                  |                    |
| Race                                                                                                  |             |                       |                       |                 |                                 |                                 |                                 |                 |                                           |                  |                    |
| White Black orAfrican American                                                                        | 1082 40     | 531 19                | 107                   | 79.1 66.0       | 551 21                          | 62 1                            | 88.8 94.7                       | 0.51 0.13       | (0.37,0.69) (0.02.1.10)                   |                  |                    |
| Asian                                                                                                 | 129         | 64                    | 6 18                  | 71.9            | 65                              | 13                              | 82.5                            | 0.65            | (0.32,1.32)                               |                  |                    |
| Amenican Indian orAlaskaNative Native Hawalian or Other PacificIslander                               | 86 1        | 50 1                  | 20 0                  | 60.3 100.0      | 36                              | 7                               | 81.8                            | 0.44 NE         | (0.18,1.03) (NE.NE)                       |                  |                    |
| Multiple Unknown                                                                                      | 2 146       | 1 77                  | 0 14                  | 100.0 08        | 1 69                            | 8                               | 100.0 90.7                      | NE 0.58         | (NE,NE) (0.24,1.38)                       |                  |                    |
| MenopausalStatus atscreening Premenopausal Postmenopausal                                             | 812 674     | 413 330               | 95 70                 | 76.7 77A        | 399 344                         | 49 42                           | 87.8 88.8                       | 0.49 0.51       | (0.35.0.69) (0.35,0.75)                   |                  |                    |
| PrimaryTumorStage(atinitial diagnosis)                                                                | 180         |                       |                       |                 | 99                              |                                 | 94.8                            | 0.33            |                                           |                  |                    |
| cT1 cT2                                                                                               | 754         | 81 389                | 13 70                 | 83.4 82.0       | 365                             | 6 36                            | 90.4                            | 0.52            | (0.13.0.88) (0.35.0.78)                   | 王                |                    |
| CT3                                                                                                   | 362 113     | 185                   | 49                    | 71.0 57.2       | 177                             | 21 19                           | 89.8 65.8                       | 0.38 0.74       | (0.23,0.63)                               |                  |                    |
| cT4.cT4a,cT4b,cT4c cT4d                                                                               | 7           |                       | 20 13                 | 65.3            | 59                              | 6                               | 78.6                            | 0.50            | (0.39.1.38) (0.21,1.17)                   |                  |                    |
| Regional LymphNodeStage(atinitial diagnosis)                                                          | 476         |                       |                       |                 |                                 |                                 |                                 | 0.32            |                                           |                  |                    |
| cNO cN1                                                                                               | 755         | 370                   | 9E 79                 | 85.2 78.2       | 237 385                         | 12 53 13                        | 95.9 87.2                       | 0.58            | (0.17.0.61) (0.41,0.82)                   |                  |                    |
| CN2                                                                                                   | 174 76      | 93                    | 35 14                 | 61.6            | 3                               | 13 0                            | 81.0                            | 0.42 0.64       | (0.22,0.80) (0.30.1.35)                   |                  |                    |
| CN3 cNX                                                                                               |             | 2                     | 1                     | 48.0 100.0      |                                 |                                 | 68.1 100.0                      | <0.01           | (0.00,NE)                                 |                  |                    |
| ypT0.ypT1a.ypT1b,ypT1mic,yTs ypT1.ypT1c                                                               |             | 9                     | 21                    | 61.1            | 75                              | 21                              | 79.8                            | 0.40            | (0.31,0.82)                               |                  |                    |
|                                                                                                       | 637         | 306                   |                       | 83.6            | 331                             | 40                              | 88.3                            |                 |                                           |                  |                    |
|                                                                                                       | 108         | 184                   | 52 42                 | 75.9            | 175 174 51                      | 14                              | 91.9                            | 0.66 0.34       | (0.44.1.00) (0.19.0.62)                   |                  |                    |
| ypT2                                                                                                  |             | 185                   | 44                    | 74.3            |                                 | 25 9                            | 88.3                            | 0.50            |                                           |                  |                    |
| ypT3 yT4.yT4a,yT4b.ypT4c                                                                              | 1           | 57 1                  | no 1                  | 29.2 100.0 NE   |                                 |                                 | 66.7 75.0                       | 0.27 66666 NE   | (0.18,0.88) (0.05.1.45) (0.00.NE) (NE,NE) |                  |                    |
| ypT4d ypTX Regional LymphNodeStage(atdefinitive surgery) ypNO ypN1 ypN2                               | 679 433 199 | 335 213 100           | 56 6                  | 83.9 75.8 88.7  | VVE 220 56                      | 28 29 15                        | 91.9 88.9                       | 0.46 0.49 0.43  | (0.30.0.73) (0.31.0.78) (0.24.0.77)       |                  |                    |
| ypN3 ypNx Typeof surgery of primarytumor Breast-conserving                                            | 118 593 893 | 62 298                | 47                    | 85.1            | 295                             | 1 20 71                         | 078 98.1 93.2                   | 0.71 0.17       | (0.35.142) (0.02.1.38)                    |                  |                    |
| Mastectomy Loco-regionalradiotherapy Yes                                                              | 1221        | 445                   | 118                   | 71.5            | 448                             | 76                              | 85.0                            | 0.41 0.53       | (0.24,0.68) (0.39,0.71)                   |                  |                    |
| No                                                                                                    | 265         | 597 146               | 136                   | 77A             | 624 119                         | 15                              | 88.3 88.2                       | 0.50 0.50       | (0.38,0.66) (0.27,0.93)                   |                  |                    |
| Central HER2statusbyISH Negative Positive Unknown                                                     | 1429 46 11  | 722 4                 | 29                    | 75.5            | 707                             | 87 NN                           | 88.2                            | >999.99 0.50    | (0.38,0.65) (0.00.NE)                     |                  |                    |
| Central HER2statusbyIHC 0/1+ 2+                                                                       |             | 17                    | 161 0 4               | 100.0 77.0 69.2 | 29 7                            |                                 | 66.7 94.4                       | 0.22            | (0.04,1.19)                               |                  |                    |
| 3+                                                                                                    | 1132 3      | 13 168                | 2                     | 83.9            | 12                              | 0 27 64                         | 100.0 84.7 89.0                 | <0.01 0.83 0.43 | (0.00.NE)                                 |                  |                    |
| Unknown                                                                                               |             |                       | 33 130                |                 | 158                             |                                 |                                 |                 | (0.50.1.38) (0.32,0.58) (NE,NE)           |                  |                    |
| IHC3+/ISH+                                                                                            | 1077        | 559 3                 | 0                     | 80.9 75.7 100.0 | 573                             | 60                              | 89.0                            | NE 0.43         |                                           |                  |                    |
| Central combinedIHC/ISH status IHC2+/ISH+ IHCOandIHC1+ISH+                                            | 326 25 1    | 540 168 13            | 126 EE                | 75.7 80.9       | 537 158                         | 27 0                            | 84.7 100.0                      | 0.83 <0.01 NE   | (0.31.0.58) (0.50.1.38) (O.00.NE)         |                  |                    |
| IHCUnknown/SH+ IHC3+/ISH-                                                                             |             | 1                     |                       | 83.9 100.0      | 12 7                            | 2                               | 66.7                            |                 | (NE,NE)                                   |                  |                    |
| IHC3+/ISHUnknown                                                                                      | 11 2 44     | 4                     |                       | 100.0           |                                 |                                 |                                 | 66666           | (0.00.NE)                                 |                  |                    |
|                                                                                                       |             |                       | 0                     | NE              |                                 |                                 | 94.4                            |                 |                                           |                  |                    |
| IHCUnknown/ISH Unknown                                                                                |             |                       |                       |                 |                                 |                                 |                                 | NE              | (0.04,1.19)                               |                  |                    |
|                                                                                                       |             |                       |                       | 69.2            |                                 |                                 |                                 |                 | (NE,NE)                                   |                  |                    |
|                                                                                                       |             | 2 15                  | 0 4                   |                 | 29                              | 2                               |                                 | 0.22            |                                           |                  |                    |

3yearKMrepresentstheKaplan-MeierestimateforIDFSat3years.Hazardratiorepresentsthehazardforpatientsrandomized totrastuzumabemtansinevs.patientsrandomized totrastuzumab.

Program:root/clinical\\_studies/RO5304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM/prod/program/g\\_effp.sas

Figure 8: IDFS Forest Plot by Subgroups, Randomized Patient Population - Study KATHERINE

<div style=\"page-break-after: always\"></div>

Forest plot focusing on small primary tumours and multiples sub-categorisation

## IDFS Forest Plot by Primary Tumor Stage, Randomized Patient Population

Protocol:BO27938Status:FINAL

Snapshot Date: 12SEP2018 Clinical Cut-Off Date: 25JUL2018

<!-- image -->

Staging at definitive surgery refers to pathologic staging.The total n appears higher due to patients counted in multiple tumor stage categories. Program: root/clinical\\_studies/RO5304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM\\_ADHOCS/prod/program/PR5652\\_g\\_ef\\_fp.sas

Figure 9: IDFS Forest Plot by primary tumor stage, Randomization Patient Population - Study KATHERINE

IDFS ForestPlotbyPlK3CA mutation status,Randomized PatientPopulation Protocol:BO27938Status:FINAL

SnapshotDate:12SEP2018ClinicalCut-OffDate:25JUL2018

<!-- image -->

Output:root/clinical\\_studies/RO5304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM/prod/outputg\\_effp\\_biom3\\_IDFS\\_IT.pdf 07DEC2018 17:40

Figure 10: IDFS Forest Plot by PIK3CA mutation status, Randomization Patient Population -Study KATHERINE

## IDFSForestPlotbySubgroups,RandomizedPatientPopulation Protocol: BO27938 Status: FINAL

SnapshotDate:12SEP2018ClinicalCut-OffDate:25JUL2018

<div style=\"page-break-after: always\"></div>

<!-- image -->

3 yearKMrepresents theKaplan-Meierestimate for IDFS at 3years.Hazard ratiorepresents thehazard for patients randomized to trastuzumab emtansinevs.patients randomized to trastuzumab.

Program:root/clinical\\_studies/RO5304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM/prod/program/g\\_ef\\_fp3.sas Output: root/clinical\\_studies/RO5304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM/prod/outputg\\_ef\\_fp3\\_IDFS\\_IT\\_NonCSR.pdf 15NOV2018 17:47

Figure 11: IDFS Forest Plot by prior anthracycline therapy, Randomization Patient Population -Study KATHERINE

Forest plot of Time toFirst IDFS Event(Months)for adjuvant radiotherapy (yesvs no), Randomized PatientPopulation

Protocol:BO27938Status:FINAL

SnapshotDate:12SEP2018ClinicalCut-OffDate:25JUL2018

<!-- image -->

Hazardratiorepresentsthehazardforpatientsrandomizedtotrastuzumabemtansinevs.patientsrandomizedtotrastuzumab.

Output:root/clinical\\_studies/RO5304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM\\_ADHOCS/prod/output/PR5198\\_g\\_ef\\_fp\\_IDFS\\_IT.pdf06MAY201915:01

Figure 12: IDFS Forest Plot by adjuvant radiotherapy, Randomization Patient Population -Study KATHERINE

<div style=\"page-break-after: always\"></div>

## Concomitant therapies

```
Summary of Anti-Estrogens and Aromatase Inhibitors Therapy By Treatment Regimen:, Safety Evaluable Patients Prot0col:B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date: 25JuL2018
```

Table 34: Summary of adjuvant radiotherapy by treatment regimen - Study KATHERINE

```
Trastuzumab Trastuzumab Emtansine (N=720) (N=740) Total number of patients with at least one treatment 512 (71.1) 525 (70.9%) Overall total number of treatments 652 633 ANTI-ESTROGENS Total number of patients with at least one treatment 322 (44.7) 347(46.96) Total number of treatments 348 361 TAMOXIFEN 321 (44.6%) 345 (46.64) FULVESTRANT (0.6) 2 ( 0.35) TOREMIFENE CITRATE (0.1%) 1 ( 0.14) AROMATASE INHIBITORS Total number of patients with at least one treatment 261(36.3) 235 (31.84) Total number of treatments 304 272 LETROZOLE 158 (21.9%) 125 (16.9) ANASTROZOLE 100 (13.9) 95 (12.85) EXEMESTANE 41 (5.7) 42( 5.7) Multiple uses of a specific medication for a patient were counted once in the frequency for the medication. Likewise, multiple uses within a specific medication class for a patient were counted once in the frequency for the medication class.Includes medications recorded on the 'Adjuvant hormone therapy' eCRF page. Tamoxifen: 2 patients trastuzumab arm and T-DMl arm) ; Fulvestrant: all patients; Letrozole:（ and both in the trastuzwmab_arm): Exemestane ( T-DM1 arm) Program: root/clinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/ program/t_dm_horm2.sas Output: root/elinical_studies/R05304020/CDPT3519/B027938/data_analysis/CSR_INTERIM/prod/ output/t_dm_horm2_SE.out 14NOV201810:11 Page l of 1
```

Table 33: Summary of anti-estrogens and aromatase inhibitors therapy by treatment regimen, Safety - Study KATHERINE

Safety Evaluable Patients

Protocol: B027938

Status: FINAL

Snapshot Date:12SEP2018

Clinical Cut-0ff Date:25JUL2018

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Follow-up treatments

## Table 35: Follow-up Medications by Treatment Regimen, Safety Evaluable Patients - Study KATHERINE

Protocol: B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date: 25JuL2018

| Cla55 Standardized Medication Namg                                                                                                                                                                                                         | Trastuzumab (N= 720)   | Trastuzumab Emtansine (N=740)    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|----------------------------------|
| Total numbcr of patients with at lcast one trcatment                                                                                                                                                                                       | 131 (18.2t)            | 72(9.76)                         |
| Overall total number of trcatments                                                                                                                                                                                                         | 442                    | 177                              |
| 5-HT3 ANTAGONISTS Total number of patients with at lcast one treatment                                                                                                                                                                     | 0                      | (0.1)                            |
| Total number of t treatments ONDANSETRON                                                                                                                                                                                                   | 0                      | 1 (0.1)                          |
| ALKYLATING AGENTS                                                                                                                                                                                                                          | 1.0)                   | (0.36)                           |
| Total number of patients with at least one treatment Total number of treatments CYCLOPHOSPHAMI DE                                                                                                                                          | 6 ( 0.8t) （0.1$)       | 2 2(0.3) 0                       |
| TEMO ZOLOMIDE ANGIOGENESIS INHIBITORS                                                                                                                                                                                                      | 18                     | (0.1)                            |
| Total number of patients with at least one trcatment Total number of treatments LEVETIRACETAM ANTIFUNGALAGENTS Total number of Total_number of treatments NYSTATIN ANTIMETABOLITES Total number of Total number of treatments CAPECITABINE | 0 0 0.1$)              | 0 1 (0.14) 0 0 1 (0.1$) 1 (0.1$) |
| Total number of patients with at lcast one treatment Total number of treatments BEVACIZUMAB                                                                                                                                                | (0.1) 0.14)            | 1 (0.1) 1 1 (0.18)               |
| ANTI-ESTROGENS Total numbcr of patients with at lcast onc trcatment                                                                                                                                                                        | (0.1)                  | 0                                |
| Total number of treatments FULVESTRANT                                                                                                                                                                                                     | 1 （0.1$）               | 0                                |
| ANTICONVULSANTS                                                                                                                                                                                                                            | 0                      | (0.1$)                           |
|                                                                                                                                                                                                                                            | 0                      |                                  |
|                                                                                                                                                                                                                                            |                        | (0.1)                            |
|                                                                                                                                                                                                                                            |                        | (0.1)                            |
| patients with at least one treatment                                                                                                                                                                                                       | 0                      | 1 (0.1)                          |
|                                                                                                                                                                                                                                            | 38 ( 5.3) 56           | 24 (3.28) 3 (0.48) 2 (0.34)      |
| patients with at least one treatment                                                                                                                                                                                                       |                        | 27(3.61) 31                      |
|                                                                                                                                                                                                                                            | 35 (4.9t)              |                                  |
| GEMCITABINE                                                                                                                                                                                                                                | 1.3t)                  |                                  |
| METHOTREXATE FLUOROURACIL                                                                                                                                                                                                                  | (0.64) （0.4$)          | 2 (0.38)                         |
|                                                                                                                                                                                                                                            | 10.3$)                 | 0                                |
| ANTINEOPLASTICAGENTS                                                                                                                                                                                                                       |                        |                                  |
| Total number of patients with at lcast one treatment                                                                                                                                                                                       | 12 （1.7)               | T (1.28)                         |
| Total number of trcatments PALBOCICLIB                                                                                                                                                                                                     |                        | 10 3                             |
| ERIBULIN                                                                                                                                                                                                                                   | 5 0.74) 5 0.78)        | (0.41) (0.36)                    |
| ABEMACICLIB                                                                                                                                                                                                                                | 1 0.14)                | 1 (0.18)                         |
| ALPELISIB                                                                                                                                                                                                                                  | 1 0.1$)                |                                  |
| ANTINEOPLASTIC AGENT NOS BLINDED ARRY-380                                                                                                                                                                                                  | 0 1 0.1)               |                                  |
| CAPECITABINE/PERTUZUMAB/TRASTUZUMAB EVEROLIMUS/EXEMESTANE                                                                                                                                                                                  | 1 0.1)                 |                                  |
| GOSERELIN/LETROZOLE IXABEPILONE                                                                                                                                                                                                            | 0.1t)                  | 0                                |
| LENVATINIB                                                                                                                                                                                                                                 | 0.1$)                  | 0 0                              |
| TRASTUZUMAB/VINORELBINE                                                                                                                                                                                                                    | 0                      | 1 (0.14)                         |
| ANTIPSYCHOTIC AND ANTIMANIC AGENTS Total number of patients with at lcast one treatment                                                                                                                                                    |                        |                                  |
| Total number of treatments HALOPERIDOL                                                                                                                                                                                                     |                        | 1 1(0.1)                         |
| AROMATASE INHIBITORS Total number of patients with at lcast one trcatment                                                                                                                                                                  |                        | 2(0.38) 2                        |
| Total number of treatments ANASTROZOLE                                                                                                                                                                                                     | (46*0                  | 1 (0.18) 1                       |
| LETROZOLE EXEMESTANE                                                                                                                                                                                                                       | 0.1t) 0.14)            | (0.16) 0                         |
| BENZODIAZEPINES                                                                                                                                                                                                                            | （0.1) 1                |                                  |
| BISPHOSPHONATES                                                                                                                                                                                                                            |                        |                                  |
| Total number of                                                                                                                                                                                                                            |                        |                                  |
| patients with at least one treatment Total number of treatments CLONAZEPAM                                                                                                                                                                 | (0.1)                  | 0                                |
| IBANDRONIC ACID                                                                                                                                                                                                                            | 0                      | 3 (0.46) 1(0.1)                  |
| BONE MODULATING AGENTS                                                                                                                                                                                                                     |                        |                                  |
| Total number of patients with at lcast one trcatment                                                                                                                                                                                       | 13 ( 1.8)              | 11 (1.5)                         |
| Total number of treatments ZOLEDRONIC ACID                                                                                                                                                                                                 | 13 12 ( 1.76)          | 11 10.99)                        |
| ALENDRONIC ACID                                                                                                                                                                                                                            | (0.1)                  |                                  |
| Total number of patients with at lcast one treatment                                                                                                                                                                                       | 2(0.38) 2              | 0 0 0                            |
| Total number of treatments ALENDRONIC ACID/COLECALCIFEROL CALCIUM COMPOUNDS AND REGULATORS                                                                                                                                                 | 2(0.3)                 | (0.18)                           |
| Total number of patients with at lcast one trcatment Total number of treatments CALCIUM CARBONATE/COLECALCIFEROL                                                                                                                           | 0                      | 1                                |
|                                                                                                                                                                                                                                            |                        | (0.1$)                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Exploratory analyses

Immunogenicity - Anti-drug antibodies

## Table 36: Baseline Prevalence and Post-Baseline Incidence of Anti-Drug Antibodies (ADAs) Safety Evaluable Patients - Study KATHERINE

<!-- image -->

## Table 37: Baseline Prevalence and Post-Baseline Incidence of Anti-Drug RO0452317 Antibodies (ADAs), Safety Evaluable Patients - Study KATHERINE

<!-- image -->

## Table 38:  Baseline Prevalence and Incidence of Neutralizing Antibodies (NAbs) to Serum RO5304020, Safety Evaluable Patients - Study KATHERINE

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 39:  IDFS by ADA Status - Study KATHERINE

IDFS by ADA Status, Randomized Patient Population

Protocol:B027938 Status:FINAL Snapshot Date: 12SEP2018 ClinicalCut-Off Date: 25JUL2018

Table 40: IDFS by NAb status - Study KATHERINE

<!-- image -->

IDFS by NAB Status,Randomized Patient Population

```
Protocol:B027938 StatuS:FINAL Snapshot Date:12SEP2018 ClinicalCut-Off Date: 25JUL2018
```

<!-- image -->

|          | TDMl NAB+ (N=5)   | TDMl NAB+ (N=5)   | TDMl NAB+ (N=5)   | TDMl NAB- (N=10)   | TDMl NAB- (N=10)   | TDMl NAB- (N=10)   |
|----------|-------------------|-------------------|-------------------|--------------------|--------------------|--------------------|
| Subgroup | Patients pergroup |                   | N Events3 Year KM | Patients per group |                    | N Events3 YearKM   |
| All      | 5                 | 0                 | 100.000           | 10                 | 1                  | 88.889             |

## Summary of main study

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 41: Summary of Efficacy for trial KATHERINE

| BO27938 (KATHERINE): A randomised, multicenter, open-label Phase III Study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy.   | BO27938 (KATHERINE): A randomised, multicenter, open-label Phase III Study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy.   | BO27938 (KATHERINE): A randomised, multicenter, open-label Phase III Study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy.   | BO27938 (KATHERINE): A randomised, multicenter, open-label Phase III Study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                            | BO27938, NCT01772472                                                                                                                                                                                                                                                                                                                                        | BO27938, NCT01772472                                                                                                                                                                                                                                                                                                                                        | BO27938, NCT01772472                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                                                                                                                                      | Phase III, multicentre, multinational, randomised, open-label, two-arm                                                                                                                                                                                                                                                                                      | Phase III, multicentre, multinational, randomised, open-label, two-arm                                                                                                                                                                                                                                                                                      | Phase III, multicentre, multinational, randomised, open-label, two-arm                                                                                                                                                                                                                                                                                      |
| Design                                                                                                                                                                                                                                                                                                                                                      | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                              | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                              | Not applicable, event-driven Not applicable Not applicable                                                                                                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                  | Superiority                                                                                                                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                                                                                                                                                                                                           | Trastuzumab                                                                                                                                                                                                                                                                                                                                                 | Trastuzumab                                                                                                                                                                                                                                                                                                                                                 | Trastuzumab 6 mg/Kg IV q3w for 14 cycles, n=743                                                                                                                                                                                                                                                                                                             |
| Treatments groups                                                                                                                                                                                                                                                                                                                                           | Kadcyla                                                                                                                                                                                                                                                                                                                                                     | Kadcyla                                                                                                                                                                                                                                                                                                                                                     | Kadcyla 3.6 mg mg/Kg IV q3w for 14 cycles, n=743                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                   | Primary endpoint                                                                                                                                                                                                                                                                                                                                            | IDFS                                                                                                                                                                                                                                                                                                                                                        | Invasive disease-free survival                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                   | Secondary endpoint                                                                                                                                                                                                                                                                                                                                          | IDFS-SPNB C                                                                                                                                                                                                                                                                                                                                                 | Invasive disease-free survival including second primary non-breast cancer                                                                                                                                                                                                                                                                                   |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                   | Secondary endpoint                                                                                                                                                                                                                                                                                                                                          | DFS                                                                                                                                                                                                                                                                                                                                                         | Disease-free survival                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                                                                                                             | Secondary endpoint                                                                                                                                                                                                                                                                                                                                          | OS                                                                                                                                                                                                                                                                                                                                                          | Overall survival                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                                                | Secondary endpoint                                                                                                                             | DRFI                                                                                                                                           | Distant recurrence-free interval                                                                                                               | Distant recurrence-free interval                                                                                                               | Distant recurrence-free interval                                                                                                               |
|------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Database lock                                  | 25 July 2018                                                                                                                                   | 25 July 2018                                                                                                                                   | 25 July 2018                                                                                                                                   | 25 July 2018                                                                                                                                   | 25 July 2018                                                                                                                                   |
| Results and Analysis                           | Results and Analysis                                                                                                                           | Results and Analysis                                                                                                                           | Results and Analysis                                                                                                                           | Results and Analysis                                                                                                                           | Results and Analysis                                                                                                                           |
| Analysis description                           | Primary Analysis (Interim analysis results crossed the efficacy stopping boundary)                                                             | Primary Analysis (Interim analysis results crossed the efficacy stopping boundary)                                                             | Primary Analysis (Interim analysis results crossed the efficacy stopping boundary)                                                             | Primary Analysis (Interim analysis results crossed the efficacy stopping boundary)                                                             | Primary Analysis (Interim analysis results crossed the efficacy stopping boundary)                                                             |
| Analysis population and time point description | Intent to treat=1486, when 257 (67%) of the targeted 384 IDFS events had occurred                                                              | Intent to treat=1486, when 257 (67%) of the targeted 384 IDFS events had occurred                                                              | Intent to treat=1486, when 257 (67%) of the targeted 384 IDFS events had occurred                                                              | Intent to treat=1486, when 257 (67%) of the targeted 384 IDFS events had occurred                                                              | Intent to treat=1486, when 257 (67%) of the targeted 384 IDFS events had occurred                                                              |
|                                                | Treatment group                                                                                                                                | Treatment group                                                                                                                                | Trastuzumab                                                                                                                                    | Trastuzumab                                                                                                                                    | Kadcyla                                                                                                                                        |
|                                                | Number of subjects                                                                                                                             | Number of subjects                                                                                                                             | 743                                                                                                                                            | 743                                                                                                                                            | 743                                                                                                                                            |
|                                                | IDFS, patients with event (%)                                                                                                                  | IDFS, patients with event (%)                                                                                                                  | 165 (22.2%)                                                                                                                                    | 165 (22.2%)                                                                                                                                    | 91 (12.2%)                                                                                                                                     |
|                                                | IDFS, 3-year event-free rate                                                                                                                   | IDFS, 3-year event-free rate                                                                                                                   | 77.02                                                                                                                                          | 77.02                                                                                                                                          | 88.27                                                                                                                                          |
|                                                | 95% CI                                                                                                                                         | 95% CI                                                                                                                                         | 73.78, 80.26                                                                                                                                   | 73.78, 80.26                                                                                                                                   | 85.81, 90.7                                                                                                                                    |
|                                                | OS, patients with event (%)                                                                                                                    | OS, patients with event (%)                                                                                                                    | 56 (7.5%)                                                                                                                                      | 56 (7.5%)                                                                                                                                      | 42 (5.7%)                                                                                                                                      |
|                                                | OS, 3-year event-free rate                                                                                                                     | OS, 3-year event-free rate                                                                                                                     | 93.59                                                                                                                                          | 93.59                                                                                                                                          | 95.18                                                                                                                                          |
|                                                | 95% CI                                                                                                                                         | 95% CI                                                                                                                                         | 91.71, 95.47                                                                                                                                   | 91.71, 95.47                                                                                                                                   | 93.58, 96.79                                                                                                                                   |
| Effect estimate per comparison                 | Time to first IDFS event                                                                                                                       | Comparison groups                                                                                                                              | Comparison groups                                                                                                                              | Kadcyla vs. Trastuzumab                                                                                                                        | Kadcyla vs. Trastuzumab                                                                                                                        |
| Effect estimate per comparison                 | Time to first IDFS event                                                                                                                       | Unstratified Hazard Ratio                                                                                                                      | Unstratified Hazard Ratio                                                                                                                      | 0.50                                                                                                                                           | 0.50                                                                                                                                           |
| Effect estimate per comparison                 | Time to first IDFS event                                                                                                                       | 95% CI                                                                                                                                         | 95% CI                                                                                                                                         | 0.39, 0.64                                                                                                                                     | 0.39, 0.64                                                                                                                                     |
| Effect estimate per comparison                 | Time to first IDFS event                                                                                                                       | P-value                                                                                                                                        | P-value                                                                                                                                        | <0.0001                                                                                                                                        | <0.0001                                                                                                                                        |
| Effect estimate per comparison                 | Overall survival                                                                                                                               | Comparison groups                                                                                                                              | Comparison groups                                                                                                                              | Kadcyla vs. Trastuzumab                                                                                                                        | Kadcyla vs. Trastuzumab                                                                                                                        |
| Effect estimate per comparison                 | Overall survival                                                                                                                               | Unstratified Hazard Ratio                                                                                                                      | Unstratified Hazard Ratio                                                                                                                      | 0.70                                                                                                                                           | 0.70                                                                                                                                           |
| Effect estimate per comparison                 | Overall survival                                                                                                                               | 95% CI                                                                                                                                         | 95% CI                                                                                                                                         | 0.47, 1.05                                                                                                                                     | 0.47, 1.05                                                                                                                                     |
| Effect estimate per comparison                 | Overall survival                                                                                                                               | P-value                                                                                                                                        | P-value                                                                                                                                        | 0.0848                                                                                                                                         | 0.0848                                                                                                                                         |
| Notes                                          | Due to stratum with <5 patients, unstratified analyses were done for all endpoints 3-year event-free rates derived from Kaplan-Meier estimates | Due to stratum with <5 patients, unstratified analyses were done for all endpoints 3-year event-free rates derived from Kaplan-Meier estimates | Due to stratum with <5 patients, unstratified analyses were done for all endpoints 3-year event-free rates derived from Kaplan-Meier estimates | Due to stratum with <5 patients, unstratified analyses were done for all endpoints 3-year event-free rates derived from Kaplan-Meier estimates | Due to stratum with <5 patients, unstratified analyses were done for all endpoints 3-year event-free rates derived from Kaplan-Meier estimates |

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

KATHERINE is a phase III, two-arm, randomised, multicentre, open label trial comparing Kadcyla versus trastuzumab as adjuvant therapy in patients with HER2+ EBC who have received preoperative chemotherapy and trastuzumab (with or without other anti-HER2 agents such as pertuzumab) followed by surgery, with a finding of residual invasive disease in the breast or axillary lymph nodes. Achieving pCR following neoadjuvant therapy has been reported as being associated with significantly improved disease recurrence and survival, particularly for triple negative and HER2+ breast cancer patients (Spring et al. SABCS 2018; GS2-03). The defined population of the trial is supported.

Currently, most patients with HER2+ EBC are treated with neoadjuvant chemotherapy + trastuzumab +/pertuzumab and after surgery, they complete one year (often 14 remaining cycles) of trastuzumab +/pertuzumab. The decision to add pertuzumab in the neoadjuvant or adjuvant setting often rests on a situation of 'high risk of recurrence', which has a rather broad definition, but it often encompasses either lymph node-positive or hormone receptor-negative disease (ESMO guideline). To date, no studies had addressed the particular issue of 'high-risk' conferred by invasive residual disease in the breast and/or lymph nodes.

No new dose-response study was submitted which is considered acceptable. The dose used in study KATHERINE is the approved dose of Kadcyla is 3.6 mg/kg bodyweight administered as an intravenous

<div style=\"page-break-after: always\"></div>

infusion every 3 weeks (21-day cycle). This dose showed favourable benefit-risk profiles when administered as monotherapy in advanced HER2+ BC across Phase II and III clinical studies (see EPAR Kadcyla).

The overall design of the trial is generally in line with the scientific advice that was given in 2011 and supported. The definitions of HER2 status, neoadjuvant chemotherapy + HER2-directed treatment, breast and lymph node surgery requirements and exclusion criteria are acceptable. However, the key inclusion criterion required pathologic evidence of residual invasive carcinoma in the breast or lymph nodes after completion of neoadjuvant therapy, entailing that patients with residual in situ disease (e.g. ypTis ypN0) were considered 'low-risk' and hence not allowed to participate. The indication wording has been revised accordingly.

Although, the adjuvant scene for HER2+ EBC patients has considerably changed in the last few years, the control arm (trastuzumab at the approved dose every 3 weeks for 14 cycles) was deemed appropriate at the time when the study was designed. Permitting patients who discontinued Kadcyla because of toxicity issues to complete treatment with trastuzumab is endorsed.

The primary efficacy endpoint of the trial, invasive disease free survival (IDFS) is acceptable for the intended adjuvant setting of EBC. It implies the decreased likelihood of local or distant relapse and has been used in the past to define benefit in the adjuvant setting of EBC. According to the study protocol, the definition of IDFS does not follow the standardized definitions for breast cancer clinical trial endpoints in the adjuvant setting from the STEEP system (Hudis et al, JCO 2007). However, the possible occurrence of second primary non-breast cancer events was assessed both as a secondary endpoint and as a sensitivity analysis for the primary endpoint. The remaining exploratory, PRO, safety and secondary efficacy endpoints are considered acceptable.

According to the SAP, a testing hierarchy was used to control the overall type I error, and OS would only be tested if IDFS were statistically significant. The MAH clarified that the formal hierarchical testing of endpoints refers  to  IDFS  and  OS.  IDFS  including  second  primary  non-breast  cancer,  DFS,  and  DRFI  were  also secondary endpoints, but they were not analysed under a testing hierarchy and therefore did not have allocated alpha spending.

The planning of the interim analysis is adequate. The type I error control for multiple looks for IDFS and OS using the Lan-DeMets alpha spending function with an O'Brien-Fleming stopping boundary is acceptable.

The sample size (~1484 subjects) was primarily driven by the analysis of IDFS. The study had approximately 80% power to detect a HR of 0.75 in IDFS by observing 384 IDFS events. This is considered adequate. However, the study only has 56% power to detect a HR of 0.80 in OS after 10 years of follow-up from the date of randomization of the first patient. It is acknowledged that a study adequately powered to show differences in OS may not have been feasible. To assess whether the current sample size is sufficient to detect an overall detrimental OS effect, various OS HR scenarios were examined. The different scenarios indicate that a detrimental effect in OS could be detected with the current sample size. The Applicant also presented an updated 5-years OS rate: 88.1% (95%CI: 85.1%, 91.1%) in the trastuzumab arm and 91.1% (95%CI: 88.5%, 93.7%) in the Kadcyla arm, which supports the positive trend in OS observed in the primary analysis.

The permuted block randomisation method is endorsed and the stratification factors used are all clinically relevant and hence acceptable. However, it is noticed that around 24% of patients where incorrectly classified in the IxRS system.  Nevertheless, the sensitivity analysis on IDFS using the eCRF stratification factors (instead of IxRS) was consistent with the primary analysis (data not shown).

The study was open-label but given the significantly different toxicity profile between both drugs, the arguments for not performing a double-blind study were accepted by the CHMP at the time of study planning.

<div style=\"page-break-after: always\"></div>

With regards to statistical methods, the use of the Cox model and the Kaplan-Meier approach to analyse the time to event endpoints is agreed. The fact that unstratified log-rank test was performed as part of the primary analysis because the smallest stratum had less than five patients is understood. However, the stratification factors were chosen by the Applicant for a reason and if any stratum had a different HR, this would not be observed in the current analysis. In this regard, it is reassuring that departures for the proportional hazards assumption are not observed in the survival curves.

Regarding the censoring rules for IDFS, data for those patients who do not experience an event were censored at the date they are last known to be alive and event-free. Data for patients who are randomized without any post-baseline assessments were censored at the date of randomization plus 1 day. All patients must be followed for approximately 10 years, regardless of treatment discontinuation. Several sensitivity analyses for IDFS where the censoring rules were modified were performed (data not shown). The results of the sensitivity analyses were concordant with those presented for the primary analysis, indicating that changes in the censoring rules are negligible on the results.

The censoring rules for OS are endorsed. The MAH also clarified the censoring rules for the secondary endpoints and performed several sensitivity analyses for OS and DRFI to assess the impact of the censoring rules (data not shown). The results of the sensitivity analyses were consistent with those presented for the primary analysis, indicating that changes in the censoring rules were negligible on the results. No sensitivity analyses were presented for other secondary endpoints since there were only 12 patients with a different result between IDFS, IDFS including second primary non-breast cancer and DFS.

1486 out of 1925 screened patients were enrolled into the study. The screen failure rate (23%) is acceptable and suggests that the recruited patients represent the target population. The reasons for screen failure were disclosed and considered pertinent. In the light of an open-label trial, the unbalance in the number of patients who were randomised but then did not receive treatment (23 patients in the trastuzumab arm and 4 patients in the Kadcyla arm) is important. However the numbers are considered too small to have a relevant impact on the results. The planned 14 cycles of therapy were received by 79% of patients in the trastuzumab arm versus 71% in the Kadcyla arm. This difference is likely driven by the significant amount of patients withdrawn from treatment because of AEs: 133 (18%) in the Kadcyla arm vs. 15 (2%) in the trastuzumab arm. As permitted by protocol, 71 out of 212 patients who prematurely discontinued Kadcyla were switched to trastuzumab. Most of the switched-patients (61 out of 71, 86%) had discontinued Kadcyla because of AEs.

The  overall  distribution  of  baseline  characteristics  is  balanced  between  both  arms  of  the  trial  and corresponds to what is expected from HER2+ EBC.

Two thirds (996 out of 1486, 67%) of patients had 'small' post-neoadjuvant tumour sizes (ypT0, ypTis, ypTmic, ypT1a, ypT1b, ypT1c). All but two of the patients with ypN0 staging had residual invasive disease at primary  tumour.  These  two  patients  did  not  fill  the  inclusion  criteria  and  constitute  a  major  protocol violation.  The  MAH  has  provided  the  numbers  and  proportions  of  the  subcategories  from  'small' post-neoadjuvant tumour sizes. Nearly half of the patients from the ITT were free of nodal disease (ypN0: 679/1486, 45.7%). However, most of those ypN0 patients were also in the subcategories with 'less' primary tumour. In fact, the proportion of ypN0 decreases as the ypT category increases: ypT1mic + ypN0: 41/64, 64.1%, ypT1a + ypN0: 169/273, 61.9%, ypT1b + ypN0: 121/190, 63.4%, ypT1c + ypN0: 184/356, 51.7%, ypT2 + ypN0: 127/359, 35.4%, ypT3 + ypN0: 29/108, 26.9%, ypT4 + ypN0: 1/21, 4.8%.

The  details  of  the  treatment  the  patients  have  received  before  the  HER2-directed  adjuvant  scheme (neoadjuvant  chemotherapy  +  HER2-directed  treatment,  type  of  surgery,  response  after  neoadjuvant treatment, concomitant hormone therapy, adjuvant radiotherapy, etc.) were also well balanced between arms. Only 272 patients (18.3%) from the ITT population of the KATHERINE study received trastuzumab + pertuzumab + chemotherapy as neoadjuvant treatment. Although such combination was not approved at

<div style=\"page-break-after: always\"></div>

the time, it currently constitutes the preferred regimen for patients with HER2+ EBC that are to receive neoadjuvant therapy.

The wording of the indication has also been amended to clearly reflect the studied population, i.e. clarifying the fact that both taxanes and trastuzumab were part of the neoadjuvant scheme.

Acknowledging the participation of 5 male patients in the study and the targeted nature of the agent, extrapolation to male patients is supported.

The protocol amendments were acceptable and none of them are considered to influence directly the efficacy endpoints. There was a considerable imbalance of major protocol deviations between both arms (21% in the Kadcyla arm vs. 12.5% in the trastuzumab arm) driven by on-study protocol deviations (11.2% in the Kadcyla arm vs. 1.2% in the trastuzumab arm). Almost all the incidences (78 out of 83) regarding this issue concern 'dose not reduced/held per protocol', which can be explained as dose reductions were only allowed in the Kadcyla arm.

## Efficacy data and additional analyses

Median follow up for both arms (40.9 months in the trastuzumab arm and 41.4 months in the Kadcyla arm) is similar and reasonable for the targeted event rate estimated for IDFS interim analysis, which had been planned to take place when ~67% (approximately 257 out of 384) of IDFS events had occurred, with an established efficacy-stopping boundary of p&lt;0.0124 or HR&lt;0.732. Of note, 230 (31.0%) alive patients in the trastuzumab arm and 202 (27.2%) patients in the Kadcyla arm from the ITT population had ≤ 3 years of follow-up on study.

After 256 IDFS events at data cut-off 25 July 2018, the study has met its primary efficacy endpoint by achieving a statistically significant improvement in IDFS for Kadcyla (91 events, estimated 3-year event-free rate 88.3%) over trastuzumab (165 events, estimated 3-year event-free rate 77.0%), with an unstratified HR of 0.50 (95% CI 0.39, 0.64) and p&lt;0.0001. Since results from this interim analysis have crossed the O'Brien-Fleming stopping boundary, they are now considered the primary analysis of IDFS and formal OS testing has been performed.

Data from the stratified analysis (HR 0.48, 95% CI 0.37, 0.62; p&lt;0.0001) are not used because one of the strata had less than 5 patients. The Kaplan-Meier curves separate from the beginning and remain divergent for the duration of follow-up but a heavy degree of censoring is obvious as of approximately 27 months of follow-up. As expected, most of this censoring comes from patients who were event-free and in follow-up.

As expected, distant recurrence was the most frequent IDFS event in both arms (66.1% of cases in the trastuzumab arm and 82.4% in the Kadcyla arm). Although 43 out of all 91 recurring patients in the Kadcyla arm (47%) vs. 30 out of 165 in the trastuzumab arm (18%) presented CNS recurrence as the earliest contributing IDFS event, the total number of patients with CNS recurrence across follow up does not differ significantly between arms (45 in the Kadcyla arm and 40 in the trastuzumab arm). One possible explanation behind this difference of particular events along time is the competing risks hypothesis, by which Kadcyla would exhibit higher effectiveness at preventing recurrences outside of sanctuary sites (distant non-CNS, locoregional and/or contralateral).

Median time to CNS recurrences on the Kadcyla arm was 17.5 months, as compared to 11.9 months in the trastuzumab arm. Furthermore, median time to OS event in patients with CNS-recurrence does not differ significantly between arms: 14.3 months in trastuzumab (21 out of 40 patients) vs. 12.5 months in Kadcyla (26 out of 45 patients).

The MAH also performed a sensitivity analysis that assigns alive-patients with CNS recurrence as death events on the date of the recurrence (worst-case scenario)(data not shown), that is consistent with the first interim OS analysis.

<div style=\"page-break-after: always\"></div>

The IDFS advantage from Kadcyla over trastuzumab is maintained across all the subgroups analysed, in particular those concerning the stratification factors. Nevertheless, the degree of benefit from Kadcyla vs. trastuzumab in patients with small tumours (ypTmic, ypT1a, ypT1b, ypT1c) without nodal disease or with little  nodal  disease  (e.g.  one  or  two  positive  lymph  nodes)  cannot  be  established  due  to  the  possible heterogeneity of patients, which leads to low numbers and non-interpretable results.

The 'trastuzumab plus additional HER2-directed agents' subgroup included 290 patients, out of which 272 (94%) had received pertuzumab + trastuzumab + chemotherapy, the currently preferred neoadjuvant regimen for HER2+ EBC. It is unlikely that the HR of that subgroup analysis would be altered if the 18 patients who received anti-HER2 agents other than pertuzumab were excluded.

Censoring the patients who began a new anti-cancer therapy or those who discontinued study treatment for any reason, as means of sensitivity analyses, did not alter the results from the primary IDFS analysis.

Albeit not corrected for multiplicity, secondary endpoints that included other clinical situations as events (secondary non breast cancer for IDFS-SPNBC and DCIS for DFS) are in line with the clinical advantage from Kadcyla over trastuzumab.

At clinical cut-off, only 98 OS events (6.6%) had occurred compared to 150 deaths estimated to have occurred at the first interim OS analysis. The 95% confidence intervals of the 3-year OS event-free rate are overlapping: 95.18% (93.58, 96.79) for Kadcyla and 93.59% (91.71, 95.47) for trastuzumab. Although a trend for improved outcome from Kadcyla over trastuzumab is maintained (unstratified HR 0.70; 95% CI 0.47, 1.05; p=0.0848), immaturity of the data prevent a firm conclusion regarding a non-detrimental OS effect from Kadcyla. It is nonetheless reassuring that departures for the proportional hazards assumption are not observed in any of the Kaplan-Meier plots for the primary or secondary endpoints. In order to confirm a non-detrimental effect on OS from Kadcyla in the targeted population, the MAH will ensure adequate post-approval follow-up of OS data from patients from the KATHERINE trial. The MAH will provide the final analysis post-approval as an Annex II condition (see PI, Annex II).

Data on follow-up treatment were presented. More patients from the trastuzumab arm experienced a distant recurrence event (121 vs. 78 in the Kadcyla arm). Consequently, it was expected that more patients in this arm would receive follow-up systemic treatments (131 vs. 72 patients in the Kadcyla arm). Most patients in both arms went on to receive anti-HER2 antibodies [trastuzumab (63% and 49%, respectively), pertuzumab (36% and 15%, respectively) and Kadcyla (25% and 5%, respectively)], and other anti-HER2 drugs, such as lapatinib (15% and 26%, respectively).

The study included Patient-Reported Outcome analyses. Although the instruments (EORTC QLQ-C30 and QLQ-BR23  selected  for  evaluating  PROs  are  considered  appropriate  for  the  target  population  and  the completion rates are adequate, the clinical relevance of such data from an open-label study are limited.  The MAH stated that mean scores of HRQoL, physical function and role function were comparable between arms throughout the course of treatment. Although the differences are slight, the proportion of patients who declared deterioration of functions (cognitive, physical and role) and global health status throughout the study was numerically higher in the Kadcyla arm. Moreover, when the percentage of patients with clinically meaningful deterioration is examined, differences clearly disfavor the Kadcyla arm in all subscales. When the number/percentage of patients with deterioration of specific symptoms is examined, appetite loss, fatigue, nausea/vomiting and systemic therapy side effects affect a considerably higher proportion of patients in the Kadcyla arm. This, in fact, corresponds to the striking differences seen in the incidence of chemotherapy-related symptoms (nausea, fatigue, dry mouth/stomatitis/dysgeusia, constipation, peripheral neuropathy and decreased appetite) (see safety section). Furthermore, results from a series of specific items from the QLQ-BR23 scale have not been interpreted by the MAH: breast symptoms, upset by hair loss, body image, future perspectives, sexual enjoyment and sexual functioning.  Overall, the inclusion of the PROs results in the SmPC is not supported.

<div style=\"page-break-after: always\"></div>

Exploratory analyses included immunogenicity assessment. With regards to ADAs, out of 720 patients included in the safety population of trastuzumab, only 386 were evaluable for ADAs to trastuzumab at baseline , with 11 positive results (2.8%). 392 patients had at least one post-dose sample available for ADA analysis, with 15 positive results. From these 15 patients, 13 (3.3%) were treatment-emergent (negative at baseline) and 2 were 'treatmentenhanced' (positive at baseline, but with a ≥4 -fold increase in titres).

Out of 740 patients included in the safety population of Kadcyla, 410 patients had baseline samples, with 17 patients who tested positive (4.1%). 401 patients gave at least one post-dose sample for ADA analysis, with 15 positive results (14 treatment-emergent and 1 treatment-enhanced). From these 15 patients, 5 tested positive for neutralising antibodies (NAbs) to Kadcyla. Only 1 IDFS event has occurred in the 15 patients from the Kadcyla arm with ADA+ status (and none in the 5 patients with NAbs), which does not allow for any conclusion regarding the impact of such antibodies in efficacy. The same is true for safety: only 1 patient who was ADA+ and NAb+ presented a SAE of hypersensitivity (Grade 3) (see discussion on clinical safety).

## 2.4.4. Conclusions on the clinical efficacy

Across subgroups and diverse time-to-relapse endpoints, the overall risk of recurrence in patients with HER2+ EBC and residual disease after neoadjuvant treatment and surgery is significantly reduced with adjuvant Kadcyla as compared to trastuzumab. This beneficial effect primarily concerns the risk of recurrence outside of sanctuary sites (distant non-CNS, locoregional and/or contralateral), since no differences between arms were seen for overall CNS-recurrence event rates. Given immature OS data, appropriate follow-up is ensured to confirm a non-detrimental effect on OS from Kadcyla in the targeted population.

The CHMP considers the following measures necessary to address issues related to efficacy:

PAES: In order to further investigate the efficacy of trastuzumab emtansine in the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the final analysis of OS from the phase 3, randomised, open-label study KATHERINE (BO27938). Due date: 30 June 2024.

## 2.5. Clinical safety

## Introduction

The safety of Kadcyla had been evaluated in 884 metastatic breast cancer patients in clinical studies before its approval in the EU. In this patient population:

- The most common adverse drug reactions (ADRs) ( ≥ 25%) with Kadcyla were haemorrhage (including epistaxis), increased transaminases, fatigue, musculoskeletal pain, and headache. The majority of ADRs reported were of Grade 1 or 2 severity.
- The most common serious ADRs were pyrexia, thrombocytopenia, vomiting, abdominal pain, nausea, constipation, diarrhoea, dyspnoea and pneumonitis.
- The  most  common  National  Cancer  Institute  -  Common  Terminology  Criteria  for  Adverse  Events (NCI-CTCAE) Grade 3 or 4 ADRs (&gt; 2%) were thrombocytopenia, fatigue, increased transaminases, anaemia, hypokalaemia, musculoskeletal pain and neutropenia.
- Thrombocytopenia, or decreased platelet counts, was commonly reported with Kadcyla and was the most common adverse reaction leading to treatment discontinuation.

<div style=\"page-break-after: always\"></div>

- Cases of bleeding events with a fatal outcome have been observed. Severe cases of haemorrhagic events, including central nervous system haemorrhage, have been reported in clinical studies.

To support the proposed indication of Kadcyla for the adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) with residual invasive disease following completion of neoadjuvant therapy, safety data from the ongoing pivotal Phase III study KATHERINE (BO27938) and supplementary safety data from completed Phase II study TDM4874g/BO22857 have been provided (see Table 1).

## Patient exposure

A total of 1460 patients who received at least one dose of study drug (Kadcyla or trastuzumab) were included in the safety analysis population (720 patients in the trastuzumab arm, 740 patients in the Kadcyla arm).  At the CCoD of 25 July 2018, all patients had completed or discontinued treatment.

|                                                                                         | Trastuzumab (N=720)   |
|-----------------------------------------------------------------------------------------|-----------------------|
| Total Treatment Duration (months)                                                       |                       |
| n                                                                                       | 720                   |
| Median                                                                                  | 10                    |
| Range                                                                                   | 1 - 13                |
| No.of cycles of Trastuzumabtreatment                                                    |                       |
| n                                                                                       | 720                   |
| Median                                                                                  | 14                    |
| Range                                                                                   | 1 - 14                |
| Number (%)of patients completing at least a total of X cycles of Trastuzumab treatment: |                       |
| 1 cycle                                                                                 | 720 (100.0%) 94.9%)   |
| 4 cycles                                                                                | 683                   |
| 7 cycles                                                                                | 664                   |
| 11 cycles                                                                               | 92.2%) 618 85.8%)     |
| 14 cycles                                                                               | 583 81.0%)            |

Table 42: Exposure to trastuzumab (safety evaluable patients) - Study KATHERINE

<!-- image -->

```
Exposure to Trastuzumab Emtansine, Safety Evaluable Patients Protocol:B027938 Status: FINAL Snapshot Date:12sEP2018 Clinical Cut-Off Date:25JUL2018
```

Table 43: Exposure to Trastuzumab Emtansine (Safety Evaluable Patients) - Study KATHERINE

<!-- image -->

|                                                                                                   | Trastuzumab Emtansine (N=740)   |
|---------------------------------------------------------------------------------------------------|---------------------------------|
| Total Treatment Duration (months)                                                                 |                                 |
| n                                                                                                 | 740                             |
| Median                                                                                            | 10                              |
| Range                                                                                             | -12                             |
| No.of cycles of Trastuzumab Emtansine treatment                                                   |                                 |
| n                                                                                                 | 740                             |
| Median                                                                                            | 14                              |
| Range                                                                                             | - 14                            |
| Number of Cycles completed of any study treatment~ including switch therapy                       |                                 |
| n                                                                                                 | 740                             |
| Median                                                                                            | 14                              |
| Range                                                                                             | - 14                            |
| Number (&)of patients completing at least a total of X cycles of Trastuzumab Emtansine treatment: |                                 |
| 1 cycle                                                                                           | 740(100.0%)                     |
| 4 cycles                                                                                          | 677 91.5)                       |
| 7. cycles                                                                                         | 637 86.1)                       |
| 11 cycles                                                                                         | 78.2)                           |
| 14 cycles                                                                                         | 579 528 (71.4)                  |
| Number (&) of patients completing at least a total of X cycles of all study treatment:            |                                 |
| 1 cycle                                                                                           | 740 (100.0%)                    |
| 4 cycles                                                                                          | 869 (94.3)                      |
| 7 cycles                                                                                          | 673 90.9%)                      |
| 11 cycles                                                                                         | 639 86.4)                       |
| 14 cycles                                                                                         | 593(80.1)                       |

<div style=\"page-break-after: always\"></div>

```
Nuumberof patients whohad at leastone dosereduction* n 740 No dose reduction 634(85.7) Dose rediuction by one level (3.0 mg/kg) 77(10.4%) Dose reduction by 2 levels (2.4 mg/kg) 29( 3.9%) Cycle of first dose reduction being Cycle 1 0 Cycle 9(1.2) Cycle 3 11 (1.5) Cycle4to7 35(4.7%) Cycle8to11 34 （4.6%) Cycle12to later 17(2.3) if there was an interruption or a flow rate change during the infusion.\"All treatment\"refers to any studly treatment including the switch therapy
```

Table 44: Exposure to Trastuzumab (Switch Patients after Discontinuation from Trastuzumab Emtansine) - Study KATHERINE

```
Exposure to Trastuzumab : Switch Patients (after discontinuation from trastuzumab emtansine) Protocol:B027938 Status:FINAL Snapshot Date:12SEp2018 Clinical Cut-Off Date:25JUL2018
```

<!-- image -->

Table 45: Summary of trastuzumab emtansine exposure (treated patients) across studies

|                               | TDM4370g/ B021977 (T-DM1 arm) N=490   | TDM4450g/ B021976C (T-DM1 arm) N=69                         | Pooled T-DM1a N=288                                                                  | Total T-DM1- exposedb N=882                                     |
|-------------------------------|---------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Numberofdosesreceived n       | 490 11.7 (8.4) 9.0 1.0-41.0           | 69 17.4 (12.2) 16.0 1.0-41.0 69 3.5 (0.5) 3.60 3.00-6.00 68 | 288 12.1 (13.5) 7.0 1.0-69.0 287 3.51 (0.20) 3.57 2.50 - 4.19 288 95.69 (8.38) 99.49 | 882 12.2 (10.8) 9.0 1.0-69.0 881 3.50 (0.24) 3.56 2.50-6.00 882 |
| Mean (SD)                     |                                       |                                                             |                                                                                      |                                                                 |
| Median                        |                                       |                                                             |                                                                                      |                                                                 |
| Range                         |                                       |                                                             |                                                                                      |                                                                 |
| Averagedosereceived (mg/kg) n | 490                                   |                                                             |                                                                                      |                                                                 |
| Mean (SD)                     | 3.49 (0.20)                           |                                                             |                                                                                      |                                                                 |
| Median                        | 3.50                                  |                                                             |                                                                                      |                                                                 |
| Range                         | 2.70-4.00                             |                                                             |                                                                                      |                                                                 |
| Dose Intensity (%)d n         | 490                                   |                                                             |                                                                                      |                                                                 |
| Mean (SD)                     | 97.85 (10.92)                         | 95.0 (11.9)                                                 |                                                                                      | 96.90 (10.58)                                                   |
| Median                        | 99.92                                 | 99.30                                                       |                                                                                      | 99.70                                                           |
| Range                         | 54.67-200.72                          | 61-158                                                      | 55.17-107.52                                                                         | 54.67-200.72                                                    |
| TreatmentDuration(months) n   | 490                                   | 69                                                          | 288                                                                                  | 882                                                             |
| Mean (SD)                     | 7.7 (6.1) 5.7                         | 11.9 (8.8)                                                  | 8.2 (10.1)                                                                           | 8.2 (7.9) 5.6                                                   |
| Median Range                  | 0.0-28.4                              | 10.4 0-29                                                   | 4.2 0.0 - 47.1                                                                       | 0.0-47.1                                                        |

<div style=\"page-break-after: always\"></div>

## Concomitant therapies

## Table 46: Concomitant medications by treatment regimen, safety evaluable patients - Study KATHERINE

```
Concomitant Medications by Treatment Regimen, Safety Evaluable Patients Protocol: B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date: 25JUL2018
```

| Clas8 Standardized Medication Name                   | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)   |
|------------------------------------------------------|-----------------------|---------------------------------|
| ANTICOAGULANTS                                       |                       |                                 |
| Total number of patients with at least one treatment | 60( 8.38)             | 44(5.98)                        |
| Total number of treatments                           | 80                    | 50                              |
| ENOXAPARIN SODIUM                                    | 25 (3.58)             | 23 (3.18)                       |
| HEPARIN SODIUM                                       | 13 (1.88)             | 8 (1.18)                        |
| RIVAROXABAN                                          | 6 0.88)               | 4 0.58)                         |
| TINZAPARIN SODIUM                                    | 4 0.68)               | 3 0.48)                         |
| NADROPARIN CALCIUM                                   | 3 0.48)               | 3 0.48)                         |
| FONDAPARINUX SODIUM                                  | 4 0.68)               | 0                               |
| WARFARIN SODIUM                                      | 3 0.48)               | 1 0.18)                         |
| DALTEPARIN SODIUM                                    | 3 0.48)               | 0                               |
| CERTOPARIN SODIUM                                    | 2 0.38)               | 0                               |
| LOW MOLECULAR WEIGHT HEPARINS                        | 1 0.18)               | 1 0.18)                         |
| PHENPROCOUMON                                        | 2 0.381               | 0                               |
| DABIGATRAN ETEXILATE                                 | 0                     | 1 0.18)                         |
| HEPARINOIDS                                          | 1 0.181               | 0                               |
| HIRUDIN                                              | 0                     | 1 0.18)                         |
| PENTOSAN POLYSULFATESODIUM                           | 1 (0.18)              | 0                               |
| PLATELETAGGREGATIONINHIBITORS                        |                       |                                 |
| Total number of patients with at least one treatment | 11 (1.58)             | (0.48)                          |
| Total number of treatments                           | 11                    | 5                               |
| ASPIRIN                                              | 2 (0.38)              | 2 (0.38)                        |
| ASPIRIN/DIPYRIDAMOLE                                 | 3 (0.48)              | 1 (0.18)                        |
| CLOPIDOGREL                                          | (0.68)                | 0                               |
| ASPIRIN DL-LYSINE                                    | 2 (0.38)              | 0                               |

## Adverse events

Verbatim descriptions of AEs were mapped to Medical Dictionary for Regulatory Activities (MedDRA) (Version 21.0) thesaurus terms and graded according to the NCI CTCAE, Version 4.0.  All AEs, including SAEs, AEs leading to death, and AEs leading to study treatment discontinuation, occurring on or after the first dose of study treatment (i.e., treatment-emergent AEs), were summarized by NCI CTCAE grade.  For repeated events of varying severity in an individual patient, the highest grade was used in the summaries.

Cardiac assessments: LVEF assessment was by ECHO/MUGA, and was performed prior to anthracycline treatment, at the end of anthracycline (chemotherapy period 1) treatment, after Cycles 2 and 4 of Kadcyla, and every 4 cycles of Kadcyla thereafter. Any time a new treatment period was started (e.g., optional docetaxel or radiotherapy), an ECHO/MUGA was obtained before and after the new treatment.  In the follow-up phase, ECHO/MUGA was obtained every 3 months for 6 months.

<div style=\"page-break-after: always\"></div>

Table 47: Overview of Safety Summary by Treatment Regimen (Safety Evaluable Patients) Study KATHERINE

Safety Summary by

Treatment Regimen,

SafetyEvaluablePatients

Protoco1: B027938

Status: FINAL

Snapshot Date:12sEp2018

Clinical Cut-0ff Date:25JUL2018

<!-- image -->

|                                                                                                      | Trastuzwmab (N=720)   | Trastuzumab Emtansine (N=740)   |
|------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------|
| Total number of patients with at least one adverse event                                             | 672 (93.3)            | 731 (98.8)                      |
| Total number of adverse events                                                                       | 5317                  | 8429                            |
| Total number of patients with at least one                                                           |                       |                                 |
| AE with fatal outcome                                                                                | 0                     | 1 (0.15)                        |
| Serious AE                                                                                           | 58 (8.1)              | 94 (12.75)                      |
| Serious Related AE                                                                                   | 8 （ 1.1$)             | 39 (5.3)                        |
| Grade >=3 AEs                                                                                        | 111 (15.4%)           | 190 (25.7)                      |
| AE leading to withdrawal from Trastuzumab/Trastuzumab                                                | 15 (2.1)              | 133 (18.0%)                     |
| Emtansine excluding switched treatment*                                                              |                       |                                 |
| AE leading to dose reduction of Trastuzumab Emtansine                                                | 0                     | (12.2)                          |
| AE leading to dose interruption of Trastuzumab/                                                      | 37 (5.13)             | 90 106 (14.3)                   |
| Trastuzumab Emtansine excluding switched treatment* AE related to Trastuzumab/Trastuzumab Emtansine* | 326 (45.3)            | 641 (86.6)                      |
| Selected AEs for trastuzumab emtansine: patients with                                                |                       |                                 |
| Hepatotoxicity (all grades)                                                                          | 76 (10.6)             | 276 (37.35) 12                  |
| NCI-CTCAE Grade >=3                                                                                  | 3 0.4)                | （ 1.6)                          |
| Cardiac_dysfunction                                                                                  | 40 5.6) 6             | 23 3.15)                        |
| NCI-CTCAE Grade >=3                                                                                  | 1.3)                  | 4 (0.5%)                        |
| Thrcmbocytopenia                                                                                     | 17                    | 211 (28.5)                      |
| NCI-CTCAE Grade >=3                                                                                  | 2.45) (0.3)           | (5.7)                           |
| Peripheral Neuropathy                                                                                | 2 122 (16.98)         | 42 239 (32.35)                  |
| NCI-CTCAE Grade >=3                                                                                  | 1 (0.1$)              | 12 (1.6)                        |
| Hemorrhage                                                                                           | 69 9.63)              | 216 (29.25)                     |
| NCI-CTCAE Grade >=3                                                                                  | 0.3$)                 | 0.4)                            |
| IRR/hypersensitivity (type 1)                                                                        | 2 19 2.6)             | 3 57 （ 7.7)                     |
| NCI-CTCAE Grade >=3                                                                                  | 0                     | 1 0.1)                          |
| IRR/hypersensitivity symptoms                                                                        | 9 1.3) 0              | 42 （ 5.73) 0                    |
| NCI-CTCAE Grade >=3                                                                                  |                       |                                 |
| Pulmonary toxicity                                                                                   | 6 (0.8%)              | 21 (2.88)                       |
|                                                                                                      | 0                     | 3 (0.45)                        |
| NCI-CTCAE Grade >=3                                                                                  |                       |                                 |

## Table 48: Most Common ( ≥ 5%) Adverse Events by Treatment Regimen in either Arm (Safety Evaluable Patients) - Study KATHERINE

Most Common (&gt;=5%) Adverse Events by Treatment Regimen in either arm, Safety Evaluable Patients

Protocol: BO27938   Status: FINAL

Snapshot Date: 12SEP2018   Clinical Cut-Off Date: 25JUL2018

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

| MedDRA Preferred Term                                    | Trastuzumab (N=720) ___________________________________________________________________________________________   | Trastuzumab (N=720) ___________________________________________________________________________________________   | Trastuzumab Emtansine (N=740)   | Trastuzumab Emtansine (N=740)   |
|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------|
| Total number of patients with at least one adverse event | 634 (88.1%)                                                                                                       | 634 (88.1%)                                                                                                       | 719 (97.2%)                     | 719 (97.2%)                     |
| Total number of events                                   | 3339                                                                                                              | 3339                                                                                                              | 5976                            | 5976                            |
| FATIGUE                                                  | 243                                                                                                               | (33.8%)                                                                                                           | 366                             | (49.5%)                         |
| NAUSEA                                                   | 94                                                                                                                | (13.1%)                                                                                                           | 308                             | (41.6%)                         |
| RADIATION SKIN INJURY                                    | 199                                                                                                               | (27.6%)                                                                                                           | 188                             | (25.4%)                         |
| ARTHRALGIA                                               | 148                                                                                                               | (20.6%)                                                                                                           | 192                             | (25.9%)                         |
| HEADACHE                                                 | 122                                                                                                               | (16.9%)                                                                                                           | 210                             | (28.4%)                         |
| ASPARTATE AMINOTRANSFERASE INCREASED                     | 40                                                                                                                | ( 5.6%)                                                                                                           | 210                             | (28.4%)                         |
| HOT FLUSH                                                | 146                                                                                                               | (20.3%)                                                                                                           | 95                              | (12.8%)                         |
| PLATELET COUNT DECREASED                                 | 17                                                                                                                | ( 2.4%)                                                                                                           | 211                             | (28.5%)                         |
| ALANINE AMINOTRANSFERASE INCREASED                       | 41                                                                                                                | ( 5.7%)                                                                                                           | 171                             | (23.1%)                         |
| MYALGIA                                                  | 80                                                                                                                | (11.1%)                                                                                                           | 114                             | (15.4%)                         |
| PERIPHERAL SENSORY NEUROPATHY                            | 50                                                                                                                | ( 6.9%)                                                                                                           | 138                             | (18.6%)                         |
| INFLUENZA LIKE ILLNESS                                   | 87                                                                                                                | (12.1%)                                                                                                           | 100                             | (13.5%)                         |
| INSOMNIA                                                 | 86                                                                                                                | (11.9%)                                                                                                           | 101                             | (13.6%)                         |
| COUGH                                                    | 86                                                                                                                | (11.9%)                                                                                                           | 100                             | (13.5%)                         |
| CONSTIPATION                                             | 59                                                                                                                | ( 8.2%)                                                                                                           | 126                             | (17.0%)                         |
| PAIN                                                     | 92                                                                                                                | (12.8%)                                                                                                           | 93                              | (12.6%)                         |
| EPISTAXIS                                                | 25                                                                                                                | ( 3.5%)                                                                                                           | 159                             | (21.5%)                         |
| DIARRHOEA                                                | 90                                                                                                                | (12.5%)                                                                                                           | 91                              | (12.3%)                         |
| PAIN IN EXTREMITY                                        | 70                                                                                                                | ( 9.7%)                                                                                                           | 86                              | (11.6%)                         |
| VOMITING                                                 | 37                                                                                                                | ( 5.1%)                                                                                                           | 108                             | (14.6%)                         |
| ANAEMIA                                                  | 60                                                                                                                | ( 8.3%)                                                                                                           | 74                              | (10.0%)                         |
| DIZZINESS                                                | 57                                                                                                                | ( 7.9%)                                                                                                           | 70                              | ( 9.5%)                         |
| BACK PAIN                                                | 66                                                                                                                | 9.2%)                                                                                                             | 53                              | ( 7.2%)                         |
| DYSPNOEA                                                 | 53                                                                                                                | ( ( 7.4%)                                                                                                         | 62                              | ( 8.4%)                         |
| UPPER RESPIRATORY TRACT INFECTION                        | 53                                                                                                                | ( 7.4%)                                                                                                           | 58                              | ( 7.8%)                         |
| DRY MOUTH                                                | 9                                                                                                                 | ( 1.3%)                                                                                                           | 100                             | (13.5%)                         |
| STOMATITIS                                               | 27                                                                                                                | ( 3.8%)                                                                                                           | 80                              | (10.8%)                         |
| PYREXIA                                                  | 29                                                                                                                | ( 4.0%)                                                                                                           | 77                              | (10.4%)                         |
| URINARY TRACT INFECTION                                  | 39                                                                                                                | ( 5.4%)                                                                                                           | 65                              | ( 8.8%)                         |

<div style=\"page-break-after: always\"></div>

| WHITE BLOOD CELL COUNT DECREASED     |   42 | ( 5.8%)   |   61 | ( 8.2%)   |
|--------------------------------------|------|-----------|------|-----------|
| PARAESTHESIA                         |   41 | ( 5.7%)   |   60 | ( 8.1%)   |
| ABDOMINAL PAIN                       |   42 | ( 5.8%)   |   58 | ( 7.8%)   |
| NEUTROPHIL COUNT DECREASED           |   36 | ( 5.0%)   |   61 | ( 8.2%)   |
| BREAST PAIN                          |   42 | ( 5.8%)   |   53 | ( 7.2%)   |
| PRURITUS                             |   42 | ( 5.8%)   |   51 | ( 6.9%)   |
| BONE PAIN                            |   35 | ( 4.9%)   |   52 | ( 7.0%)   |
| DEPRESSION                           |   44 | 6.1%)     |   41 | ( 5.5%)   |
| LYMPHOEDEMA                          |   48 | ( ( 6.7%) |   37 | ( 5.0%)   |
| DRY SKIN                             |   36 | ( 5.0%)   |   48 | ( 6.5%)   |
| OEDEMA PERIPHERAL                    |   52 | ( 7.2%)   |   29 | ( 3.9%)   |
| DECREASED APPETITE                   |   16 | 2.2%)     |   62 | ( 8.4%)   |
| MUSCLE SPASMS                        |   45 | ( 6.3%)   |   33 | ( 4.5%)   |
| HYPERTENSION                         |   35 | ( 4.9%)   |   42 | ( 5.7%)   |
| BLOOD ALKALINE PHOSPHATASE INCREASED |   13 | ( ( 1.8%) |   61 | ( 8.2%)   |
| DYSGEUSIA                            |   11 | ( 1.5%)   |   60 | ( 8.1%)   |
| ANXIETY                              |   42 | ( 5.8%)   |   28 | ( 3.8%)   |
| OROPHARYNGEAL PAIN                   |   33 | ( 4.6%)   |   37 | ( 5.0%)   |
| RASH MACULO-PAPULAR                  |   26 | ( 3.6%)   |   42 | ( 5.7%)   |
| HYPOKALAEMIA                         |   14 | ( 1.9%)   |   48 | ( 6.5%)   |
| DERMATITIS ACNEIFORM                 |   21 | ( 2.9%)   |   39 | ( 5.3%)   |
| LACRIMATION INCREASED                |   13 | ( 1.8%)   |   41 | ( 5.5%)   |
| CHILLS                               |   14 | ( 1.9%)   |   39 | ( 5.3%)   |
| BLOOD BILIRUBIN INCREASED            |    2 | ( 0.3%)   |   49 | ( 6.6%)   |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ Investigator text for AEs encoded using MedDRA version 21.0.  Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once Table includes all AEs during treatment period to 30 days post last dose and AEs related to study treatment or study procedures in the follow up period.

Program: root/clinical\\_studies/RO5304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM/prod/ program/t\\_ae\\_inc.sas Output: root/clinical\\_studies/RO5304020/CDPT3519/BO27938/data\\_analysis/CSR\\_INTERIM/prod/ output/t\\_ae\\_inc\\_5PER\\_SE.out 06NOV2018 16:23

<div style=\"page-break-after: always\"></div>

Table 49: Adverse Events (any Grade) with a Difference of at least 5% between Treatment Arms by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

Treatment Regimen,Safety Evaluable Patients Protocol:B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date:25JUL2018

| MedDRA Preferred Term                                                                          | Trastuzumal (N=720)       | Trastuzumab Emtansine (N=740)   |
|------------------------------------------------------------------------------------------------|---------------------------|---------------------------------|
| Total number of patients with at least one adverse event                                       | 486 (67.54)               | 672 (90.83)                     |
| Overall Totalnumber of events                                                                  | 1279                      | 3473                            |
| GENERALDISORDERSANDADMINISTRATION SITE CONDITIONS                                              |                           |                                 |
| Total number of patients with at least one adverse event                                       | 259 (36.0)                | 394 (53.25)                     |
| FATIGUE                                                                                        | 243 (33.8%)               | 366 (49.55)                     |
| PYREXIA                                                                                        | 29 (4.0%)                 | 77 (10.43)                      |
| Total number of events                                                                         | 308                       | 555                             |
| GASTROINTESTINAL DISORDERS                                                                     |                           |                                 |
| Total number of patients with at least one adverse                                             | 175 (24.3%)               | 429 (58.0%)                     |
| NAUSEA                                                                                         | 94 (13.1)                 | 308 (41.6)                      |
| CONSTIPATION                                                                                   | 59 (8.23)                 | 126 (17.0%)                     |
| VOMITING                                                                                       | 37 (5.1$)                 | 108 (14.6)                      |
| DRY MOUTH                                                                                      | 6 1.3)                    | 100 (13.5)                      |
| STOMATITIS                                                                                     | 27 (3.8)                  | 80 (10.8%)                      |
| Total number of events                                                                         | 265                       | 939                             |
| NERVOUS SYSTEM DISORDERS                                                                       |                           |                                 |
| Total number of patients with at least one adverse                                             | 169 (23.5)                | 337 (45.5%)                     |
| event HEADACHE                                                                                 | 122 (16.9%)               | 210 (28.45)                     |
| PERIPHERALSENSORYNEUROPATHY                                                                    | 50 (6.95)                 | 138 (18.65)                     |
| DYSGEUSIA                                                                                      | 11 (1.5)                  | 60 (8.13)                       |
| Total number of events                                                                         | 209                       | 497                             |
| INVESTIGATIONS                                                                                 |                           |                                 |
| Total number of patients with at least one adverse                                             | 78 (10.8%)                | 360 (48.63)                     |
| event ASPARTATE AMINOTRANSFERASEINCREASED                                                      | 40 (5.6)                  | 210 (28.4)                      |
| PLATELET COUNT DECREASED                                                                       | 17 2.48)                  | 211 (28.5)                      |
| ALANINE AMINOTRANSFERASE INCREASED                                                             | 41 5.73)                  | 171 (23.18)                     |
| BLOOD ALKALINE PHOSPHATASE INCREASED                                                           | 13 1.8$)                  | 61 (8.2)                        |
| BLOOD BILIRUBIN INCREASED                                                                      | 2 (0.3)                   | 49 (6.6)                        |
| Total number of events                                                                         | 132                       | 870                             |
| MUSCULOSKELETALAND CONNECTIVE TISSUE DISORDERS                                                 |                           |                                 |
| Total number of patients with at least one adverse event                                       | 148 (20.6)                | 192 (25.9)                      |
| ARTHRALGIA Total number of events                                                              | 148 (20.6) 162            | 192 (25.93) 221                 |
| event HOT FLUSH Total number of events                                                         | 146 (20.3) 146 (20.3) 154 | 95 (12.8) 95 (12.8) 99          |
| RESPIRATORY,THORACICANDMEDIASTINALDISORDERS Total number of patients with at least one adverse | 25(3.5)                   | 159 (21.5)                      |
| event EPISTAXIS                                                                                | 25(3.5)                   |                                 |
|                                                                                                | 30                        |                                 |
| Total number of events                                                                         |                           | 159 (21.58) 222                 |
| METABOLISMANDNUTRITIONDISORDERS                                                                |                           |                                 |
| Total number of patients with at least one adverse event                                       | 16 ( 2.2)                 | 62(8.4)                         |
| DECREASED APPETITE Total number of events                                                      | 16 ( 2.2) 19              | 62 (8.4) 70                     |

<div style=\"page-break-after: always\"></div>

## Grade 3-4 AEs

Table 50: NCI-CTCAE Grade ≥ 3 AEs with at least 1% Incidence in either arm by PT and by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

| NCI-CTCAE Grade >=3 Adverse Events by Treatment Regimen,Safety Evaluable Patients Protoco1:B027938 Status: FINAL Snapshot Date:12SEP2018 Clinical Cut-0ff Date:25JUL2018   | NCI-CTCAE Grade >=3 Adverse Events by Treatment Regimen,Safety Evaluable Patients Protoco1:B027938 Status: FINAL Snapshot Date:12SEP2018 Clinical Cut-0ff Date:25JUL2018   | NCI-CTCAE Grade >=3 Adverse Events by Treatment Regimen,Safety Evaluable Patients Protoco1:B027938 Status: FINAL Snapshot Date:12SEP2018 Clinical Cut-0ff Date:25JUL2018   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MedDRA Preferred Term                                                                                                                                                      | TrastuzumabTrastuzumabEmtansine (N=720)                                                                                                                                    | (N=740)                                                                                                                                                                    |
| INVESTIGATIONS                                                                                                                                                             |                                                                                                                                                                            |                                                                                                                                                                            |
| PLATELETCOUNT DECREASED                                                                                                                                                    | 0.3                                                                                                                                                                        | 42 5.7                                                                                                                                                                     |
| NEUTROPHILCOUNT DECREASED                                                                                                                                                  | 0.7%)                                                                                                                                                                      | 1.2）                                                                                                                                                                       |
| INJURY,POISONINGAND PROCEDURALCOMPLICATIONS RADIATION SKIN INJURY                                                                                                          | 7 (1.0)                                                                                                                                                                    | 10 ( 1.4)                                                                                                                                                                  |
| VASCULAR DISORDERS HYPERTENSION                                                                                                                                            | 9(1.3)                                                                                                                                                                     | 15 (2.0)                                                                                                                                                                   |
| S PERIPHERALSENSORYNEUROPATHY                                                                                                                                              | 0                                                                                                                                                                          | 10 ( 1.4)                                                                                                                                                                  |
| METABOLISMANDNUTRITIONDISORDERS HYPOKALAEMIA                                                                                                                               | 1 (0.15)                                                                                                                                                                   | 9(1.2)                                                                                                                                                                     |
| GENERALDISORDERSANDADMINISTRATIONSITE CONDITIONS FATIGUE                                                                                                                   | 1 ( 0.1)                                                                                                                                                                   | 8 (1.1)                                                                                                                                                                    |
| ANAEMIA                                                                                                                                                                    | 1 ( 0.15)                                                                                                                                                                  | 8 (1.1$)                                                                                                                                                                   |

## Adverse drug reactions

The safety of trastuzumab emtansine has been evaluated in 2,611 breast cancer patients in clinical studies. In this patient population:

- the most common serious ADRs (&gt; 0.5% of patients) were haemorrhage, pyrexia, thrombocytopenia, dyspnoea, abdominal pain, musculoskeletal pain, and vomiting.
- the most common adverse drug reactions (ADRs) ( ≥ 25%) with trastuzumab emtansine were nausea, fatigue, musculoskeletal pain, haemorrhage, headache, transaminases increased, thrombocytopenia, and peripheral neuropathy. The majority of ADRs reported were of Grade 1 or 2 severity.
- the most common National Cancer Institute - Common Terminology Criteria for Adverse Events (NCICTCAE) Grade ≥ 3 ADRs (&gt; 2%) were thrombocytopenia, increased transaminases, anaemia, neutropenia, fatigue and hypokalaemia.

The table below presents pooled data from the overall treatment period in the MBC studies (N= 1871; median number of cycles of trastuzumab emtansine was 10) and in KATHERINE (N=740; median number of cycles was 14).

<div style=\"page-break-after: always\"></div>

| System Organ Class                                   | Very Common                                                                      | Common                                                                                          | Uncommon                                                                               |
|------------------------------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Infections and infestations                          | Urinary tract infection                                                          |                                                                                                 |                                                                                        |
| Blood and lymphatic system disorders                 | Thrombocytopenia, Anaemia                                                        | Neutropenia, Leucopoenia                                                                        |                                                                                        |
| Immune system disorders                              |                                                                                  | Drug hypersensitivity                                                                           |                                                                                        |
| Metabolism and nutrition disorders                   |                                                                                  | Hypokalaemia                                                                                    |                                                                                        |
| Psychiatric disorders                                | Insomnia                                                                         |                                                                                                 |                                                                                        |
| Nervous system disorders                             | Neuropathy peripheral, Headache                                                  | Dizziness, Dysgeusia, Memory impairment                                                         |                                                                                        |
| Eye disorders                                        |                                                                                  | Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased                                  |                                                                                        |
| Cardiac disorders                                    |                                                                                  | Left ventricular dysfunction                                                                    |                                                                                        |
| Vascular disorders                                   | Haemorrhage                                                                      | Hypertension                                                                                    |                                                                                        |
| Respiratory, thoracic and mediastinal disorders      | Epistaxis, Cough, Dyspnoea                                                       |                                                                                                 | Pneumonitis (ILD)                                                                      |
| Gastrointestinal disorders                           | Stomatitis, Diarrhoea, Vomiting, Nausea, Constipation, Dry mouth, Abdominal pain | Dyspepsia, Gingival bleeding                                                                    |                                                                                        |
| Hepatobiliary disorders                              | Transaminases increased                                                          | Blood alkaline phosphatase increased, blood bilirubin increased                                 | Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia, Portal hypertension |
| Skin and subcutaneous tissue disorders               |                                                                                  | Rash, Pruritus, Alopecia, Nail disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria |                                                                                        |
| Musculoskeletal and connective tissue disorders      | Musculoskeletal pain, Arthralgia, Myalgia                                        |                                                                                                 |                                                                                        |
| General disorders and administration site conditions | Fatigue, Pyrexia, Asthenia                                                       | Peripheral oedema, Chills                                                                       | Injection site extravasation                                                           |
| Injury, poisoning and procedural complications       |                                                                                  | Infusion-related reactions                                                                      | Radiation pneumonitis                                                                  |

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious AEs

## Table 51: Summary of Serious Adverse Events by Treatment Regimen Occurring in at least 2 Patients in either Treatment Arm (Safety Evaluable Patients) - Study KATHERINE

Serious Adverse Events by Treatment Regimen, Safety Evaluable Patients Protocol: BO27938   Status: FINAL

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Snapshot Date: 12SEP2018   Clinical Cut-Off Date: 25JUL2018

| MedDRA MedDRA                                                                                                                                               | System Organ Class Trastuzumab Preferred Term (N=720)   | Trastuzumab Emtansine (N=740)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|---------------------------------|
| __________________________________________________________________________________________________ Total number of patients with at least one adverse event | 58 (8.1%)                                               | 94 (12.7%)                      |
| Overall Total number of events                                                                                                                              | 70                                                      | 114                             |
| INFECTIONS AND INFESTATIONS                                                                                                                                 |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 21 (2.9%)                                               | 37 ( 5.0%)                      |
| MASTITIS                                                                                                                                                    | 6 (0.8%)                                                | 8 ( 1.1%)                       |
| DEVICE RELATED INFECTION                                                                                                                                    | 0                                                       | 6 ( 0.8%)                       |
| BRONCHITIS                                                                                                                                                  | 1 (0.1%)                                                | 3 ( 0.4%)                       |
| PNEUMONIA                                                                                                                                                   | 1 (0.1%)                                                | 3 ( 0.4%)                       |
| SKIN INFECTION                                                                                                                                              | 2 (0.3%)                                                | 2 ( 0.3%)                       |
| LUNG INFECTION                                                                                                                                              | 1 (0.1%)                                                | 2 ( 0.3%)                       |
| URINARY TRACT INFECTION                                                                                                                                     | 2 (0.3%)                                                | 1 ( 0.1%)                       |
| WOUND INFECTION                                                                                                                                             | 2 (0.3%)                                                | 1 ( 0.1%)                       |
| APPENDICITIS                                                                                                                                                | 0                                                       | 2 ( 0.3%)                       |
| GASTROENTERITIS                                                                                                                                             | 0                                                       | 2 ( 0.3%)                       |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS                                                                                                              |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 8 (1.1%)                                                | 8 ( 1.1%)                       |
| WOUND DEHISCENCE                                                                                                                                            | 1 (0.1%)                                                | 3 ( 0.4%)                       |
| RADIATION PNEUMONITIS                                                                                                                                       | 0                                                       | 2 ( 0.3%)                       |
| TIBIA FRACTURE                                                                                                                                              | 0                                                       | 2 ( 0.3%)                       |
| GASTROINTESTINAL DISORDERS                                                                                                                                  |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 5 (0.7%)                                                | 10 ( 1.4%)                      |
| VOMITING                                                                                                                                                    | 2 (0.3%)                                                | 3 ( 0.4%)                       |
| ABDOMINAL PAIN                                                                                                                                              | 1 (0.1%)                                                | 3 ( 0.4%)                       |
| INVESTIGATIONS                                                                                                                                              |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 1 (0.1%)                                                | 12 ( 1.6%)                      |
| PLATELET COUNT DECREASED                                                                                                                                    | 0                                                       | 10 ( 1.4%)                      |
| NERVOUS SYSTEM DISORDERS                                                                                                                                    |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 1 (0.1%)                                                | 8 ( 1.1%)                       |
| PERIPHERAL SENSORY NEUROPATHY                                                                                                                               | 0                                                       | 3 ( 0.4%)                       |
| PERIPHERAL MOTOR NEUROPATHY                                                                                                                                 | 0                                                       | 2 ( 0.3%)                       |
| SYNCOPE                                                                                                                                                     | 0                                                       | 2 ( 0.3%)                       |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                                                                                                             |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 1 (0.1%)                                                | 8 ( 1.1%)                       |
| EPISTAXIS                                                                                                                                                   | 0                                                       | 2 ( 0.3%)                       |
| PNEUMONITIS                                                                                                                                                 | 0                                                       | 2 ( 0.3%)                       |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                                                        |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 4 (0.6%)                                                | 4 ( 0.5%)                       |
| NON-CARDIAC CHEST PAIN                                                                                                                                      | 2 (0.3%)                                                | 3 ( 0.4%)                       |
| HEPATOBILIARY DISORDERS                                                                                                                                     |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 2 (0.3%)                                                | 5 ( 0.7%)                       |
| VASCULAR DISORDERS                                                                                                                                          |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 5 (0.7%)                                                | 2 ( 0.3%)                       |
| EMBOLISM                                                                                                                                                    | 3 (0.4%)                                                | 1 ( 0.1%)                       |
| CARDIAC DISORDERS                                                                                                                                           |                                                         |                                 |
| Total number of patients with at least one adverse event                                                                                                    | 4 (0.6%) (0.3%)                                         | 2 ( 0.3%)                       |
| CARDIAC FAILURE IMMUNE SYSTEM DISORDERS                                                                                                                     | 2                                                       | 2 ( 0.3%)                       |
| Total number of patients with at least one adverse event                                                                                                    | 0                                                       | 4 ( 0.5%)                       |
| HYPERSENSITIVITY                                                                                                                                            | 0                                                       | 4 ( 0.5%)                       |

<div style=\"page-break-after: always\"></div>

## Deaths and primary cause of deaths

Table 52: Summary of Deaths by Reason for Death by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

Summary of Deaths by Reason for Death by Treatment Regimen, Safety Evaluable Patients

Protoco1:B027938

Status: FINAL

Snapshot Date:12SEp2018

ClinicalCut-Off Date:25JUL2018

| Cause of Death               | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)   |
|------------------------------|-----------------------|---------------------------------|
| Total No.of Deaths           | 56 (7.8%)             | 42(5.7)                         |
| Cause of Death Breast cancer | 52 (7.2%)             | 39(5.3)                         |
| Adverse event                | 1 (0.1)               | 1 (0.15)                        |
| Other                        | 3(0.4%)               | 2 (0.3号)                        |

<!-- image -->

Five  patients  died  with  reason  reported  as  \"other\"  (terms  reported  were  pneumonia  [n=2],  and cerebrovascular event [n=1] in the trastuzumab arm; cerebrovascular event with renal insufficiency [n=1] and death after osteosynthesis [n=1] in the Kadcyla arm). Per protocol, these were non-reportable adverse events because they occurred &gt;30 days after last study treatment and were not related to study treatment or study procedures.

There was one fatal AE during the protocol-defined AE reporting period: intracranial haemorrhage in a patient receiving Kadcyla.  The patient received the first cycle of Kadcyla on Study Day 1 and died on Day 32 due to intracranial haemorrhage.  The investigator assessed the fatal intracranial haemorrhage to be related to Kadcyla.

In addition, one patient in the trastuzumab arm died due to encephalitis infection. This event occurred outside the protocol-specified reporting period for adverse events of 30 days (the patient had discontinued from  study  treatment  on  Study  Day  212  and  had  subsequently  received  one  dose  of  trastuzumab  as non-study treatment on Study Day 239), was not related to study treatment or study procedure. Therefore this was not reportable as an AE, but was erroneously marked as a death due to an AE on the eCRF instead of under 'other', and therefore appears in Table 52 under the AE category.

This patient had neurological symptoms (disorientation and incoherent speech on Study Day 252; CT scan of the brain showed decrease in size, oedema of brain, and metastases (previously reported). No bleeding or new lesions were found. The cerebrospinal fluid was positive for herpes virus type 1 and the patient was diagnosed  with  encephalitis.  On  Study  Day  257,  the  patient  died  due  to  encephalitis  and  secondary neurological deterioration. No autopsy was performed. The physician assessed encephalitis infection to be not related to trastuzumab, but related to disease under study and concomitant medication (dexamethasone) that may have increased her susceptibility to infection.

## Selected AEs

## Thrombocytopenia

Thrombocytopenia was reported in 28.5% of patients in EBC clinical studies with trastuzumab emtansine and was the most common repor ted adverse reaction for all grades and grades ≥ 3, as well as the most common adverse reaction leading to treatment discontinuation (4.2%), dose interruptions, and dose reductions.

Independent of race, the incidence of Grade 3 or 4 events (&lt; 50,000/mm 3 ) was 5.7% in patients with EBC.

<div style=\"page-break-after: always\"></div>

Table 53: Summary of Selected AEs of Thrombocytopenia by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

Selected Adverse Events by Highest NCI CTCAE Grade，Safety Evaluable Patients Protocol:B027938 StatuS: FINAL Snapshot Date: 12SEP2018 ClinicalCut-Off Date:25JUL2018

| MedDRA System Organ Class Preferred Term   | Grac                | Trastuzumab (N=720)                                        | Trastuzumab Emtansine (N=740)                                                                                    |
|--------------------------------------------|---------------------|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Thrombocytopenia Overall                   | -Any Grade 1 23 4 5 | 17 (2.4%) 14 1.9%) 1 0.1%) 1 0.1%) 1 0.1%) 0 17 14 1 1 1 0 | 211 (28.5%) 105 (14.2%) 64 (8.6%) 27 (3.6%) 15 (2.0%) 0 211 (28.5%) 105 (14.2%) 64 (8.6%) 27 （ 3.6%) 15 (2.0%) 0 |
| PLATELETCOUNTDECREASED                     | Any Grade 1 2 3 4 5 | (2.4%) 1.9%) 0.1%) 0.1%) 0.1%)                             |                                                                                                                  |

Investigator text for AEs encoded using MedDRA version 21.0.All counts represent patients.Multiple occurrences of the same AE in one individual are counted once at the highest grade for this patient. To the Soc Overall row counts，a patient contributes only with the AE occurring with the highest grade within the Soc.Percentages are based on N in the column headings.Table includes allAEs duringtreatmentperiodto30days postlastdose andAEs relatedtostudytreatment or study procedures in the follow up period.

Table 54: Summary of Reversibility/Resolution of Grade ≥ 3 Selected AEs of Thrombocytopenia (Safety Evaluable Patients) - Study KATHERINE

Reversibility/Resolution of Grade &gt;=3 Selected Adverse Events,Safety Evaluable Patients Protoco1:Bo27938 Status: FINAL Snapshot Date: 12sEP2018 Clinical Cut-Off Date: 25JUL2018

Selected AEs :Thrombocytopenia

|                                                                                                                                           | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)   |
|-------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------|
| No.pts with Grade >=3 AE Pts with resolved AEs Pts with unresolved AEs Pts with recovering/resolving AEs                                  | 2 2 (100.0%) 0 0      | 42 40 (95.2%) 0 2 4.8%)         |
| No.pts with T-DMldiscontinuation due to Grade >=3 event Pts with resolved AEs Pts with unresolved AEs Pts with recovering/resolving AEs   | 0 0 0 0               | 12 10 (83.3%) 0 2 (16.7%)       |
| No.pts with T-DM1 dose reductions due to Grade >= 3 event Pts with resolved AEs Pts with unresolved AEs Pts with recovering/resolving AEs | 0 0 0                 | 9 6 (100.0%) 0 0                |
| No.pts with T-DMl dose delays due to Grade >= 3 event Pts with resolved AEs Pts with unresolved AEs Pts with recovering/resolving AEs     | 0 0 0                 | 0 0 0 0                         |

reductions and delays. For example, if an adverse event led to dose delay, then dose reduction and finally dose discontinuation,it would only appear under study drug discontinuations.Apatient who dies prior to resolution of AE(due to AE or other reasons) will show up under \"Pts with unresolved AEs\".AE resolution date may be after data cut-off as this is not subject to the data cut.

## Haemorrhage

More patients in the trastuzumab emtansine arm (216 patients [29.2%]) had at least one AE in the hemorrhage category than in the trastuzumab arm (69 patients [9.6%]). The most commonly reported AEs (in at least 1% patients in either arm) were: epistaxis (3.5% for trastuzumab vs. 21.5% for trastuzumab emtansine), contusion (1.1% vs. 1.8%), vaginal haemorrhage (0.8% vs. 1.6%), haematoma (0.8% vs. 1.4%), rectal haemorrhage (0.7% vs. 1.4%), menorrhagia (0.3% vs. 1.5%), mouth haemorrhage (0.1% vs. 1.6%), and gingival bleeding (0.1% vs. 1.2%). No patient had an AE of Grade 4 intensity in either arm.

Two patients (0.3%) in the trastuzumab arm and three patients (0.4%) in the trastuzumab emtansine arm had at least one Grade ≥ 3 AE. A total of 4 patients (2 patients in each arm) were reported to have AEs resolved at CCoD. In the trastuzumab emtansine arm, one patient had a Grade 5 event (haemorrhage intracranial). No other events of CNS haemorrhage were reported.

In some of the observed cases the patients had thrombocytopenia, or were also receiving anti-coagulant therapy or antiplatelet therapy; in others there were no known additional risk factors.

<div style=\"page-break-after: always\"></div>

## Cardiac safety

Table 55: Summary of Selected AE of Cardiotoxicity by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

Selected Acverse Events by Highest NCI CICAE Grade, Safety Evaluable Patients Protocol: B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-Off Date: 25JUL2018

Table 56: Summary of Reversibility/Resolution of Grade ≥ 3 Selected AE of Cardiotoxicity (Safety Evaluable Patients) - Study KATHERINE

| MedDRA System Organ Class Preferred Term   | Grade             | Trastuzumab (N=720)        | Trastuzumab Emtansine (N=740)   |
|--------------------------------------------|-------------------|----------------------------|---------------------------------|
| Cardiac dysfunction                        |                   |                            |                                 |
| Overail                                    | Any Gradle １２３4５— | 40 5.6%) 1. 0.3 3号) 0号) 38 | 3.1%) 0.3 38)                   |
|                                            | Any Grade 12345—  | (4.3%) 28 3.98) 0.48)      | (2.6号) 2.28) 0.48)              |
| LEFTVENIRICULARDYSFUNCTION                 | Any Grade 12345—  | (0.68) (0.68) 00           | 0.48) 0.38) (0.18)              |
| CARDIAC FAILURE                            | Any Grade 12345—  | (0.68) 0.3号) 0.38)         | (0.38) 0.18) 0.1%) 00           |
| DIASTOLICDYSFUNCTION                       | Any Gracle 12345  | 402200220000 0.38) 0.38)   | 00000                           |

Reversibility/Resolution of Grade &gt;=3Selected AdverseEvents，SafetyEvaluablePatients Prot0co1:B027938 Status: FINAL Snapshot Date:12SEP2018 Clinical Cut-0ff Date:25JUL2018

Selected AEs:Cardiac dysfunction

|                                                                                                                                            | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)   |
|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------|
| No. pts with Grade >=3 AE Pts with resolved AEs Pts with unresolved AEs Pts with recovering/resolving AEs                                  | 9 6 (100.0%) 00       | 4 4 (100.0%) 00                 |
| No. pts with T-IMl discontinuation due to Grade >= 3 event Pts with resolved AEs Pts with unresolved AEs Pts with recovering/resolving AEs | 0 0                   | 3 (100.0%) 00                   |
| No.ptswith T-DMldosereductions due to Grade>=3event Pts with resolved AEs Pts with unresolved AEs Pts with recovering/resolving AEs        | 0 00                  | 0 00:0                          |
| No.pts with T-DMl dose delays clue to Grade >= 3 event Pts with resolved AEs Pts with unresolved AEs Pts with recovering/resolving AEs     | 0 0                   | 0 000                           |

reductions and delays. For exanple, if an adverse event led to dose delay, then dose reduction and finallydosediscontinuation,\\_itwouldonlyaypearunder studydrugdiscontinuations.Apatientwho dies prior to resolution of AE (due to AE or other reasons) will show up under \"Pts with unresolved AEs\".AE resolution date may be after data cut-off as this is not subject to the data cut.

<div style=\"page-break-after: always\"></div>

Table 57: Cardiac Events as Adjudicated Positively by the Cardiac Review Committee by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

Cardiac Events as adjudicated positively by the Cardiac Review Committee by Treatment Regimen，Safety Evaluable Patients Protocol:B027938 StatuS: FINAL Snapshot Date:12sEP2018 ClinicalCut-Off Date: 25JUL2018

|                                                                                                                                                                                                           | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------|
| Any cardiac event Treatment difference(trastuzumab emtansine - trastuzumab) 95CI*                                                                                                                         | 27 (3.8%)             | 19 (2.6%) 1.2 (-3.0， 0.7)       |
| Definite cardiac death Probable cardiac death                                                                                                                                                             | 1 (0.1%)              | 0                               |
| Symptomatic NYHA Class III or IVwith a decreasein LVEFof>=10percentage points from baseline to anLVEF<50 Symptomatic LvsD not meeting protocol specified cardiac event criteria (NYHA Class II)           | 3 (0.4%) 9 (1.3%)     | 1 (0.1%) 6 5(0.8%)              |
| Asymptomatic Asymptomatic confirmed decrease in LvEF of >=10 percentage points from baseline to an LvEF <50& Asymptomaticunconfirmed decreasein LVEF of>=10percentage points from baseline to an LVEF<50& | 6(0.8%) 10 (1.4)      | 4(0.5) 8 (1.1%)                 |
| Other                                                                                                                                                                                                     | 0                     | 0                               |
| Non-evaluable                                                                                                                                                                                             | 1 (0.1%)              | 0                               |

Percentages are based on N in the column headings.* 95&amp; confidence interval with Hauck-Anderson correction

## Table 58: Recovery from Cardiac Events as Adjudicated Positively by the Cardiac Review Committee by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

Recovery from Cardiac Events as adjudicated positively by the Cardiac Review Committee by Treatment Regimen, Safety Evaluable Patients

Snapshot Date: 12SEP2018   Clinical Cut-Off Date: 25JUL2018

Protocol: BO27938   Status: FINAL

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

| ______________________________________________________________________________________                                | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)   |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------|
| Number of patients with any non-fatal cardiac event#                                                                  | 26 ( 3.6%)            | 19 ( 2.6%)                      |
| LVEF recovery achieved*                                                                                               |                       |                                 |
| n                                                                                                                     | 26                    | 19                              |
| Yes                                                                                                                   | 22 (84.6%)            | 14 (73.7%)                      |
| No                                                                                                                    | 4 (15.4%)             | 5 (26.3%)                       |
| Time to recovery (weeks)                                                                                              |                       |                                 |
| n                                                                                                                     | 22                    | 14                              |
| Median                                                                                                                | 7.5                   | 9.7                             |
| Range                                                                                                                 | 3.0 - 52.6            | 3.0 - 87.0                      |
| Number of patients with symptomatic left ventricular dysfunction (NYHA class III or IV) with confirmed LVEF decrease# | 0                     | 0                               |
| LVEF recovery achieved*                                                                                               |                       |                                 |
| n                                                                                                                     | 0                     | 0                               |
| Yes                                                                                                                   | 0                     | 0                               |
| No                                                                                                                    | 0                     | 0                               |
| Time to recovery (weeks)                                                                                              |                       |                                 |
| n                                                                                                                     | 0                     | 0                               |
| Median                                                                                                                | NE                    | NE                              |
| Range                                                                                                                 | NE - NE               | NE - NE                         |
| Number of patients with asymptomatic left ventricular dysfunction with confirmed LVEF decrease#                       | 6 ( 0.8%)             | 4 ( 0.5%)                       |
| LVEF recovery achieved*                                                                                               |                       |                                 |
| n                                                                                                                     | 6                     | 4                               |
| Yes                                                                                                                   | 4 (66.7%)             | 2 (50.0%)                       |
| No                                                                                                                    | 2 (33.3%)             | 2 (50.0%)                       |
| Time to recovery (weeks)                                                                                              |                       |                                 |
| n                                                                                                                     | 4                     | 2                               |
| Median                                                                                                                | 12.3                  | 57.6                            |
| Range                                                                                                                 | 7.3 - 20.4            | 28.3 - 87.0                     |

*Recovery defined as at least 2 consecutive LVEF assessments &gt;=50% after the date of the cardiac event. #Excluding patients with later cardiac death.

<div style=\"page-break-after: always\"></div>

Figure 13: Plot of Mean LVEF over Time with 95%CI by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

<!-- image -->

Left ventricular dysfunction occurred in 3.0% of patients with EBC, with Grade 3 or 4 in 0.5% of patients.

28 patients (vs. 24 in the Kadcyla arm) presented a significant change from basal LVEF (defined as an absolute value &lt;50% and decrease ≥10 points from bas eline). 4 patients in the trastuzumab arm and 2 in the Kadcyla arm reached LVEF values &lt;40%, all 6 of them previously treated with anthracyclines.

<div style=\"page-break-after: always\"></div>

Table 59: Summary of Maximum Decrease in LVEF Measures by Treatment Regimen (Absolute Value &lt; 50% and Decrease from Baseline ≥ 10  or ≥ 15 EF Points) (Safety Evaluable Patients) -Study KATHERINE

Summary of Maximum Decrease in LvEF Measures by Treatment Regimen, absolute value &lt;5o? and decrease from baseline &gt;=l0 or &gt;=15 EF points, Safety Evaluable Patients Protocol:B027938 StatuS: FINAL Snapshot Date:12SEP2018 ClinicalCut-OffDate:25JUL2018

<!-- image -->

## Hepatotoxicity

Increased transaminases (AST/ALT) were reported in 32.4% of patients with EBC. Grade 3 and 4 increased transaminases were reported in 1.5% of patients with EBC.

Table 60: Summary of Selected AE of Hepatotoxicity by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Selected Adverse Events by Highest NCI CTCAE Grade, Safety Evaluable Patients Protocol: BO27938   Status: FINAL Snapshot Date: 12SEP2018   Clinical Cut-Off Date: 25JUL2018

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

| MedDRA System Organ Class Preferred Term   | Grade   | Grade   | Grade   | Trastuzumab (N=720)   | Trastuzumab (N=720)       | Trastuzumab Emtansine (N=740)   | Trastuzumab Emtansine (N=740)                                                               |
|--------------------------------------------|---------|---------|---------|-----------------------|---------------------------|---------------------------------|---------------------------------------------------------------------------------------------|
| Hepatotoxicity                             |         |         |         |                       |                           |                                 | ___________________________________________________________________________________________ |
| - Overall -                                | -       | Any     | Grade - | 76                    | (10.6%)                   | 276                             | (37.3%)                                                                                     |
|                                            | 1       |         |         | 65                    | ( 9.0%)                   | 191                             | (25.8%)                                                                                     |
|                                            | 2       |         |         | 8                     | ( 1.1%)                   | 73                              | ( 9.9%)                                                                                     |
|                                            | 3       |         |         | 3                     | ( 0.4%)                   | 12                              | ( 1.6%)                                                                                     |
| ASPARTATE AMINOTRANSFERASE                 | 4       | Any     | -       | 0 0 40                | ( 5.6%)                   | 0 0 210                         |                                                                                             |
|                                            | 5 - 1 2 |         | Grade - | 36 2 2 0              | ( 5.0%) ( 0.3%) ( 0.3%) ( | 171 35 4 0 171 136 32 3 0       | (28.4%) (23.1%) ( 4.7%) ( 0.5%)                                                             |
| ALANINE AMINOTRANSFERASE INCREASED         | 5 3 4   | Any     | Grade   | 35 4 2 0 0 13         | ( 4.9%) ( 0.6%) ( 0.3%)   |                                 | ( 4.3%) ( 0.4%)                                                                             |
| BLOOD ALKALINE PHOSPHATASE INCREASED       | 3 4 1 2 | Any     |         | 0 41                  | 5.7%)                     |                                 | (23.1%)                                                                                     |
|                                            | -       |         | -       |                       |                           | 0                               | (18.4%)                                                                                     |
|                                            |         |         |         | 0                     |                           | 8 1                             |                                                                                             |
|                                            |         |         | Grade   | 0                     | 1.8%)                     |                                 | ( 1.1%)                                                                                     |
|                                            | 3       |         |         | 0                     | (                         | 0 61 52                         | ( ( 0.1%)                                                                                   |
|                                            | 2       |         |         |                       |                           |                                 | ( 8.2%) 7.0%)                                                                               |
|                                            | 5 - 1   |         |         | 13                    | 1.8%)                     |                                 |                                                                                             |
|                                            |         |         |         |                       | (                         |                                 |                                                                                             |
|                                            | 4       |         |         |                       |                           | 0                               |                                                                                             |

trastuzumab

<div style=\"page-break-after: always\"></div>

| BLOOD BILIRUBIN INCREASED           | 5 - Any Grade - 1 2 3   | 0 2 ( 1 ( 1 ( 0                     | 0 0.3%) 49 0.1%) 36 0.1%) 13 0   | ( 6.6%) ( 4.9%) ( 1.8%)         |
|-------------------------------------|-------------------------|-------------------------------------|----------------------------------|---------------------------------|
| GAMMA-GLUTAMYLTRANSFERASE INCREASED | 5 - Any Grade - 1 2 3 4 | 0 4 ( 0.6%) 2 ( 0.3%) 2 ( 0.3%) 0 0 | 0 27 10 13 4 0                   | ( 3.6%) ( 1.4%) ( 1.8%) ( 0.5%) |
| HYPOALBUMINAEMIA                    | 5 - Any Grade - 1 2 3   | 0 7 ( 1.0%) 7 ( 1.0%) 0 0           | 0 8 8 0 0                        | ( 1.1%) ( 1.1%)                 |
| HEPATIC STEATOSIS                   | 5 - Any Grade - 1 2 3 4 | 0 5 ( 5 ( 0 0 0                     | 0 0.7%) 6 0.7%) 6 0 0 0          | ( 0.8%) ( 0.8%)                 |
| SPIDER NAEVUS                       | 5 - Any Grade - 1 2 3   | 0 1 ( 0.1%) 1 ( 0.1%) 0 0           | 0 6 6 0 0                        | ( 0.8%) ( 0.8%)                 |
| HEPATIC PAIN                        | 5 - Any Grade - 1 2 3   | 0 2 ( 0.3%) 2 ( 0.3%) 0 0           | 0 1 1 0 0                        | ( 0.1%) ( 0.1%)                 |
| NODULAR REGENERATIVE HYPERPLASIA    | 4 5 - Any Grade - 1 2   | 0 0 0 0 0                           | 0 0 2 0 0                        | ( 0.3%)                         |
| ASCITES                             | 5 - Any Grade - 1 2 3 4 | 0 0 0 0 0 0                         | 0 1 1 0 0 0                      | ( 0.1%) ( 0.1%)                 |
| HEPATITIS                           | 5 - Any Grade - 1 2 3 4 | 0 0 0 0 0 0                         | 0 1 0 1 0 0                      | ( 0.1%) ( 0.1%)                 |
| HEPATOCELLULAR INJURY               | 5 - Any Grade - 1 2 3 4 | 0 0 0 0 0 0                         | 0 1 0 1 0 0 0                    | ( 0.1%) ( 0.1%)                 |
| TRANSAMINASES INCREASED             | 5 - Any Grade - 1 2 3 4 | 0 0 0 0 0 0                         | 1 1 0 0 0 0                      | ( 0.1%) ( 0.1%)                 |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 61 : Summary of Reversibility/Resolution of Grade ≥ 3 Selected AE of Hepatotoxicity (Safety Evaluable Patients) - Study KATHERINE

Reversibility/Resolution of Grade &gt;=3 Selected Adverse Events, Safety Evaluable Patients Protoco1:B027938 StatuS: FINAL Snapshot Date: 12SEP2018 ClinicalCut-Off Date:25JUL2018

Selected AEs :Hepatotoxicity

|                                                                              | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)                                        |
|------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------------------|
| No.pts with Grade >=3 AE                                                     | 3 33.3%)              | 12 7(58.3%) 2 (16.7%) 3( 25.0%) 2 50.0%) 0 1(50.0%) 2 2 (100.0%) 0 0 |
| Pts with resolved AEs                                                        |                       |                                                                      |
| Pts with unresolved AEs                                                      | 2 66.7%)              |                                                                      |
| Pts with recovering/resolving AEs                                            | 0                     |                                                                      |
| No.pts with T-DMl discontinuation due to Grade >= 3 event                    | 0                     |                                                                      |
| Pts with resolved AEs                                                        | 0                     |                                                                      |
| Pts with unresolved AEs                                                      | 0                     |                                                                      |
| Pts with recovering/resolving AEs                                            | 0                     |                                                                      |
| No.pts withT-DMldose reductions due toGrade>=3 event                         |                       |                                                                      |
| Pts with resolved AEs                                                        | 0                     |                                                                      |
| Pts with unresolved AEs                                                      | 0                     |                                                                      |
| Pts with recovering/resolving AEs                                            | 0                     |                                                                      |
| No. pts with T-DMl dose delays due to Grade >= 3 event Pts with resolved AEs |                       | 0                                                                    |
|                                                                              | 0                     | 0                                                                    |
| Pts with unresolved AEs                                                      | 0                     | 0                                                                    |
| Pts with recovering/resolving AEs                                            | 0                     | 0                                                                    |

reductions and delays. For example,if an adverse event led to dose delay, then dose reduction and finally dose discontinuation, it would only appear under study drug discontinuations..A patient who dies prior to resolution of AE (due to AE or other reasons) will show up under \"Pts with unresolved AEs\".AE resolution date may be after data cut-off as this is not subject to the data cut.

<div style=\"page-break-after: always\"></div>

## Peripheral neuropathy

The overall incidence was 32.3% and 10.3% for Grade ≥ 2.

Table 62: Summary of selected AE of peripheral neuropathy by treatment regimen (safety evaluable patients)

Selected Adverse Events by Highest NCI CTCAE Grade, Safety Evaluable Patients Protocol:B027938 StatuS: FINAL Snapshot Date: 12SEP2018 Clinical Cut-Off Date:25JUL2018

| MedDRA System Organ Class Preferred Tem   | Grade       | Trastuzumab (N=720)   | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)   | Trastuzumab Emtansine (N=740)   |
|-------------------------------------------|-------------|-----------------------|-----------------------|---------------------------------|---------------------------------|
| Peripheral Neuropathy                     |             |                       |                       |                                 |                                 |
| Overall                                   | Any Grade   | 122                   | (16.9%)               | 239                             | (32.38)                         |
|                                           |             | 100                   | (13.9%)               | 163                             | (22.0%)                         |
|                                           | 2           | 21                    | 2.9%)                 | 64                              | (8.6%)                          |
|                                           | 3           |                       | (( 0.1%)              | 12                              | (1.6%)                          |
|                                           | 4           | 100                   |                       | 0                               |                                 |
|                                           | 5           |                       |                       | 0                               |                                 |
| PERIPHERALSENSORYNEUROPATHY               | Any Gradle  | 50                    | (6.9%)                | 138                             | (18.6%)                         |
|                                           | 1           | 39                    | 5.4%)                 | 90                              | (12.2%)                         |
|                                           | 2           | 11                    | 1.5%)                 | 38                              | (5.1%)                          |
|                                           | 3           |                       |                       | 10                              | 1.4%)                           |
|                                           | 4           |                       |                       | 0                               |                                 |
|                                           | 5           |                       |                       | 0                               |                                 |
| PARAESTHESIA                              | Any Grade   |                       | 5.7%)                 | 60                              | 8.1%)                           |
|                                           | 1           | 38                    | 5.38)                 | 49                              | 6.6%)                           |
|                                           | 2           |                       | 0.3%)                 | 10                              | 1.4%)                           |
|                                           | 3           |                       | 0.1%)                 | 1                               | 0.1%)                           |
|                                           | 4           |                       |                       | 0                               |                                 |
|                                           | 5           |                       |                       | 0                               |                                 |
| MUSCULAR WEAKNESS                         | Any Grade   |                       | 1.7%)                 | 15                              | 2.0%)                           |
|                                           | 1           |                       | 1.3%)                 | 13                              | 1.8%)                           |
|                                           | 2           | 921008                | 0.3%)                 | 2                               | 0.3%)                           |
|                                           | 3           |                       | 0.1%)                 |                                 |                                 |
|                                           | 4           |                       |                       | 0                               |                                 |
|                                           | 5           |                       |                       | 0                               |                                 |
| PERIPHERALMOTORNEUROPATHY                 | Any Grade   |                       | 1.1%)                 | 16                              | (2.2%)                          |
|                                           | 1           | 8                     | 1.1%)                 | 8                               | 1.1%)                           |
|                                           | 2           |                       |                       | 5                               | 0.7%)                           |
|                                           | 3           | 00007                 |                       | 3                               | 0.4%)                           |
|                                           | 4           |                       |                       | 0                               |                                 |
|                                           | 5           |                       |                       | 0                               |                                 |
| DYSAESTHESIA                              | 一 Any Grade |                       | 1.0%)                 | 7                               | 0.9%)                           |
|                                           | 1           | 6                     | 0.8%)                 | 7                               | 0.9%)                           |
|                                           | 2           | 1                     | 0.1%)                 | 0                               |                                 |
|                                           | 3           | ００0５２３                |                       | 0                               |                                 |
|                                           | 4           |                       |                       | 0                               |                                 |
|                                           | 5           |                       |                       | 0                               |                                 |
| NEURALGIA                                 | Any Grade   |                       | 0.7%)                 | 9                               | 1.2%)                           |
|                                           | 1           |                       | 0.3%)                 | 2                               | 0.3%)                           |
|                                           | 2           |                       | 0.4%)                 | 7                               | 0.9%)                           |
|                                           | 3           | 0007                  |                       | 0                               |                                 |
|                                           | 4           |                       |                       |                                 | 0                               |
|                                           | 5           |                       |                       |                                 | 0                               |
| NEUROPATHYPERIPHERAL                      | 一 Any Grade |                       | 1.0%)                 | 6                               | (0.8%)                          |
|                                           | 1           |                       | 0.7%)                 | 3                               | 0.4%)                           |
|                                           | 2           | ５２０００                 | 0.3%)                 | 3                               | (0.4%)                          |
|                                           | 3           |                       |                       |                                 | 0                               |
|                                           | 4           |                       |                       |                                 | 0                               |
|                                           | 5           |                       |                       |                                 | 0                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| HYPOAESTHESIA         | Any Gradle                   | ６６０００００           | （ 0.8%)   | ( 0.7%)                              |
|-----------------------|------------------------------|-------------------|-----------|--------------------------------------|
|                       |                              |                   | 0.8%)     | 0.7%)                                |
|                       |                              |                   |           | 55000033000022000011000011000011000: |
| SKIN BURNINGSENSATION | Any Grade                    |                   |           | 0.4%)                                |
|                       |                              |                   |           | 0.4%)                                |
|                       |                              | 0                 |           |                                      |
|                       |                              | 00                |           |                                      |
| GAIT DISTURBANCE      | Any Grade                    |                   |           | 0.3%) 0.3%)                          |
|                       |                              | 00                |           |                                      |
| NEUROTOXICITY         | １２３４５—１２３４５—１２３４５— Any Grade | OOOOOOTTOOOOTTOOO | 0.1%)     | 0.1%)                                |
|                       |                              |                   | 0.1%)     | 0.1%)                                |
| POLYNEUROPATHY        | Any Grade                    |                   | 0.1%)     | 0.1%)                                |
|                       |                              |                   | 0.18)     | 0.1%)                                |
| BURNINGSENSATION      | １２34５-１２３４5— Any Grade       |                   |           | 0.1%)                                |
|                       |                              |                   |           | 0.1%)                                |
|                       |                              |                   |           | 0 0                                  |
|                       | Any Gradle                   | 0000110000        | 0.1%)     |                                      |
|                       |                              |                   | 0.1%)     |                                      |
| NEURITIS              | Any Gradle                   |                   |           | 0.1%)                                |
|                       | GＺT-SＺT-εＺT-GＺT              |                   |           | 0.1%)                                |
|                       |                              | 0:0               |           |                                      |
| PERONEALNERVEPALSY    | Any Grade                    | 00                |           | 0.1%)                                |
|                       |                              |                   |           | 0.1%)                                |
|                       |                              | 0000              |           |                                      |
|                       |                              |                   |           | OOOOTTOOOOTTOOOOO                    |

## Other events

Infusion-related reactions were reported in 1.6% of patients with EBC, with no Grade 3 or 4 events reported. Hypersensitivity was reported in 2.7% of patients with EBC, with Grade 3 or 4 in 0.4% of patients.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Table 63: Laboratory abnormalities observed in patients treated with trastuzumab emtansine in study BO27938/KATHERINE

|                          | Trastuzumab emtansine (N=740)   | Trastuzumab emtansine (N=740)   | Trastuzumab emtansine (N=740)   |
|--------------------------|---------------------------------|---------------------------------|---------------------------------|
| Parameter                | All Grade%                      | Grade 3 (%)                     | Grade 4 (%)                     |
| Hepatic                  |                                 |                                 |                                 |
| Increased bilirubin      | 11                              | 0                               | 0                               |
| Increased AST            | 79                              | <1                              | 0                               |
| Increased ALT            | 55                              | <1                              | 0                               |
| Haematologic             |                                 |                                 |                                 |
| Decreased platelet count | 51                              | 4                               | 2                               |
| Decreased haemoglobin    | 31                              | 1                               | 0                               |
| Decreased neutrophils    | 24                              | 1                               | 0                               |
| Potassium                |                                 |                                 |                                 |
| Decreased potassium      | 26                              | 2                               | <1                              |

Table 64: Laboratory Test Results Shift Table for Hematology: Highest NCI CTACE Grade Post Baseline by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 65: Laboratory Test Results -Shift Table for Hepatic Chemistry: Highest NCI CTACE Grade Post Baseline by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

<!-- image -->

With regards to platelet count shifts, 87% of patients with normal baseline platelet count remained with normal count in the trastuzumab arm. Conversely, 52% of patients from the Kadcyla arm with normal baseline  platelet  count  underwent  platelet  count  decreases  that  re-classified  them  as platelet  count decreased. 45 patients from the Kadcyla arm (6.1%) experienced clinically relevant shifts (baseline G0-1 to post-baseline G3-4) as compared to only 2 patients in the trastuzumab arm (0.3%).

<div style=\"page-break-after: always\"></div>

In terms of liver enzyme shifts, adjuvant treatment with trastuzumab had minimal impact in liver enzymes. On the contrary, treatment with Kadcyla adversely affected their values, particularly ASAT (38 patients with baseline G0-1 to post-baseline G2-3) and ALAT (29 patients). Of note, 5 patients treated with Kadcyla suffered bilirubin shifts from baseline G0 to post-baseline G3.

## Safety in special populations

## AEs by age

The vast majority of patients (90.8%-92.2%) were below 65 years old, with a median age of 49.0 years in both arms. No notable clinically meaningful differences were observed and there were no major additional safety concerns associated with Kadcyla in patients aged 65-74.

The number of patients ≥75 years old (N=9 total) was small. In the trastuzumab arm, 2 out of 7 patients ≥75  years  old  experienced at  least  one  SAE.  In  the  Kadcyla  arm,  no  patient  was  reported  to  have experienced any SAE in this age group.

The incidence of Grade ≥3 AEs was similar across the treatment arms for patients between 65 -74 years old. Further, no notable difference was observed between the age group of 40-64 years versus 65-74 years in terms of incidence of Grade ≥3 AEs. However, the older patients (65 -74 years) in the trastuzumab arm tended to have numerically higher incidence of Grade ≥3 AEs than the younger patients in tha t treatment arm.

## AEs by race

The majority of patients in this study were white (71.5% patients in the trastuzumab armand 74.2% patients in the trastuzumab emtansine arm, per randomized population). Overall, 8.6% of the randomized population was Asian. In the trastuzumab emtansine arm, the incidence of Grade ≥ 3 AEs and SAEs was higher in Asian patients than in White patients: this difference was not seen in the trastuzumab arm. In the trastuzumab emtansine arm, the difference between the Asian and White patients in terms of SAEs and Grade ≥ 3 AEs was mainly due to the event of platelet count decreased (SAE: 7.8% in Asian patients vs. 0.4% in White patients; Grade ≥ 3 AEs: 18.8% in Asian patients vs.3.1% in White patients).

In the trastuzumab emtansine arm, a higher incidence of all Grade and Grade ≥ 3 thrombocytopenia was reported among Asian patients compared with other subgroups (All Grade: White [135 patients, 24.5%] vs. Asian [32 patients, 50.0%] vs. Black [5 patients, 25.0%] vs. Other [39 patients, 36.8%]); Grade ≥ 3AEs: White [17 patients, 3.1%] vs. Asian [12 patients, 18.8%] vs. Black [2 patients, 10.0%] vs. Other [11 patients, 10.4%]) which is consistent with previous findings.

In the trastuzumab emtansine arm, overall there was a higher incidence of patients with at least one AE leading to withdrawal from the study treatment among Asian compared with other races (White [90 patients, 16.4%] vs. Asian [20 patients, 31.3%] vs. Black [3 patients, 15.0%] vs. Other [20 patients, 18.9%]). Similarly, a higher incidence of AEs leading to dose reduction and interruption of trastuzumab emtansine was reported among Asian patients compared with patients from other races.

<div style=\"page-break-after: always\"></div>

## Table 66: Safety Summary by Treatment Regimen and Race, Safety Evaluable Patients - Study KATHERINE

Safety Summary by Treatment Regimen and Race,Safety Evaluable Patients Protoco1:B027938 Status: FINAL Snapshot Date:12SEP2018 Clinical Cut-0ff Date: 25JUL2018

|                                                                                                                                                          | Trastuzumab (N=720)   | Trastuzumab (N=720)        | Trastuzumab (N=720)   | Trastuzumab (N=720)   | Trastuzumab Emtansine (N=740)   | Trastuzumab Emtansine (N=740)   | Trastuzumab Emtansine (N=740)   | Trastuzumab Emtansine (N=740)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------|-----------------------|-----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                                                                                                          | White (N=510)         | Asian (N=62)               | Black (N=20)          | other (N=128)         | Whi te (N=550)                  | Asian (N=64)                    | Black (N=20)                    | other (N=106)                   |
| Total number of patients with at least one adverse event Total number of adverse events                                                                  | 473(92.78) 3565       | 57(91.98) 343              | 20(100.0%) 177        | 122(95.38) 1232       | 543(98.78) 6016                 | 64 (100.08) 664                 | 20(100.0%) 294                  | 104(98.1$) 1455                 |
| Total number ofpatients with at least one                                                                                                                |                       |                            |                       |                       |                                 |                                 |                                 |                                 |
| AE with fatal outcome                                                                                                                                    | 0                     | 0                          | 0                     | 0                     | 0                               | 1( 1.6%)                        | 0                               | 0                               |
| Serious AE                                                                                                                                               | 39 7.6$)              | 1 1.6%)                    | 2 (10.0%)             | 16 (12.58)            | 66 (12.0%)                      | 14 21.9%)                       | 3 (15.0%)                       | 11 (10.4%)                      |
| Serious Related AE                                                                                                                                       | 1.0%)                 | 0                          | 0                     | 3 (2.38)              | 23 (4.28)                       | 6 14.18)                        | 1 5.0%)                         | 6(5.78)                         |
| Grade >=3 AEs                                                                                                                                            | 75 (14.7%)            | 5 (8.18)                   | 5 (25.08)             | 26 (20.38)            | 131 (23.8%)                     | 26 40.6%)                       | （ 45.08)                        | 24 (22.68)                      |
| AE leading to withdrawal from Trastuzumab/Trastuzumab Emtansine excluding switched treatment*                                                            | 14 (2.7%)             | 0                          | 0                     | 1 (0.88)              | 06 (16.48)                      | 20 31.38)                       | 3 (15.0%)                       | 20 (18.9$)                      |
| AE leading to dose reduction of Trastuzumab Emtansine AE leading to dose interruption of Trastuzumab/Trastuzumab Emtansine excluding switched treatment* | 0 21 (4.18)           | 0 2 3.28)                  | 0 2 (10.0%)           | 0 12 (9.48)           | 66 (12.0%) 70 (12.78)           | 13 （20.38) 16 （ 25.0%)          | 5.0%) 2 10.08)                  | 10 （9.4%) 18 (17.0%)            |
|                                                                                                                                                          | 222 (43.5%)           | 25 (40.38)                 | 13 (65.0%)            | 66 (51.68)            | 465 (84.58)                     | 61 (95.38)                      | 18 (90.0%)                      | 97 (91.5%)                      |
| AE related to Trastuzumab/Trastuzumab Emtansine* Selected AEs for trastuzumab emtansine:patients with Hepatotoxicity (all grades)                        | 48 1 0.2%) 9.4%)      | 1 7 3 (1.68) (11.3%) 4.8$) | 0 ( 5.0%)             | 20 1 (15.68) (0.8%)   | 191 6 (34.78) 1.18)             | 26 2 40.6%) 3.18) 3.18)         | 1 8 40.0%) 5.0$)                | 51 3(2.8%) (48.18)              |
| Cardiac dysfunction NCI-CTCAE Grade>=3                                                                                                                   | 28 5.5%)              | 0                          | 2 (10.0%)             | 7 1 5.5) 0.88)        | 15 2 0.48) 2.78)                | 0                               | 2 1 10.0%) 5.0$)                | 4 3.8$)                         |
| NCI-CTCAE Grade>=3                                                                                                                                       | 8 1.6%)               | 3 (4.8%)                   | 0                     | 3 (2.38) （            | 135 (24.58)                     | 32 50.0%)                       | 5 25.0%)                        | 39 1 (36.8%) (0.98)             |
| Thrombocytopenia NCI-CTCAE Grade >=3                                                                                                                     | 11 2 (0.48) 2.2%)     | 0                          | 0                     | 0                     | 17 (3.18)                       | 12 18.8%)                       | 2 10.0$)                        | 11 (10.48)                      |
| Peripheral Neuropathy                                                                                                                                    |                       | 0                          | 0                     | 28 1 (0.8%)           | 147 10 (1.8$) (26.78)           | 16 2 25.08) 3.18)               | 0                               | 30 (28.3%) 0                    |
| NCI-CTCAE Grade >=3                                                                                                                                      | 83 0 (16.3%)          | 8 (12.9%)                  | 3 (15.0%)             | (21.98)               | 186 (33.88)                     |                                 | 7 35.0%)                        |                                 |
| Hemorrhage                                                                                                                                               | 43 1 8.4$)            | 5 (8.18)                   | 1 5.0%)               | 20 (15.6%)            | 1                               | 2 4 37.5%)                      | 7 35.0%)                        | 38 (35.8%)                      |
| NCI-CTCAE Grade >=3                                                                                                                                      | 0.2%)                 | 0                          | 0                     | 1 0.88)               | (0.28)                          | 1 1.6%)                         | 1 5.0%)                         | 0                               |
| IRR/hypersensitivity (type 1)                                                                                                                            | 9 (1.8%)              | 2 (3.28)                   | 1                     | 7 5.58)               | 42 7.68)                        | 3 4.78)                         | 1 5.0%)                         | 11 (10.48)                      |
| NCI-CTCAE Grade>=3                                                                                                                                       | 0                     | 0                          | 0 5.08)               | 0                     | 1 0.28)                         | 0                               | 0                               | 0                               |
| IRR/hypersensitivity symptoms                                                                                                                            | 4 (0.8%)              | 2 3.28)                    | 5.0%)                 | 2 1.68)               | 33 （ 6.08)                      | 2 3.18)                         | 1 5.0%)                         | 6                               |
|                                                                                                                                                          | 6 1.2%)               |                            | 1                     |                       | 12                              | 4                               |                                 | (5.7%)                          |
| Pulmonary toxicity                                                                                                                                       |                       | 0                          | 0                     | 0                     | 2.28)                           | 6.38)                           | 0                               | 5 （ 4.7%)                       |
| NCI-CTCAE Grade >=3                                                                                                                                      | 0                     | 0                          | 0                     | 0                     | 1 (0.28)                        | 1 （ 1.68)                       | 0                               | 1(0.98)                         |

column headings.Multiple occurrences of the same AE inone individual are counted only once except for'Total number of AEs'row in which multiple occurrences of the same AE are counted separately. Table includes all AEs during treatment period to 30 days post last dose and AEs related to study treatment or study procedures in the follow up period. follow-up.*In the Trastuzumab emtansine arm,only adverse events related to Trastuzumab Total emtansine are evaluated. number of deaths are counted over the whole study period,including post-treatment White = white.Black =Black or African American, Asian = Asian: Indian subcontinent or Asian: Other than Indian subcontinent ，Other = American Indian or Alaska Native ， Native Hawaiian or Pacific Islander or Other or Unknownor multiple.

Output:root/clinical\\_studies/R05304020/CDPT3519/B027938/data\\_analysis/CSR\\_INTERIM/prod/output/t\\_saf\\_sum\\_race\\_SE.out 16NOV2018 17:27

## Safety related to drug-drug interactions and other interactions

No new study was submitted to assess safety related to drug-drug interactions.

## Immunogenicity

A total of 1243 patients from seven clinical studies were tested at multiple time points for anti-drug antibody (ADA) responses to trastuzumab emtansine.

Table 67: Anti-drug Antibody Responses to Trastuzumab Emtansine

| Study Number                  | Study Phase                   | No. of ADA Evaluable Patients a   | No. of Patients Determined to be Positive for ADA b   |
|-------------------------------|-------------------------------|-----------------------------------|-------------------------------------------------------|
| TDM3569                       | I                             | 48                                | 1                                                     |
| TDM4258g                      | II                            | 108                               | 8                                                     |
| TDM4374g                      | II                            | 108                               | 6                                                     |
| TDM4688g                      | II                            | 47                                | 0                                                     |
| TDM4450g/BO21976              | II                            | 65                                | 9                                                     |
| TDM4370g/BO21977              | III                           | 466                               | 24                                                    |
| BO27938                       | III                           | 401                               | 15                                                    |
| Total                         | Total                         | 1243                              | 63                                                    |
| Overall Kadcyla ADA Incidence | Overall Kadcyla ADA Incidence | 5.1% (63/1243)                    | 5.1% (63/1243)                                        |

Source: 2.7.2 Summary of Clinical Pharmacology Studies a  Patients with at least one evaluable post-treatment ADA time point were considered evaluable for an ADA response to trastuzumab emtansine.

b  Except for study BO27938, patients with at least one positive post-dose ADA response were considered to be ADA positive, irrespective of baseline status.  For study BO27938, patients with treatment-emergent responses were considered to be ADA positive.

Following trastuzumab emtansine dosing, 5.1% (63/1243) of patients tested positive for anti-trastuzumab emtansine antibodies at one or more post-dose time points. In the Phase I and Phase II studies, 6.4% (24/376) of patients tested positive for anti- trastuzumab emtansine antibodies. In the EMILIA study (TDM4370g/BO21977), 5.2% (24/466) of patients tested positive for anti-trastuzumab emtansine

Page 1 of 1

<div style=\"page-break-after: always\"></div>

antibodies, of which 13 were also positive for neutralizing antibodies. In the KATHERINE (BO27938) study, 3.7% (15/401) of patients tested positive for anti-trastuzumab emtansine antibodies, of which 5 were also positive for neutralizing antibodies.

## Discontinuation due to adverse events

## Table 68: AEs Leading to Study Treatment Discontinuation Occurring in at Least 2 Patients in either Treatment Arm (Safety Evaluable Patients) - Study KATHERINE

Adverse  Events  Leading  to  Discontinuation  of  Trastuzumab  /Trastuzumab  emtansine  by  Treatment  Regimen,  Safety  Evaluable Patients

Protocol: BO27938   Status: FINAL

Snapshot Date: 12SEP2018   Clinical Cut-Off Date: 25JUL2018

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

| MedDRA System Organ Class MedDRA Preferred Term                                                                                                             | Trastuzumab Trastuzumab (N=720) (N=740)   | Emtansine   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-------------|
| __________________________________________________________________________________________________ Total number of patients with at least one adverse event | 15 (2.1%)                                 | 133 (18.0%) |
| Overall Total number of events                                                                                                                              | 17                                        | 198         |
| INVESTIGATIONS                                                                                                                                              |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 10 (1.4%)                                 | 74 (10.0%)  |
| PLATELET COUNT DECREASED                                                                                                                                    | 0                                         | 31 ( 4.2%)  |
| BLOOD BILIRUBIN INCREASED                                                                                                                                   | 0                                         | 19 ( 2.6%)  |
| EJECTION FRACTION DECREASED                                                                                                                                 | 10 (1.4%)                                 | 9 ( 1.2%)   |
| ASPARTATE AMINOTRANSFERASE INCREASED                                                                                                                        | 0                                         | 12 ( 1.6%)  |
| ALANINE AMINOTRANSFERASE INCREASED                                                                                                                          | 0                                         | 11 ( 1.5%)  |
| NEUTROPHIL COUNT DECREASED                                                                                                                                  | 0                                         | 3 ( 0.4%)   |
| NERVOUS SYSTEM DISORDERS                                                                                                                                    |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 0                                         | 22 ( 3.0%)  |
| PERIPHERAL SENSORY NEUROPATHY                                                                                                                               | 0                                         | 11 ( 1.5%)  |
| HEADACHE                                                                                                                                                    | 0                                         | 4 ( 0.5%)   |
| PERIPHERAL MOTOR NEUROPATHY                                                                                                                                 | 0                                         | 4 ( 0.5%)   |
| DIZZINESS                                                                                                                                                   | 0                                         | 2 ( 0.3%)   |
| GASTROINTESTINAL DISORDERS                                                                                                                                  |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 1 (0.1%)                                  | 13 ( 1.8%)  |
| NAUSEA                                                                                                                                                      | 0                                         | 7 ( 0.9%)   |
| ABDOMINAL PAIN                                                                                                                                              | 0                                         | 3 ( 0.4%)   |
| DIARRHOEA                                                                                                                                                   | 0                                         | 3 ( 0.4%)   |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                                                                                                             |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 1 (0.1%)                                  | 12 ( 1.6%)  |
| PNEUMONITIS                                                                                                                                                 | 0                                         | 7 ( 0.9%)   |
| EPISTAXIS                                                                                                                                                   | 0                                         | 2 ( 0.3%)   |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                                                        |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 0                                         | 11 ( 1.5%)  |
| FATIGUE                                                                                                                                                     | 0                                         | 3 ( 0.4%)   |
| INFLUENZA LIKE ILLNESS                                                                                                                                      | 0                                         | 3 ( 0.4%)   |
| PYREXIA                                                                                                                                                     | 0                                         | 3 ( 0.4%)   |
| PAIN                                                                                                                                                        | 0                                         | 2 ( 0.3%)   |
| CARDIAC DISORDERS                                                                                                                                           |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 3 (0.4%)                                  | 5 ( 0.7%)   |
| CARDIAC FAILURE                                                                                                                                             | 1 (0.1%)                                  | 2 ( 0.3%)   |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS                                                                                                             |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 0                                         | 7 ( 0.9%)   |
| ARTHRALGIA                                                                                                                                                  | 0                                         | 2 ( 0.3%)   |
| MYALGIA                                                                                                                                                     | 0                                         | 2 ( 0.3%)   |
| PAIN IN EXTREMITY                                                                                                                                           | 0                                         | 2 ( 0.3%)   |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS                                                                                                              |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 0                                         | 5 ( 0.7%)   |
| RADIATION PNEUMONITIS                                                                                                                                       | 0                                         | 3 ( 0.4%)   |
| PSYCHIATRIC DISORDERS                                                                                                                                       |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 1 (0.1%)                                  | 4 ( 0.5%)   |
| DEPRESSION                                                                                                                                                  | 1 (0.1%)                                  | 2 ( 0.3%)   |
| _________________________________________________________________________________________________ BLOOD AND LYMPHATIC SYSTEM DISORDERS                      |                                           |             |
| Total number of patients with at least one adverse event                                                                                                    | 0                                         | 2 ( 0.3%)   |
| ANAEMIA                                                                                                                                                     | 0                                         | 2 ( 0.3%)   |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Note: In the trastuzumab emtansine arm, only adverse events leading to discontinuation of trastuzumab emtansine are evaluated.Investigator text for AEs encoded using MedDRA version 21.0.

<div style=\"page-break-after: always\"></div>

```
Adverse_Events Leading to Dose Reduction of Trastuzumab/Trastuzumab emtansine by Treatment Regimen, Safety Evaluable Patients Prot0co1:B027938 Status: FINAL Snapshot Date: 12SEP2018 Clinical Cut-0ff Date: 25JUL2018
```

Table 69: AEs Leading to Dose Reduction of Study Drug by Treatment Regimen (Safety Evaluable Patients) - Study KATHERINE

|                                                          | Trastuewmab   | Trastuzumab Emtansine   |
|----------------------------------------------------------|---------------|-------------------------|
| MedDRA Preferred Term                                    | (N=720)       | (N=740)                 |
| Total number of patients with at least one adverse event | 0             | 90(12.24)               |
| Overall Total nwmber of events                           | 0             | 128                     |
| INVESTIGATIONS                                           |               |                         |
| Total number of patients with at least one adverse event | 0             | 65 (8.8)                |
| PLATELET COUNTDECREASED                                  | 0             | 23 ( 3.14)              |
| BLOOD BILIRUBIN INCREASED                                | 0             | 20 (2.74)               |
| ALANINE AMINOTRANSFERASE INCREASED                       | 0             | 14 (1.94)               |
| ASPARTATE AMINOTRANSFERASE INCREASED                     | 0             | 11 (1.54)               |
| WEIGHT DECREASED                                         | 0             | 2 (0.34)                |
| WHITE BLOOD CELLCOUNTDECREASED                           | 0             | 2 (0.34)                |
| BLOOD ALKALINE PHOSPHATASE INCREASED                     | 0             | 1 ( 0.14)               |
| NEUTROPHILCOUNT DECREASED                                | 口             | ( 0.14)                 |
| Total number of events                                   | 0             | 81                      |
| GENERALDISORDERS AND AIMINISTRATION SITECONDITIONS       |               |                         |
| Total number of patients with at least one adverse event | 0             | 6 (1.2)                 |
| FATIGUE                                                  |               | 8 1.14)                 |
| PAIN                                                     | 000           | (0.1%)                  |
| PYREXIA                                                  |               | 1 ( 0.14)               |
| Total number of events                                   | 0             | 10                      |
| NERVOUS SYSTEM DISORDERS                                 |               |                         |
| Total number of patients with at least one adverse event |               | 8 1.14)                 |
| PERIPHERAL SENSORY NEUROPATHY                            | 00            | 4 0.54)                 |
| HEADACHE                                                 | 0             | 1 0.14)                 |
| NERVE COMPRESSION                                        | 口             | 1 (0.14)                |
| PARAESTHESIA                                             |               | (0.19)                  |
| SYNCOPE                                                  | 60            | ( 0.14)                 |
| Total number of events                                   | 口             | 8                       |
| GASTROINTESTINALDISORDERS                                |               |                         |
| Total number of patients with at least one adverse event | 0             | 6 (0.81)                |
| NAUSEA                                                   | 0             | 0.54)                   |
| DIARRHOEA                                                | 0             | 2 0.34)                 |
| ABDOMINAL PAIN                                           | 0             | 1 0.14)                 |
| ABDOMINAL PAIN UPPER                                     | 0             | 1 ( 0.14)               |
| CONSTIPATION                                             | 0             | 1 [ 0.14)               |
| DRY MOUTH                                                | 0             | 1 (0.1)                 |
| DYSPHAGIA                                                | 0             | 1 ( 0.14)               |
| MOUTH HAEMORRHAGE                                        | 0             | (0.14)                  |
| VOMITING Total number of events                          | 0 0           | (0.1) 14                |
| INFECTIONS AND INFESTATIONS                              |               |                         |
| Total number of patients with at least one adverse event | 口             | 3 ( 0.44)               |
| DEVICE RELATED INFECTION                                 | 口             | 1 (0.1)                 |
| MASTITIS                                                 | 口             | ( 0.11)                 |
| UPPER RESPIRATORY TRACT INFECTION                        | 口             | ( 0.1t)                 |
| Total number of events                                   | 0             | 3                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| METABOLISMAND NUTRITION DISORDERS                         |    |           |
|-----------------------------------------------------------|----|-----------|
| Total number of patients with at least one adverse event  | 0  | 3 (0.4)   |
| DECREASED APPETITE                                        | 口  | 0.34)     |
| HYPOKALAEMIA                                              |    | ( 0.14)   |
| Total number of events                                    | 00 | 3         |
| MUSCULOSKELETALANDCONNECTIVE TISSUEDISORDERS              |    |           |
| Total number of patients with at least one adverse event  | 口  | 3 (0.4%)  |
| ARTHRALGIA                                                | 口  | 1 (0.14)  |
| MUSCULOSKELETAL PAIN                                      | 口  | 1 (0.14)  |
| MYALGIA                                                   |    | (0.1%)    |
| Total number of events                                    | 00 | 3         |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS           |    |           |
| Total number of patients with at least one adverse event. | 0  | 2 2(0.3)  |
| EPISTAXIS                                                 | 口  | 2 (0.3%)  |
| Total number of events                                    | 0  | 2         |
| EYE DISORDERS                                             |    |           |
| Total number of patients with at least one adverse event  | 0  | 0.14)     |
| VISION BLURRED                                            | 0  | 0.14)     |
| Total number of events                                    | 0  | 1         |
| HEPATOBILIARYDISORDERS                                    |    |           |
| Total number of patients with at least one adverse event  | 0  | [ 0.14)   |
| CHOLECYSTITIS                                             | 0  | 0.14)     |
| Total number of events                                    | 0  | 1         |
| INJURY,POISONING AND PROCEDURAL COMPLICATIONS             |    |           |
| Total number of patients with at least one adverse event  | 0  | 0.14)     |
| SEROMA                                                    | 0  | 0.1%)     |
| Total number of events                                    | 0  |           |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                    |    |           |
| Total number of patients with at least one adverse event  | 0  | 1 ( 0.14) |
| RASH MACULO-PAPULAR                                       | 0  | ( 0.14)   |
| Total number of events                                    | 0  |           |

<div style=\"page-break-after: always\"></div>

## Table 70: AEs Leading to Drug Interruption by Treatment Regimen (Safety Evaluable Patients) Study KATHERINE

```
Adverse Events Leading to Drug Interruption of Trastuzumab/Trastuzumab emtansine by Treatment Regimen, Safety Evaluable Patients Protocol:B027938 Status: FINAL Snapshot Date:12SEP2018 Clinical Cut-0ff Date: 25JUL2018
```

<!-- image -->

| MedDRA System Organ Class                                | Trastuzumab   | Trastuzumab Emtansine   |
|----------------------------------------------------------|---------------|-------------------------|
| MedDRA Preferred Term                                    | (N=720)       | (N=740)                 |
| Total number of patients with at least one adverse event | 37(5.14)      | 106 (14.3)              |
| Overall Totalnumber of events                            | 45            | 158                     |
| INVESTIGATIONS                                           |               |                         |
| Total number of patients with at least one adverse event | 13 (1.8%)     | 46 6.24)                |
| EJECTION FRACTION DECREASED                              | 11 (1.5)      | 7 0.9%)                 |
| PLATELET COUNT DECREASED                                 | 1 (0.14)      | 14 1.94)                |
| ASPARTATE AMINOTRANSFERASE INCREASED                     | 0             | 12 1.64)                |
| NEUTROPHIL COUNT DECREASED                               | 口             | 6 1.24)                 |
| BLOOD BILIRUBIN INCREASED                                | 0             | 0.5)                    |
| WHITE BLOOD CELL COUNT DECREASED                         | 0             | 4 0.541                 |
| ALANINE AMINOTRANSFERASE INCREASED                       | 0             | 3 0.4%)                 |
| LYMPHOCYTE COUNT DECREASED                               | 1 (0.14)      | 1 ( 0.14)               |
| TROPONIN T INCREASED                                     | 0             | 一 ( 0.14)               |
| Total number of events                                   | 13            | 60                      |
| INFECTIONS AND INFESTATIONS                              |               |                         |
| Total number of patients with at least one adverse event | 8 (1.14)      | 18 2.4)                 |
| BRONCHITIS                                               | 2 (0.35)      | 2 0.34)                 |
| MASTITIS                                                 | (0.3)         | 2 0.3%)                 |
| HERPES ZOSTER                                            | 1 (0.14)      | 2 0.3)                  |
| GASTROENTERITIS                                          | 0             | 2 0.34]                 |
| LUNG INFECTION                                           | 1 (0.14)      | 1 0.14)                 |
| PNEUMONIA                                                | 口             | 2 0.3%)                 |
| UPPER RESPIRATORY TRACT INFECTION                        | 口             | 2 0.34)                 |
| DIVERTICULITIS                                           | 0             | 1 0.14)                 |
| FOLLICULITIS                                             | 0             | 0.14)                   |
| HERPES SIMPLEX                                           | 口             | 0.14)                   |
| INFLUENZA                                                | 0             | 0.14)                   |
| NAIL INFECTION                                           | 1 (0.14)      | 0                       |
| TONSILLITIS                                              |               | 0.1$) 0.14)             |
| VIRAL INFECTION WOUND INFECTION                          | 1 (0.14)      | 0                       |
| Total number of events                                   | 8             | 20                      |
| GENERALDISORDERS AND AIMINISTRATION SITE CONDITIONS      |               |                         |
| Total number of patients with at least one adverse event | 4 (0.6)       | 14 (1.94)               |
| INFLUENZA LIKE ILLNESS                                   | 1 (0.14)      | 6 0.84)                 |
| PYREXIA                                                  | 2 (0.34)      | 4 (0.54)                |
| FATIGUE                                                  | 口             | 2 (0.3)                 |
| NON-CARDIAC CHEST PAIN                                   | 1 (0.14)      | 1 (0.14)                |
| CHILLS                                                   | 0             | 1 ( 0.14)               |
| Total number of events                                   | 4             | 15                      |
| RESPIRATORY,THORACIC AND MEDIASTINAL DISORDERS           |               |                         |
| Total number of patients with at least one adverse event | 3 [0.44)      | 10 (1.44)               |
| COUGH                                                    | 1 (0.14)      | 3 0.44)                 |
| EPISTAXIS                                                | 01            | 3 0.44)                 |
| DYSPNOEA                                                 | (0.14)        | 1 0.14)                 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE                    | 00            | 1 0.14)                 |
| NASAL CONGESTION                                         | 1             | 1 ( 0.14)               |
| OROPHARYNGEALPAIN PLEURAL EFFUSION                       | (0.14) 0      | 0 ( 0.14)               |
| Total number of events                                   | 3             | 10                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| GASTROINTESTINALDISORDERS Total number of patients with at least one adverse event                                                                | 3(0.4) (0.49)             | 6 (1.2)                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|----------------------------|
| DIARRHOEA NAUSEA                                                                                                                                  | 3                         | 0 2 0.3)                   |
| STOMATITIS                                                                                                                                        | 0 0                       | 2 0.35)                    |
| ABDOMINAL PAIN                                                                                                                                    | 0                         | 1 0.14)                    |
| DRY MOUTH                                                                                                                                         | 0                         | 1 0.1$)                    |
| MOUTH HAEMORRHAGE RECTALHAEMORRHAGE                                                                                                               | 0 0                       | 1 0.14) ( 0.14)            |
| VOMITING                                                                                                                                          | 0                         | 1 0.1+)                    |
| Total number of events                                                                                                                            | 3                         | 6                          |
| INJURY,POISONING AND PROCEDURAL COMPLICATIONS                                                                                                     |                           |                            |
| Totainumber of patients with at least one adverse event INFUSION RELATED REACTION                                                                 | 2 (0.35)                  | 10 ( 1.44)                 |
|                                                                                                                                                   | 1 (0.14)                  | 6 0.85)                    |
| RADIATION PNEUMONITIS RADIATION SKIN INJURY                                                                                                       | 0                         | 0.1) 0.14)                 |
| RECALL PHENOMENON                                                                                                                                 | 口 0                       | 11 ( 0.14)                 |
| SKIN WOUND                                                                                                                                        |                           | 1 (( 0.14) 0               |
| WRIST FRACTURE Total number of events                                                                                                             | (0.1%)                    |                            |
|                                                                                                                                                   | 1 2                       | 10                         |
| CARDIAC DISORDERS                                                                                                                                 |                           |                            |
| Total number of patients with at least one adverse event                                                                                          | 4 (0.6)                   | 3 0.45)                    |
| CARDIAC FAILURE                                                                                                                                   | (0.3)                     |                            |
| PALPITATIONS ANGINA PECTORIS                                                                                                                      | 00                        | 02100 0.341 0.14)          |
| ATRIAL FIBRILLATION                                                                                                                               | 1 (0.1%)                  |                            |
| CONDUCTION DISORDER                                                                                                                               | 1 (0.14)                  |                            |
| Total number of events                                                                                                                            | 4                         | 3                          |
| NERVOUS SYSTEM DISORDERS                                                                                                                          |                           |                            |
| Total number of patients with at least one adverse event                                                                                          | 1 (0.15) 1 (0.1)          | 6 0.851 0.14)              |
| PARAESTHESIA PERIPHERALSENSORY NEUROPATHY                                                                                                         | 0                         | ( 0.34)                    |
| DYSAESTHESIA                                                                                                                                      | 口                         | 21 0.14)                   |
| HEADACHE NYSTAGMUS                                                                                                                                | 0 0                       | ( 0.14)                    |
| Total number of events                                                                                                                            |                           | (0.14) 7                   |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                                            |                           |                            |
| Total number of patients with at least one adverse event                                                                                          | 1 (0.14)                  | ( 0.74) 0.35)              |
| RASHMACULO-PAPULAR DERMATITIS BULLOUS                                                                                                             | 0 0                       | ( 0.14)                    |
| PRURITUS                                                                                                                                          | 0                         | ( 0.14)                    |
| SKIN REACTION                                                                                                                                     | 0                         | 21110 (0 0.14)             |
| URTICARIA                                                                                                                                         | 1 (0.1)                   |                            |
| Total number of events                                                                                                                            | 1                         | 5                          |
| VASCULAR DISORDERS Total number of patients with at least one adverse event HYPERTENSION PHLEBITIS                                                | (0.14) 1 (0.15) 0         | 3 (0.45) 2 (0.35) 1 (0.1t) |
| Total number of events                                                                                                                            | 1                         | 3                          |
| IMMUNE SYSTEM DISORDERS Total number of patients with at least one adverse event HYPERSENSITIVITY                                                 | 2 [0.3] 2 (0.3) 2         | 0.14) ( 0.14) 8            |
| Total number of events BLOOD ANDLYMPHATICSYSTEMDISORDERS                                                                                          | 0                         | 2 (0.3)                    |
| Total number of patients with at least one adverse event ANAEMIA Total number of events                                                           | 0 0                       | (0.34) 2                   |
| MUSCULOSKELETALAND CONNECTIVE TISSUE DISORDERS Total_number of patients with at least one adverse event MYALGIA ARTHRALGIA Total number of events | 0 0 0 0                   | 2 0.3%) 2 ( 0.3%) 1 (0.14) |
| REPRODUCTIVESYSTEMAND BREAST DISORDERS UTERINE HAEMORRHAGE                                                                                        |                           | 3                          |
| Total number of patients with at least one adverse event UTERINE PROLAPSE Total number of events                                                  | 2(0.3) 1 (0.1) 1 (0.15) 2 | 0 0                        |
| EAR AND LABYRINTH DISORDERS Total number of patients with at least one adverse event EAR PAIN Total number of events                              | 0 0 0                     | 0.1) 0.14) 1               |
| EYE DISORDERS Total number of patients with at least one adverse event STRABISMUS                                                                 | 0 0                       | 0.14) 0.14) 1              |
| Total number of events PSYCHIATRIC DISORDERS                                                                                                      |                           |                            |
| Total number of patients with at least one adverse event SUICIDAL IDEATION                                                                        | 0                         | (0.1) 0.14)                |
| Total number of events                                                                                                                            | 0 0                       |                            |
| SURGICALANDMEDICALPROCEDURES Total_number of patients with at least one adverse event MENINGIOMA SURGERY                                          | (0.1)                     | D 0                        |
| Total number of events                                                                                                                            | (0.1) 1                   |                            |

<div style=\"page-break-after: always\"></div>

## Post marketing experience

As of 21 February 2018 (the Data Lock Point for the Kadcyla annual Periodic Benefit Risk Evaluation Report [PBRER]), an estimated cumulative total of 75,448 patients have received Kadcyla in the marketed setting.

The cumulative post-marketing data is consistent with the data submitted in previous PBRERs.  No new safety concerns were identified.

## 2.5.1. Discussion on clinical safety

To  support  the  proposed  indication  safety  data  from  the  ongoing  pivotal  Phase  III  study  KATHERINE (BO27938) and supplementary safety data from completed Phase II study TDM4874g/BO22857 have been provided (data not shown). The safety data of the two studies were not pooled because of significant differences between the studies, primarily in treatment modalities with respect to chemotherapy and/or radiotherapy given as part of the study treatment.

Post-marketing  signal  evaluation  from  the  global  safety  database  has  confirmed  thrombocytopenia, hepatotoxicity and haemorrhage as Kadcyla's major safety risks. It must be emphasised that, to date, Kadcyla has mainly been used in patients with metastatic incurable disease, i.e. in a palliative setting. The toxicity threshold tolerated in the palliative setting is very different from that in the adjuvant one.

Kadcyla as a single agent in early breast cancer was  first evaluated in the phase  II study TDM4874g/BO22857, designed primarily to assess safety, with a focus on cardiac events.  There were no symptomatic cardiac events and the incidence and severity of thrombocytopenia and hepatotoxicity were similar to that from MBC studies, but haemorrhages (43.9%) and peripheral neuropathy (33%) were more frequent than expected (data not shown). It was nevertheless concluded that such safety results indicated that Kadcyla was well tolerated in the EBC setting.

The target population of the KATHERINE trial was constituted by patients already exposed to cytotoxic chemotherapy in the neoadjuvant setting, nearly all suffering alopecia, fatigue and a degree of peripheral neuropathy, and after surgery, most of them will still face the unpleasant effects from radiotherapy and endocrine treatment. Safety population was constituted by 720 patients in the trastuzumab arm and 740 patients from the Kadcyla arm. The majority of patients in the trastuzumab arm (81.0%) completed all 14 cycles of treatment compared to the Kadcyla arm (71.4%). This considerable difference matters because most of the patients who prematurely discontinued Kadcyla did so because of toxic AEs: 133 (18%) in the Kadcyla arm vs. 15 (2%) in the trastuzumab arm. AEs from Kadcyla also led to one-level dose reductions in 77 (10.4%) patients and two-level dose reductions in 29 (3.9%). Furthermore, 71 (9.6%) patients from the Kadcyla arm ended up being switched to trastuzumab.

Overall exposure to Kadcyla in the KATHERINE trial (median number of cycles = 14) considerably exceeds that from the pivotal EMILIA trial (median number of cycles = 9).

In general, in safety terms, adjuvant Kadcyla compares quite unsatisfactorily to trastuzumab. Although most patients  in  both  arms  from  the  KATHERINE  study  experienced  at  least  one  AE,  the  amount  and proportion of ≥ G3 AEs (26% vs. 15%), serious AEs (5% vs. 1%) and AEs leading to treatment withdrawal (18% vs. 2%) in the Kadcyla arm is significantly higher than those at the trastuzumab arm.

Likewise, the higher incidence of those AEs that particularly concern Kadcyla as compared to trastuzumab is notorious:  any-grade  hepatotoxicity  (38%  vs.  11%),  thrombocytopenia  (29%  vs.  2%),  peripheral neuropathy (32% vs. 17%), haemorrhage (29% vs. 10%), infusion-related reactions (8% vs. 3%) and pulmonary  toxicity  (3%  vs.  1%).  Furthermore,  Kadcyla  is  more  often  associated  to  the  occurrence  of typically  chemotherapy-related  symptoms  such  as  nausea,  fatigue,  dry  mouth/stomatitis/dysgeusia, constipation, peripheral neuropathy and decreased appetite.

<div style=\"page-break-after: always\"></div>

For the management of ADRs, adequate dose modification guidelines for patients with early breast cancer have been included in section 4.2 of the SmPC.

The incidence of baseline peripheral neuropathy was similar in both arms (22.7% in the Kadcyla arm vs 21.4% patients in the trastuzumab arm). In most cases, this neuropathy was attributable to neoadjuvant taxanes, although of course, there might be other causalities. The fact that the overall incidence of peripheral neuropathy is 16.9% in the adjuvant trastuzumab arm supports the hypothesis that in clinical practice, peripheral neuropathy symptoms tend to reduce over the course of months after chemotherapy (at least in a group of patients). In patients who received Kadcyla, nevertheless, the post-adjuvant incidence of peripheral neuropathy affects one third of the patients. Sensory/motor neuropathy is a disabling AE with likely chronic consequences and a detrimental impact in quality of life. Considering its overall incidence (29.0% in MBC and 32.3% in EBC), peripheral neuropathy has been added in the listing of 'most common ADRs' in Section 4.8 of the SmPC. Mainly Grade 1 and predominantly sensory, has been reported in clinical studies with trastuzumab emtansine. MBC patients with ≥ Grade 3 and EBC patients with ≥ Grade 2 peripheral neuropathy at baseline were excluded from clinical studies. Furthermore a warning has been included in section 4.4 of the SmPC to reflect that treatment with trastuzumab emtansine should be temporarily discontinued in patients experiencing Grade 3 or 4 peripheral neuropathy until symptoms resolve or improve to ≤ Grade 2. Patients should be clinically monitored on an ongoing basis for signs/symptoms of neurotoxicity.

There were 4 cases of serious hypersensitivity in  the  Kadcyla  arm  and  none  in  the  trastuzumab  arm. However, in 3 of these patients the event was deemed unrelated to Kadcyla and more likely a consequence from antihypertensive medication.

In study KATHERINE, 211 patients from the Kadcyla arm (28.5%) experienced any-grade thrombocytopenia. Half of the patients experienced G1 thrombocytopenia, while the remaining half had ≥G2 events. 20% of patients experienced highgrade (≥G3) events. Most of the high -grade events (40, 95.2%) had resolved by the CCOD. In comparison, only 17 patients (2.4%) from the trastuzumab arm presented this AE. The proportion of thrombocytopenia in the supportive study was similar.

Overall, thrombocytopenia is Kadcyla's most common drug-specific AE (any-grade), highgrade (≥G3) AE, AE leading to treatment reduction and AE leading to treatment discontinuation. A significant number of haemorrhagic events (with or without relationship to thrombocytopenia) have been reported in patients treated with Kadcyla. A few of these bleeding events have had fatal outcomes, both in clinical trials and in the post-marketing routine signal detection activity. Considering thrombocytopenia and haemorrhage as Kadcyla's most important adverse drug reactions, the existing warning in section 4.4 of the SmPC has been updated to reflect that thrombocytopenia was the most common adverse reaction leading to treatment discontinuation, dose reduction, and dose interruption.

A significant number of haemorrhagic events (with or without relationship to thrombocytopenia) have been reported in patients treated with Kadcyla in study KATHERINE. 216 patients (29.2%) from the Kadcyla arm and 69 patients (9.6%) from the trastuzumab arm experienced haemorrhage of diverse categories. Most of these AEs were low-grade and with minor clinical implications, but 5 patients from both arms suffered high-grade bleeding AEs. The proportion of haemorrhage AEs in the supportive study TDM4874g/BO22857 was even higher: 43.9% of any-grade events. Most of the events were G1 and G2, but there were 2 patients with G3 epistaxis.

It  is  noted  that  71  patients  from  the  trastuzumab  arm  and  47  from  the  Kadcyla  arm  were  taking anticoagulant or antiplatelet therapy in Study KATHERINE. The SmPC already includes a warning about the added risk of anticoagulant and antiplatelet agents (see section 4.4 of SmPC).

Regarding cardiac toxicity, it has to be recalled that patients from the KATHERINE study were highly selected (see inclusion/exclusion criteria). The incidence of overall cardiac dysfunction was higher in the trastuzumab

<div style=\"page-break-after: always\"></div>

arm. All 14 Grade 3 events (9 in the trastuzumab arm and 4 in the Kadcyla arm) were however resolved at the time of the clinical cut-off date. Symptomatic cardiac failure (NYHA III/IV) or asymptomatic decrease in LVEF ≥10% from baseline, as adjudicated by the Cardiac Re view Committee, was also more frequent in the trastuzumab arm as compared with the Kadcyla arm. When these cardiac events were separated based on the prior use of anthracyclines, their proportion was slightly higher in patients from both arms who have received these cytotoxics as expected (3.5% vs. 2.1% in patients who have not). The differences between arms were not significant in either group (data not shown).

As anticipated, a considerable proportion of these cardiac events occurred in the first 6 months of the study (63%), i.e. while the patients were still on treatment; 6 out of 46 events happened after the IDFS events and could have been confounded by ulterior treatments. Recovery of the LVEF occurred in 80% of the patients, without considerable differences between arms. Looking at the mean LVEF over time, the very subtle decline in LVEF occurs only in the trastuzumab arm and peaks towards end of treatment.

The co-primary endpoint of the supportive study TDM4874g/BO22857 (N=148) was the rate of cardiac events within the first 12 weeks of Kadcyla treatment, but there were none observed (data not shown). However, there were 5 patients who presented asymptomatic cardiac dysfunction events (ejection fraction decreased) at any time during the study: 4 patients experienced a G2 event (3 of them recovered) and 1 patient had a G1 event.

Overall, existing risk minimisation activities are adequate to address cardiac toxicity. A warning on left ventricular dysfunction is already included in section 4.4 of the SmPC.

The rate of hepatotoxic events in the Kadcyla arm tripled that from the trastuzumab arm: 37.3% vs. 10.6%. G1 events were the most prevalent, but G2-3 events occurred in 85 patients (11.5%) from the Kadcyla arm and 12 patients (1.7%) from the control arm. The most common any-grade hepatotoxic events in the Kadcyla arm were increases of ASAT (28.4%), ALAT (23.1%), alkaline phosphatase (8.2%), bilirubin (6.6%) and GGT (3.6%). At least for the first three events, their incidences were considerably higher than those reported previously for Kadcyla (N=882): 23%, 15% and 6%, respectively (EPAR). 12 patients from the Kadcyla arm experienced G3 hepatotoxicity events (vs. 3 in the trastuzumab arm). These AEs had resolved in 7 patients and were resolving in 3 at the CCOD. The other 2 patients had unresolved events, one had nodular  regenerative  hyperplasia  (NRH)  and  the  other  had  GGT  increased).  The  narratives  from  both patients  who  developed  NRH suggest the AE was related to the Kadcyla. No patient fulfilled Hy's Law laboratory criteria.  It is considered that the risk of hepatotoxicity is adequately covered in section 4.4 of the SmPC and in the RMP.

In relation to pulmonary toxicity, the existing warning has been amended to cover radiation pneumonitis. Treatment with trastuzumab emtansine is to be permanently discontinued in patients who are diagnosed with ILD or pneumonitis, except for radiation pneumonitis in the adjuvant setting, where trastuzumab emtansine should be permanently discontinued for ≥ Grade 3 or for Grade 2 not responding to standard treatment (see SmPC sections 4.2 and 4.4). Patients with dyspnoea at rest due to complications of advanced malignancy, co morbidities, and receiving concurrent pulmonary radiation therapy may be at increased risk of pulmonary events.

Most of the deaths in the study were associated to progression of the underlying breast cancer (91 out of 98, 93%). The narratives of the 5 patients who died for reasons other than breast cancer or AEs are concise and render unlikely the participation of trastuzumab or Kadcyla in the final cause of death. However, one patient died from intracranial haemorrhage after the first dose of Kadcyla.

Regarding special populations, o nly 126 patients from the ITT (8.5%) were ≥65 years old, limiting a specific safety analysis in this age subgroup. However, the incidence of serious or ≥G3 AEs in both arms arm does not seem to vary significantly across age subgroups.

<div style=\"page-break-after: always\"></div>

Regarding race, 129 patients (8.7%) from the ITT of the KATHERINE trial were Asian. 32 out of 64 (50%) patients in the Kadcyla arm experienced any-grade thrombocytopenia (compared to 25% of white or black patients). The incidence of ≥G3 thrombocytopenia was also higher in Asian patients: 18.8% (vs. 3.1% of white patients and 10.0% of black patients). Alarmingly, 5 out of all 10 patients (50%) who experienced serious  thrombocytopenia  were  Asian.  The  SmPC  from  Kadcyla  already  states  that  the incidence  and severity of thrombocytopenia were higher in Asian patients (see SmPC section 4.4).

Based on the review of the data, section 4.7 of the SmPC has also been updated to reflect that trastuzumab emtansine has minor influence on the ability to drive and use machines. The significance of reported adverse reactions such as fatigue, headache, dizziness and blurred vision on the ability to drive or use machines is unknown. Patients experiencing infusion related reactions (flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia) should be advised not to drive and use machines until symptoms abate.

No new study of drug-drug interaction was provided which is considered acceptable. Available information on drug-drug interactions is reflected in the current SmPC.

Section 4.8 of the SmPC has been updated to reflect updated safety information. Pulmonary toxicity and hepatotoxicity are known risks for trastuzumab emtansine, two new adverse drug reactions (ADRs: radiation pneumonitis and blood bilirubin increased) were added to section 4.8 of the SmPC to fully characterize the safety profile in the adjuvant EBC setting. For the majority of the ADRs, the frequency categories were consistent between the MBC and EBC settings. The following ADRs are now listed in a lower frequency category based on updated safety data: Hypokalaemia (from very common to common), Rash (from very common to common), Chills (from very common to common). Furthermore, a sub-section has been added to present information on peripheral neuropathy.

As with all therapeutic proteins, there is the potential for an immune response to trastuzumab emtansine. Due to the low incidence of ADA, conclusions cannot be made on the impact of anti- trastuzumab emtansine antibodies on the pharmacokinetics, safety, and efficacy of trastuzumab emtansine.

Overall, the safety profile of trastuzumab emtansine in the proposed indication of early breast cancer is currently  not  expected to  be  different  from  the  known  safety  profile  in  terms  of  type  of  adverse  drug reactions reported. However, the frequency and severity of Kadcyla-specific AEs are increased in EBC. The SmPC has been updated to reflect the safety information available in EBC and update existing warnings as appropriate. No additional pharmacovigilance activities were considered needed as a result of the present procedure (see RMP).

## 2.5.2. Conclusions on clinical safety

The frequency and severity of Kadcyla-specific AEs is increased in the EBC setting. The product information has  been  updated  to  inform  healthcare  professionals  about  the  major  safety  risks  derived  from thrombocytopenia, haemorrhage and hepatotoxicity when considering adjuvant Kadcyla in patients with HER2+ EBC and residual invasive disease. Peripheral neuropathy is not a life-threatening symptom, but its much higher incidence from Kadcyla must be considered, since this disabling adverse effect can worsen quality of life for prolonged periods.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 9.2 is acceptable. The PRAC endorsed PRAC Rapporteur assessment report is attached.

The CHMP endorsed the Risk Management Plan version 9.2 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                             |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • ILD / ARDS • Hepatic toxicity • Nodular regenerative hyperplasia • Infusion related reactions • Hypersensitivity • Left ventricular dysfunction • Thrombocytopenia • Peripheral neuropathy                                                           |
| Important potential risks    | • Foetal harm • Medication error                                                                                                                                                                                                                       |
| Missing information          | • Use in patients with hepatic impairment • Use in patients with LVEF < 50% • Use in elderly patients (> 75 years) • Use in pregnant women • Use in lactation women • Clinical impact of anti-therapeutic antibodies • Use of non-validated HER2 tests |

## Pharmacovigilance plan

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| MO28231 (KAMILLA) A multicenter, single arm study of trastuzumab emtansine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received                                                | Primary objective: To evaluate the safety and tolerability of trastuzumab emtansine. Secondary Objectives: • Progression Free Survival (PFS) • Overall survival (OS) • Overall response                                    | • Left Ventricular Dysfunction • Safety in Elderly Patients • Use of a non-validated HER2 test                                                                                                                             | Primary Analysis Primary CSR Final Analysis Final CSR                                                                                                                                                                      | Q4 2016 Q4 2017 (Complete) Q4 2020 Q4 2021                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                                                                                                                             | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                           | Safety concerns addressed                                                                 | Milestones                                                        | Due dates                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------|
| prior anti-HER2 and chemotherapy-based treatment                                                                                                                                                                                                                                                                                                         | rate (ORR) • Clinical Benefit Rate (CBR) • Duration of Response (DoR) • Time to Response (TTR) Pharmacoeconomics Outcome Objective: • Health Resource                                                                                                                                                                                                                                           |                                                                                           |                                                                   |                                                       |
| BO27938 (KATHERINE) A randomized, multicenter, open label Phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy. | Utilization Objectives • To compare invasive disease free survival in patients with residual invasive breast cancer after treatment with preoperative chemotherapy and HER2-directed therapy including trastuzumab followed by surgery between the 2 treatment arms The secondary efficacy objective for this study is as follows: • To compare cardiac safety and overall safety between the 2 | • Left Ventricular Dysfunction • Safety in Elderly Patients • Anti-therapeutic antibodies | Study start Primary Analysis Primary CSR Final Analysis Final CSR | April 2013 Q4 2018 Q1 2019 (Complete) Q2 2023 Q2 2024 |
| BO28407 (KAITLIN) A randomized, multicenter, openlabel, Phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer                                             | treatment arms EBC - Adjuvant Efficacy Objectives: The co-primary efficacy objectives for this study are as follows: • To compare invasive diseasefree survival (IDFS) (1) in the node-positive subpopulation and (2) in the overall protocol- defined population of patients with HER2-positive breast cancer randomized to either receive a taxane and 1 year of trastuzumab plus pertuzumab  | • Left Ventricular Dysfunction • Safety in Elderly Patients • Anti-therapeutic antibodies | Study start Primary Analysis Primary CSR Final Analysis Final CSR | 31 January 2014 Q3 2019 Q3 2020 Q1 2024 Q1 2025       |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Safety concerns addressed                                                                 | Milestones                                                        | Due dates                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|
|                                                                                                                                                             | following anthracycline-base d chemotherapy or 1 year of trastuzumab emtansine plus pertuzumab following anthracycline-base d chemotherapy. The secondary efficacy objectives for this study are as follows: • To compare IDFS plus second non-breast primary cancers, disease-free survival (DFS), and distance recurrence-free interval (DRFI) (1) in the node-positive subpopulation and (2) in the overall protocol defined population between the two treatment arms • To compare overall survival (OS) (1) in the node-po sitive subpopulation and (2) in the overall protocol-defined population between the two treatment arms Safety Objectives: • To compare overall safety, cardiac safety, hepatic, and pulmonary safety in the overall protocol defined population between the two |                                                                                           |                                                                   |                                                                     |
| BO28408 (KRISTINE) A randomized, multicenter, openlabel,two-arm, Phase III neoadjuvant study evaluating trastuzumab emtansine plus pertuzumab compared with | treatment arms. EBC - Neoadjuvant Efficacy Objectives: • To compare the pathological complete response (pCR) rate (ypT0/is, ypN0) between chemotherapy, trastuzumab plus pertuzumab (Arm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | • Left Ventricular Dysfunction • Safety in Elderly Patients • Anti-therapeutic antibodies | Study start Primary Analysis Primary CSR Final Analysis Final CSR | 25 June 2014 25 February 2016 Q2 2017 (Complete) Q3 2018 (Complete) |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                  | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Safety concerns addressed                                                                          | Milestones                                    | Due dates                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------------------------|---------------------------|
| chemotherapy plus trastuzumab and pertuzumab for patients with HER2-positive breast cancer.                                                                   | A) and trastuzumab emtansine plus pertuzumab (Arm B) using local evaluation The secondary efficacy objectives for this study are: • To evaluate event-free survival EFS), invasive disease-free survival (IDFS), overall survival (OS) and rate of breast conserving surgery across treatment arms Safety Objectives: • To evaluate cardiac, hepatic, and overall safety in each treatment arm                                                                                                                                                                                                           |                                                                                                    |                                               | Q2 2019                   |
| BO39807 A retrospective cohort study based on the secondary use of Flatiron's US electronic health records database (Flatiron Health, Inc. New York, NY, USA) | Objective of PV activity: • To evaluate the risk for patients who have a LVEF between 40 - 49% prior to initiating treatment with trastuzumab emtansine. Objectives of this study are: • To describe the characteristics of the patients in this cohort prior to or at trastuzumab emtansine initiation in terms of demographics, disease characteristics and risk factors for cardiac events. • To describe the evolution of LVEF as recorded over time from the latest LVEF measurement recorded within the 60 days prior to treatment with trastuzumab emtansine (baseline) to the 84th day following | Patients who have a LVEF between 40 - 49% prior to initiating treatment with trastuzumab emtansine | Study Start Interim Study Report Final Report | 2017 2018 (Complete) 2019 |

<div style=\"page-break-after: always\"></div>

| Study Status   | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Safety concerns addressed   | Milestones   | Due dates   |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------|-------------|
|                | treatment discontinuation (absolute value and incidence of LVEF decrease > 10% from baseline). • To describe the event rate, incidence rate and cumulative incidence of the following cardiac events in this cohort from the initiation of treatment with trastuzumab emtansine (index date) to the 84th day following treatment discontinuation: - congestive heart failure - other relevant cardiac events (active cardiac tachyarrhythmia, ventricular tachycardia or ventricular fibrillation, acute coronary syndrome, unstable angina or myocardial infarction, cardiac hospitalization, death attributed to a cardiac event and any event referred to as 'treatment discontinuation due to cardiac toxicity' in the charts). |                             |              |             |

## Risk minimisation measures

| Safety concern                                                | Risk minimization measures                                          | Pharmacovigilance activities                                                |
|---------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Interstitial lung disease/Acute Respiratory Distress Syndrome | Routine risk communication: SmPC: Section 4.4 (Special warnings and | Routine pharmacovigilance activities beyond adverse reactions reporting and |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pharmacovigilance activities                                                                                       |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| (ILD/ARDS)       | precautions for use) Section 4.8 (Undesirable effects) Routine risk minimization activities recommending specific clinical measures to address the risk: It is recommended that treatment with trastuzumab emtansine be permanently discontinued in patients who are diagnosed with ILD or pneumonitis, except for radiation pneumonitis in the adjuvant setting, where trastuzumab emtansine should be permanently discontinued for ≥ Grade 3 or for Grade 2 not responding to standard treatment. This has been adequately captured in Section 4.4 of European Union Summary of Product Characteristic (EU SmPC). Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization | signal detection None Additional pharmacovigilance activities: None                                                |
| Hepatic Toxicity | Routine risk communication: SmPC: Section 4.2 (Posology and method of administration) Section 4.4 (Special warnings and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Guided questionnaires |

<div style=\"page-break-after: always\"></div>

| Safety concern                         | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance activities                                                                                                                                |
|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                        | precautions for use) Section 4.8 (Undesirable effects) Section 5.2 (Pharmacokinetic properties) Routine risk minimization activities recommending specific clinical measures to address the risk: Liver function should be monitored prior to initiation of treatment and each dose. Treatment in patients with serum transaminases > 3 × upper limit of normal (ULN) and concomitant total bilirubin > 2 × ULN should be permanently discontinued. This has been adequately captured in Section 4.4 of EU SmPC. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization | Additional pharmacovigilance activities: None                                                                                                               |
| Nodular regenerative hyperplasia (NRH) | Routine risk communication: SmPC: Section 4.4 (Special warnings and precautions for use) Section 4.8 (Undesirable effects) Routine risk minimization activities recommending                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Guided questionnaires Additional pharmacovigilance activities: |

<div style=\"page-break-after: always\"></div>

| Safety concern            | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance activities                                                                                                                    |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|                           | specific clinical measures to address the risk: Diagnosis of NRH can be confirmed only by histopathology. Upon diagnosis of NRH, trastuzumab emtansine treatment must be permanently discontinued. This has been adequately captured in EU SmPC Section 4.4 Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: None                                            | None                                                                                                                                            |
| Infusion-related reaction | Routine risk communication: SmPC: Section 4.4 (Special warnings and precautions for use) Section 4.7 Effects on ability to drive and use machines Section 4.8 (Undesirable effects) Routine risk minimization activities recommending specific clinical measures to address the risk: The infusion rate of trastuzumab emtansine should be slowed or interrupted if the patient develops infusion-related symptoms (see sections 4.4 and 4.8 of EU SmPC). Trastuzumab emtansine should be discontinued in case of | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Pharmacovigilance activities                                                                                                                    |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | life-threatening infusion reactions. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                 |
| Hypersensitivity | Routine risk communication: SmPC: Section 4.2 (Posology and method of administration) Section 4.3 (Contraindications) Section 4.4 (Special warnings and precautions for use) Section 4.8 (Undesirable effects) Routine risk minimization activities recommending specific clinical measures to address the risk: The infusion rate of trastuzumab emtansine should be slowed or interrupted if the patient develops infusion-related symptoms (see sections 4.4 and 4.8 of EU SmPC). Trastuzumab emtansine should be discontinued in case of life-threatening infusion reactions. Other risk minimization measures beyond the Product Information: Medicine's legal status: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern               | Risk minimization measures                                                                                                                                                                                                                                                                                                                      | Pharmacovigilance activities                                                                                                                                                                                                                                                                     |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: None                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                  |
| Left ventricular dysfunction | Routine risk communication: SmPC: Section 4.2 (Posology and method of administration) Section 4.4 (Special warnings and precautions for use) Section 4.8 (Undesirable effects) Routine risk minimization activities recommending specific clinical measures to address the risk: Standard cardiac function testing should be performed prior to | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities: Collection and separate analysis of cardiological safety data in the following studies: - MO28231 (KAMILLA) - BO27938 (KATHERINE) - BO28407 (KAITLIN) |
| Thrombocytopenia             | Routine risk communication: SmPC:                                                                                                                                                                                                                                                                                                               | Routine pharmacovigilance activities beyond adverse                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Safety concern        | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance activities                                                                                                                    |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|                       | Section 4.2 (Posology and method of administration) Section 4.4 (Special warnings and precautions for use) Section 4.8 (Undesirable effects) Routine risk minimization activities recommending specific clinical measures to address the risk: It is recommended that platelet counts are monitored prior to each trastuzumab emtansine dose. See Section 4.4 EU SmPC Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization | reactions reporting and signal detection None Additional pharmacovigilance activities: None                                                     |
| Peripheral neuropathy | Routine risk communication: SmPC: Section 4.4 (Special warnings and precautions for use) Section 4.8 (Undesirable effects) Routine risk minimization activities recommending specific clinical measures to address the risk: Patients should be clinically monitored on an ongoing basis for                                                                                                                                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pharmacovigilance activities                                                                                                                                                                        |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | signs/symptoms of neurotoxicity . This has been adequately captured in Section 4.4 of EU SmPC. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: None                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                     |
| Fetal harm       | Routine risk communication: SmPC: Section 4.6 (Fertility, pregnancy and lactation) Section 5.3 (Preclinical safety data) Routine risk minimization activities recommending specific clinical measures to address the risk: Women of childbearing potential should be advised to use effective contraception during treatment with trastuzumab emtansine and for at least 7 months after treatment has concluded. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Global Enhanced Pharmacovigilance (PV) pregnancy program Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern                          | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance activities                                                                                                                    |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|                                         | Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                 |
| Medication error                        | Routine risk communication: SmPC: Section 4.2 (Posology and method of administration) Routine risk minimization activities recommending specific clinical measures to address the risk: In order to prevent medication errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab). Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: Educational materials for health care providers. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities: None |
| Use in patients with hepatic impairment | Routine risk communication: SmPC: Section 4.2 (Posology and method of administration) Section 4.4 (Special warnings and precautions for use) Section 4.8 (Undesirable effects)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance                  |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                      | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                     | Routine risk minimization activities recommending specific clinical measures to address the risk: Liver function should be monitored prior to initiation of treatment and each dose. Treatment in patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN should be permanently discontinued. This has been adequately captured in Section 4.4 of EU SmPC. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: | activities: None                                                                                                                                            |
| Use in patients with left ventricular ejection fraction (LVEF) <50% | Routine risk communication: SmPC: Section 4.4 (Special warnings and precautions for use) Section 4.8 (Undesirable effects) Routine risk minimization activities recommending specific clinical measures to address the risk: Standard cardiac function testing should be performed prior to initiation and at regular intervals during treatment. The dose                                                                                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse \\reactions reporting and signal detection None Additional pharmacovigilance activities: - Study BO39807 |

<div style=\"page-break-after: always\"></div>

| Safety concern                        | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                  | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                 |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                       | should be delayed or treatment discontinued as necessary in cases of left ventricular dysfunction (see section 4.2). This has been adequately captured in Section 4.4 of EU SmPC. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: None                                |                                                                                                                                                                                                                                                                                                                              |
| Use in elderly patients (>= 75 years) | Routine risk communication: SmPC: Section 4.2 (Posology and method of administration) Section 5.1 Pharmacodynamic properties Section 5.2 Pharmacokinetic properties Routine risk minimization activities recommending specific clinical measures to address the risk: None Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities: Collection and separate analysis of safety data for elderly patients in the following studies: - MO28231 (KAMILLA) - BO27938 (KATHERINE) - BO28407 (KAITLIN) - BO28408 (KRISTINE) |

<div style=\"page-break-after: always\"></div>

| Safety concern         | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Pharmacovigilance activities                                                                                                                                                                        |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                        | prescription. Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                     |
| Use in pregnant women  | Routine risk communication: SmPC: Section 4.6 (Fertility, pregnancy and lactation) Routine risk minimization activities recommending specific clinical measures to address the risk: Women of childbearing potential should be advised to use effective contraception during treatment with Trastuzumab emtansine and for at least 7 months after treatment has concluded. If a pregnant woman is treated with trastuzumab emtansine, close monitoring by a multidisciplinary team is recommended. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Global Enhanced Pharmacovigilance (PV) pregnancy program Additional pharmacovigilance activities: None |
| Use in lactating women | Routine risk communication: SmPC: Section 4.6 (Fertility, pregnancy and lactation) Routine risk minimization activities recommending                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Safety concern                                 | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                                                                                              |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                | specific clinical measures to address the risk: Women should discontinue nursing prior to initiating treatment with trastuzumab emtansine. Women may begin nursing 7 months after concluding treatment. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: | Additional pharmacovigilance activities: None                                                                                                                                                             |
| Clinical impact of anti-therapeutic antibodies | Routine risk communication: SmPC: Section 4.8 (Undesirable effects) Routine risk minimization activities recommending specific clinical measures to address the risk: None Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures:                              | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities: - BO27938 (KATHERINE) - BO28407 (KAITLIN) - BO28408 (KRISTINE) |

<div style=\"page-break-after: always\"></div>

| Safety concern                  | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance activities                                                                                                                                   |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                 | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                |
| Use of non-validated HER2 tests | Routine risk communication: SmPC: Section 4.2 (Posology and method of administration) Routine risk minimization activities recommending specific clinical measures to address the risk: Patients treated with trastuzumab emtansine should have HER2 positive tumour status, assessed by a CE-marked In Vitro Diagnostic (IVD) medical device. If a CE-marked IVD is not available, the HER2-status should be assessed by an alternate validated test. Other risk minimization measures beyond the Product Information: Medicine's legal status: Trastuzumab emtansine is subject to restricted medical prescription. Additional risk minimization measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection None Additional pharmacovigilance activities: • MO28231 (KAMILLA) |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.7, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

<div style=\"page-break-after: always\"></div>

The proposed Type II variation seeks to extend the Kadcyla Marketing Authorisation to include adjuvant treatment for patients with HER2- positive EBC.  User consultation was conducted at the time of the initial marketing authorisation application for Kadcyla, approved in patients with MBC. It is reasonable not to conduct a User Consultation for the Package Leaflet for this variation because:

- -No significant changes affecting the readability of the Package Leaflet have been made.
- -The new additions follow the same structure and use similar descriptions and terminology as used in the approved Package Leaflet.
- -The posology proposed in this application does not differ from that previously described; only the timing and duration of the treatment is different.
- -The safety profile remaims consistent with the known profile for Kadcyla, with no new safety signals seen in the adjuvant setting.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The MAH is currently seeking an extension of indication of Kadcyla for the adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane and HER2 targeted therapy.

## 3.1.2. Available therapies and unmet medical need

Preoperative chemotherapy plus trastuzumab and pertuzumab attains high rates of pCR and constitutes the standard  of  care  in  the  neoadjuvant  setting  of  HER2+  EBC.  To  further  minimise  the  risk  of  relapse, trastuzumab is often maintained for up to a year in the adjuvant setting. Despite this progress, however, approximately  15%  to  25%  of  HER2-positive  patients  will  eventually  experience  local  or  metastatic recurrence, which calls for the identification and investigation of newer and better therapies.

It  has  been  reported  that  achieving  pCR  following  neoadjuvant  therapy  is  associated  with  significantly improved disease recurrence and survival, particularly for triple negative and HER2+ BC patients. To date, no  specific  adjuvant  regiments  are  recommended  for  patients  with  HER2+  BC  who  did  not  achieve  a complete response (i.e. those with residual disease) and are thus at higher risk of disease recurrence and decreased survival. Therefore, this population has a high level of unmet medical need.

## 3.1.3. Main clinical studies

The  application  is  based  on  efficacy  and  safety  data  from  KATHERINE  (Study  BO27938),  a  phase  III, two-arm, randomised, open label trial in patients with HER2+ BC with residual invasive disease in the breast or lymph nodes after neoadjuvant chemotherapy and HER2-targeted agents, data cut-off 25 Jul 2018.

## 3.2. Favourable effects

After 256 IDFS events (predefined IA by protocol), the study has met its primary efficacy endpoint by achieving a statistically significant improvement in IDFS for Kadcyla with an unstratified HR of 0.50 (95% CI 0.39,  0.64)  and  p&lt;0.0001.  The  efficacy-stopping  boundary  has  been  crossed  and  the  results  are  now considered the primary analysis.

The  IDFS  benefit  from  Kadcyla  is  maintained  across  all  the  subgroups  analysed,  particularly  those concerning the stratification factors.

<div style=\"page-break-after: always\"></div>

The lowered risk of IDFS events from Kadcyla vs. trastuzumab seems limited to recurrence outside of sanctuary sites (distant non-CNS, locoregional and/or contralateral), since no differences between arms were seen for overall CNS-recurrence event rates.

Albeit not corrected for multiplicity, secondary endpoints that included other clinical situations as events (secondary non breast cancer for IDFS-SPNBC, DCIS for DFS, distant recurrence as or beyond the earliest IDFS event for DRFI) support the advantage from adjuvant Kadcyla over trastuzumab.

98 OS events (6.6%) had occurred to cut-off date. Although OS data are immature, a benefit trend of Kadcyla was observed.

Sensitivity analyses (censoring patients who began a new anti-cancer therapy or those who discontinued study treatment for any reason) were consistent with the primary analysis of IDFS.

## 3.3. Uncertainties and limitations about favourable effects

Albeit adjusted to the statistical plan of the trial, median follow-up (40.9 months in the trastuzumab arm and 41.4 months in the Kadcyla arm) is certainly limited for a study in the adjuvant setting of breast cancer. In fact, nearly one third of alive patients from the ITT had ≤3 years of follow -up on study.

Although  the  benefit  trend  of  Kadcyla  is  observed  in  formal  OS  testing,  the  result  is  not  statistically significant (unstratified HR 0.70; 95% CI 0.47, 1.05; p=0.0848). Hence, a long-term non-detrimental OS effect from Kadcyla cannot be yet established. To further investigate the efficacy of Kadcyla in the claimed indication, the MAH will provide the final analysis results by the second quarter of 2024 (see Annex II of the PI).

Although the IDFS forest plot suggests that the benefit from Kadcyla was seen across most stage and substage subgroups, the high variability of breast cancer according to specific staging creates too small fractions to determine the absolute benefit in patients with small residual tumours and none or little nodal disease, as compared to the more apparent benefit in patients with bigger tumours and/or N2/N3 stage.

Immaturity of the IDFS data prevents determining the potential effect of ADAs on efficacy. The clinical impact of anti-therapeutic antibodies will continue to be monitored (see RMP).

## 3.4. Unfavourable effects

T he  incidence  of  ≥G3  AEs  (26%  vs.  15%),  serious  AEs  (5%  vs.  1%)  and  AEs  leading  to  treatment discontinuation (18% vs. 2%) in the Kadcyla arm was higher than in the trastuzumab arm.

Kadcyla-specific AEs were expectedly more frequent than the control arm: hepatotoxicity (38% vs. 11%), thrombocytopenia (29% vs. 2%), peripheral neuropathy (32% vs. 17%), haemorrhage (29% vs. 10%) and pulmonary toxicity (3% vs. 1%).

Certain symptoms typically related to chemotherapy (nausea, fatigue, dry mouth/stomatitis/dysgeusia, constipation,  peripheral  neuropathy  and  decreased  appetite)  were  also  more  prevalent  in  the  safety population of Kadcyla.

211 patients treated with Kadcyla (28.5%) experienced any-grade thrombocytopenia. Half of them (105 out of 211) experienced G1 thrombocytopenia, while the remaining 106 patients had ≥G2 events. High -grade (≥G3)  thrombocytopeni a occurred  in  42  patients  (5.7%)  and  serious  events  were  reported  in  10. Undoubtedly, thrombocytopenia was also the AE most frequently implied in dose interruptions (14 patients), dose reductions (23 patients) and permanent discontinuations (31 patients) from the Kadcyla arm. The incidence  and  severity  of  thrombocytopenia  was  higher  in  the  Asian  subgroup  than  in  the  other  race subgroups.

<div style=\"page-break-after: always\"></div>

There was one G5 AE related to Kadcyla in a patient with traumatic intracranial haemorrhage and G4 thrombocytopenia.

216 patients (29.2%) from the Kadcyla arm and 69 patients (9.6%) from the trastuzumab arm experienced haemorrhage  of  diverse  categories.  Most  of  these  events  were  of  low  grade  and  with  minor  clinical consequences, but 5 patients from both arms suffered high-grade events.

The rate of hepatotoxic events in the Kadcyla arm tripled that from the trastuzumab arm: 37.3% vs. 10.6%. G2-3  events  occurred  in  85  patients  (11.5%)  treated  with  Kadcyla.  The  most  common  any-grade hepatotoxic events in the Kadcyla arm were increased ASAT (28.4%), ALAT (23.1%), alkaline phosphatase (8.2%), bilirubin (6.6%) and GGT (3.6%).

The incidence of peripheral neuropathy, a disabling AE with likely chronic consequences and a detrimental impact in quality of life, in the Kadcyla arm (32.3%) nearly doubles that of the trastuzumab arm (16.9%).

Cardiotoxicity from Kadcyla did not raise major concerns. The incidence of overall cardiac dysfunction events was higher in the trastuzumab arm (40 vs. 23 patients in the Kadcyla arm).

Nearly 1 out of each 5 patients withdrew from the Kadcyla arm because of intolerable toxicity. Almost one quarter of all discontinuations in the Kadcyla arm were a result of thrombocytopenia: 31 events in 133 patients  (23.3%).  Other  AEs  leading  to  permanent  treatment  withdrawal  from  Kadcyla  were  increased bilirubin, ASAT increased, ALAT increased, peripheral sensory neuropathy and ejection fraction decreased.

## 3.5. Uncertainties and limitations about unfavourable effects

Safety  analysis  in  the  ≥65 -year-old  age  subgroup  was  limited  and  inconclusive  by  the  low  number  of patients. The use of Kadcyla in elderly patients will continue to be closely monitored (see also RMP).

## 3.6. Effects Table

Table 71: Effects Table for Kadcyla vs. trastuzumab in the adjuvant treatment of patients with HER2+ EBC and residual invasive disease after neoadjuvant chemotherapy and HER2-targeted agents, data cut-off 25 Jul 2018.

| Effect                      | Short description                                                                              | Unit                    | Kadcyla (experiment al)   | Trastuzum ab (control)   | Uncertainties / Strength of evidence                                                                                                        | References           |
|-----------------------------|------------------------------------------------------------------------------------------------|-------------------------|---------------------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects          | Favourable Effects                                                                             | Favourable Effects      | Favourable Effects        | Favourable Effects       | Favourable Effects                                                                                                                          | Favourable Effects   |
| IDFS                        | Time between randomization and date of first occurrence of any one of the following IDFS event | Patients with event (%) | 91 (12.2)                 | 165 (22.2)               | Unstratified HR 0.50 (0.39, 0.64) p < 0.0001 *CNS recurrence rates do not differ between Kadcyla and trastuzumab                            |                      |
| IDFS 3-year event-free rate | 3-year IDFS event free rate                                                                    | Rate (95% CI)           | 88.27 (85.81, 90.72)      | 77.02 (73.78, 80.26)     |                                                                                                                                             |                      |
| OS                          | Time from randomization to death due to any cause                                              | Patients with event (%) | 42 (5.7)                  | 56 (7.5)                 | Unstratified HR 0.70 (0.47, 1.05) p = 0.0848 *Immaturity of data (6.6% of events) does not establish non-detrimental OS effect from Kadcyla |                      |
| OS 3-year event-free rate   | 3-year OS event free rate                                                                      | Rate (95% CI)           | 95.18 (93.58, 96.79)      | 93.59 (91.71, 95.47)     | Unstratified HR 0.70 (0.47, 1.05) p = 0.0848 *Immaturity of data (6.6% of events) does not establish non-detrimental OS effect from Kadcyla |                      |
| Unfavourable Effects        | Unfavourable Effects                                                                           | Unfavourable Effects    | Unfavourable Effects      | Unfavourable Effects     | Unfavourable Effects                                                                                                                        | Unfavourable Effects |
| ≥G rade 3 AEs               | ≥G rade 3 AEs                                                                                  | %                       | 25.7                      | 15.4                     |                                                                                                                                             |                      |
| AEs leading to treatment    | AEs leading to treatment                                                                       | %                       | 18.0                      | 2.1                      |                                                                                                                                             |                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect                | Short description   | Unit   | Kadcyla (experiment al)   | Trastuzum ab (control)   | Uncertainties / Strength of evidence   | References   |
|-----------------------|---------------------|--------|---------------------------|--------------------------|----------------------------------------|--------------|
| discontinuation       |                     |        |                           |                          |                                        |              |
| Thrombocytope nia     | Any grade Grade ≥ 3 | %      | 28.5 5.7                  | 2.4 0.3                  |                                        |              |
| Haemorrhage           | Any grade Grade ≥ 3 | %      | 29.2 0.4                  | 9.6 0.3                  |                                        |              |
| Hepatotoxicity        | Any grade Grade ≥ 3 | %      | 37.3 1.6                  | 10.6 0.4                 |                                        |              |
| Peripheral neuropathy | Any Grade Grade ≥ 3 | %      | 32.3 0                    | 16.9 1.4                 |                                        |              |

Abbreviations: CI= confidence interval; IDFS= invasive disease free survival; OS= Overall Survival

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Results from the first interim analysis from the KATHERINE trial suggest that residual invasive disease can also be a predictive biomarker in HER2+ EBC: patients treated with Kadcyla presented an overall lower risk of invasive recurrence than those who received trastuzumab.

Recurrence in the CNS, often in the form of brain metastases, is a particularly dreadful event with higher incidence in HER2+ and triple negative breast cancer, entailing the worst survival prognosis from all types of recurrence events. However, the beneficial effect from adjuvant Kadcyla seems to be exerted outside of sanctuary sites such as the brain.

With this limitations and uncertainties in consideration, the overwhelming difference in acute and chronic toxicity between standard-of-care trastuzumab and Kadcyla must be considered. Undeniably, adjuvant Kadcyla was not well tolerated and compared quite unsatisfactorily to trastuzumab in safety terms, putting a considerable amount of patients at risk for unpleasant, disabling and even life-threatening adverse events.

## 3.7.2. Balance of benefits and risks

As compared to trastuzumab, Kadcyla demonstrated a clinically meaningful reduction in the overall recurrence rate in the targeted population of the KATHERINE trial. Significant toxicity and obvious safety risks are observed in patients treated with Kadcyla. Nonetheless, the magnitude of clinical benefit of Kadcyla in the proposed patient population outweighs the observed safety concerns. Furthermore, measures are in place to minimise the risks as reflected in the PI and RMP.

## 3.8. Conclusions

The overall B/R of Kadcyla as a single agent, for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have invasive residual disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy is positive.

The CHMP considers the following measures necessary to address issues related to efficacy:

PAES: In order to further investigate the efficacy of trastuzumab emtansine in the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the final analysis of OS from the phase 3, randomised, open-label study KATHERINE (BO27938). Due date: 30 June 2024.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include the use of Kadcyla as a single agent for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have invasive residual disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.7, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce editorial changes throughout the product information. An updated RMP version 9.2 has been agreed.

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

This CHMP recommendation is subject to the following new condition:

## Conditions and requirements of the marketing authorisation

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                                                                                                                       | Due date     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| PAES: In order to further investigate the efficacy of trastuzumab emtansine in the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the final analysis of OS from the phase 3, randomised, open-label study KATHERINE (BO27938). | 30 June 2024 |